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Acute lymphoblastic leukemia (ALL) is a malignancy that is characterized by the 
development of large numbers of immature lymphocytes.1-3 Children with ALL present 
with symptoms including fatigue caused by anemia, bleeding caused by thrombocytopenia, 
and infection caused by neutropenia.2 ALL develops rapidly and leads to patient death 
within weeks or months if left untreated. ALL is one of the most common cancers in 
children and accounts for more than 20% of all newly diagnosed cases.4 In the Netherlands, 
approximately 120 children are diagnosed with ALL each year.
Treatment protocols for ALL in children are largely based on risk-stratification. When patients 
are diagnosed with ALL, they are stratified into different groups according to their risks to 
relapse (Figure 1.1). This risk stratification is deduced from various clinico-pathological 
features, such as white blood cell (WBC) counts, immunophenotypes, cytogenetics and 
genomic alterations,5-9 and is crucial for the selection of optimal therapy regimens in order 
to maintain high cure rates and to avoid excessive toxicity for, in particular, low risk patients.
Since the first report of a temporary remission of acute leukemia induced by aminopterin in 
1948,10 many therapy trials using chemotherapeutic agents have been carried out. Whereas 
ALL treatment regimens may differ in content, they typically contain three phases: induction, 
consolidation and maintenance (Figure 1.1). The goal of induction therapy is to eradicate 
more than 99% of the leukemic cells present at primary diagnosis. To achieve this goal, this 
therapeutic phase includes very intensive chemotherapy almost always involving glucocorticoids 
(prednisone, prednisolone or dexamethosone), and asparaginase.11 Glucocorticoids (GCs) 
were among the first drugs used in ALL treatment.12 Their anti-leukemic effects are mediated 
through binding to GC receptors, which then translocate to the nucleus and interact with 
GC response elements to transactivate gene expression or repress the activity of transcription 
factors.13, 14 In the mid-1960s, asparaginase was added to this first-line chemotherapy.15-17 The 
cytotoxic effect of asparaginase is due to the fact that leukemia cells are not able to produce 
adequate amounts of the non-essential amino acid asparagine and, therefore, heavily rely on 
external supply. Asparaginase catalyzes the conversion of asparagine to aspartate and ammonia, 
thereby depleting serum asparagine, starving leukemic cells and may ultimately lead to cell 
death.17, 18 When normal hematopoiesis is restored after a month of intensive induction therapy, 
patients will receive consolidation therapy. This therapeutic phase lasts for a few months and 
aims to eliminate leukemic cells that survive the induction therapy. Finally, maintenance 
therapy is used as a long-term process to entirely remove persistent leukemic cells, prolong 
complete remission and eventually cure patients.
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Figure 1.1. Schematic overview of chemotherapy regimens for patients diagnosed with ALL. Children 
diagnosed with ALL are stratified into different risk groups. The number of risk groups is protocol de-
pendent, but usually involves three groups. Patients with a higher risk to develop a relapse are assigned to 
a more severe chemotherapy regimen, while milder intensity treatment regimens are applied to children 
with a medium or low risk to relapse. Some patients may shift to another risk category based on their 
response to treatment and/or minimal residual disease (MRD) level (marked by *).
Clinical studies from many countries have vastly increased the treatment outcome of 
children with ALL. The first protocol attempting to cure childhood ALL was conducted 
by the St Jude Children’s hospital in Memphis, USA, in the late-1960s. This protocol, 
called “Total Therapy”, combined multiple agents to eradicate leukemic cells, and achieved 
durable remissions in 50% of the patients.19 In the late 1970s, the German Berlin-Frankfurt-
Münster (BFM) study group took a second major step towards ALL treatment: with an 
intensified induction and consolidation therapy, the long-term remission rate was improved 
to 70%.20, 21 Since then, many efforts have focused on risk stratification, aiming to identify 
high-risk (HR) patients who need intensive treatment and to reduce the long-term toxicity 
for patients with a lower risk. With better risk-stratifications and subsequent treatment 
adaption, the ALL survival rates have been improved to nearly 90% in most countries.22, 23
Between 1991 and 2012, over 2000 children with newly diagnosed ALL have been 
enrolled in three consecutive Dutch Children Oncology Group (DCOG) clinical studies: 
ALL8, ALL9 and ALL10.24-26 The ALL8 study (1991-1997) was based on trials from the 
BFM study group, and was aiming to decrease chemotherapy toxicity and to increase the 
efficacy of the BFM-oriented treatment protocol.26 The protocol adopted the BFM risk 
stratification criteria that were based on the initial day 8 prednisone response, tumor load 
and cell biological characteristics.26 Compared to the German ALL-BFM90 protocol, 
this risk-adaptive treatment strategy in ALL8 included more intensive induction, early 




ALL9 study (1997-2004) was based on the St Jude “Total Therapy” approach,27 and aimed 
to confirm the results of the DCOG ALL6 protocol for non-high-risk (NHR) patients 
while improving the results for the high-risk (HR) patients.28 It replaced prednisone with 
high doses of dexamethasone to treat NHR patients,29-31 but limited the use of additional 
drugs.28 The ALL10 study (2004-2012) adopted parts of the ALL8 study backbone, and 
aimed to improve the overall treatment results and to decrease the treatment intensity 
in patients with a lower risk of relapse.25 The risk stratification in the ALL10 study was 
determined by minimal residual disease (MRD) levels at two time points during the first 
months of therapy.25 MRD refers to small numbers of leukemic cells (one leukemic cell in 
103 to 106 cells) that remain in the patient’s bone marrow. The MRD levels in ALL have 
been shown to serve as a strong prognostic factor.32, 33 Absence of MRD after remission 
induction is associated with a good prognosis, while MRD positivity after remission 
induction is associated with relapse. Therefore, the MRD-based stratification has also 
been implemented into the ongoing ALL11 protocol, which has been running since 2012.
Figure 1.2. Overall survival (A) and incidence of relapse (B) in three Dutch ALL studies (8, 9 and 10). 
The figure is adapted from the DCOG ALL11 report (https://www.skion.nl/workspace/uploads/C1-
-ALL11-Protocol-v9- 0_03-09-2018.pdf).
Despite significant improvements in long-term survival rates during the last decades 
(Figure 1.2), a subset of patients still experiences relapse, which is one of the major causes 
of treatment failure. The 5-year overall survival (OS) rate has increased from 83% in ALL8 
to 92% in ALL10.25, 26, 34 Especially the 5-year OS for patients with a high risk of relapse 
has significantly increased from 40% in ALL8 to 82% in ALL10.25, 26 The relapse rates 
in ALL8, ALL9 and ALL10 were found to be 25%, 15% and 8.3%, respectively.25, 26, 28 
Relapsed ALL has a poor prognosis and the 5-year OS is only 40% to 60%,35-40, much 
lower than the OS after primary diagnosis. As a consequence, relapsed ALL accounts for a 
15
General introduction
large proportion of cancer-related deaths in children every year.41 To decrease the number 
of relapses in ALL, it is important to understand the mechanisms underlying treatment 
failure and the biology of relapse development.
GENETIC BASIS OF ALL
Extraordinary advances have been made in our understanding of the genetic landscape of 
ALL. There are two types of childhood ALL according to the precursor lineage involved: 
B-cell precursor ALL (BCP-ALL; 85% of cases) and T-lineage ALL (T- ALL; 15% of cases). 
Both are composed of multiple subtypes defined by structural chromosomal alterations 
that serve as initiating events in ALL development (Figure 1.3A). Chromosomal 
alterations, including aneuploidy and gross chromosomal rearrangements, can cause 
oncogene deregulation and/or expression of chimeric fusion genes. At primary diagnosis, 
the most common cytogenetic subtypes in BCP- ALL are defined by t(12;21)(p13;q21) 
translocations, resulting in ETV6-RUNX1 gene fusions, and by hyperdiploidy with more 
than 50 chromosomes, both of which are associated with a relatively good clinical 
outcome.42, 43 In addition, it has been found that TCF3-PBX1 gene fusions resulting from 
t(1;19)(q23;p13) translocations occur in about 5% of BCP-ALL, and are associated with 
a relatively favorable clinical outcome.44 More recently, another good prognosis subtype 
has been identified with distinct expression deregulation profiles of the DUX4 and ERG 
genes in up to 7% of BCP-ALL.51, 52 In contrast, it has been found that patients with 
t(9;22)(q34;p11) translocations resulting in BCR-ABL1 gene fusions, 11q23 rearrangements 
(MLL- rearrangements), or hypodiploidy with less than 45 chromosomes have a poor 
clinical outcome.53-55 One decade ago, yet another poor prognosis ALL subtype has been 
identified, termed BCR-ABL1-like BCP-ALL, which exhibits a similar gene expression 
profile as the BCR-ABL1 positive cases, but lacks the BCR-ABL1 fusion gene.56, 57 Genomic 
and transcriptomic studies have revealed that a highly diverse repertoire of genomic 
alterations which uniformly result in activating kinase and cytokine receptor signaling, 
and are associated with inferior outcome.56, 57 About 50% of T-ALL patients harbor 
rearrangements of the transcription factors TAL1, TLX1, TLX3 and LYL1.58, 59 In 2009, 
another T-ALL subtype has been identified, termed “early T-cell precursor” (ETP) ALL, 
encompassing about 15% of T-ALLs, and is associated with a high risk of relapse if treated 




Figure 1.3. Childhood ALL subtypes defined by chromosomal alterations. (A) ALL subtypes at primary 
diagnosis. Data are adapted from.
3, 45-49
 (B) Frequency of main subtypes in relapsed BCP-ALL. The figure 
is adapted from the international ALLR3 study.
50
 Subtypes with a good or poor prognosis are depicted 
in black and red, respectively.
The spectrum of chromosomal alterations that define distinct subtypes are similar between 
primary diagnosis and relapse in BCP-ALL (Figure 1.3B). Therefore, high hyperdiploidy 
and ETV6-RUNX1 positive cases are also encountered as frequent subtypes in relapsed 
BCP-ALL, representing up to 30% and 20% of the relapsed patients, respectively.37, 62, 63 
Nevertheless, similar to primary diagnosis, these alterations are associated with a favorable 
outcome.50, 63 The BCR-ABL1 positive, MLL- rearranged and hypodiploidy subtypes are 
again found in a minor subset of relapsed BCP-ALL, and are consistently associated with 
an unfavorable outcome.40, 50, 63 Notably, in spite of the good prognostic feature of the TCF3-
PBX1 gene fusion at primary diagnosis, when patients with this fusion do relapse they tend 
to do so very early and to exhibit a poor outcome after relapse therapy.50
Cooperating or secondary alterations, including copy number alterations (CNAs) and 
sequence mutations, have been found to be associated with BCP-ALL. CNAs, defined as 
DNA segments of 1kb or larger in size, can impact gene expression by disrupting coding 
sequences, altering gene dosage and/or perturbing long-range gene regulation.64, 65 IKZF1 
deletions at primary diagnosis, for example, are the hallmark of BCR-ABL1 and BCR-ABL1-
like ALL, but also occur in other subtypes, and are associated with a poor treatment 
outcome. Since in ALL10, a large number of relapses in IKZF1-deleted patients occurred 
directly after treatment, it was decided that in the ongoing Dutch ALL11 study, IKZF1 




In relapsed BCP-ALL, CNAs and sequence mutations are mainly targeting genes involved 
in lymphoid development, cell cycle progression, cell signaling, epigenetic remodeling, and 
DNA repair (Figure 1.4). Among the most common CNAs in relapsed BCP-ALL is the 
deletion of CDKN2A/B (9p21.3), which is present in approximately 40% of these patients.50, 
69-73 Similarly, deletions in genes regulating hematopoietic and B-cell development (IKZF1, 
EBF1, ETV6, PAX5) have frequently been detected in relapsed BCP-ALL.50, 71-73 Notably, 
in the German relapse protocol ALL-REZ BFM 2002, the presence of IKZF1 deletions in 
high-risk relapse patients strongly correlated with the occurrence of a second relapse after 
stem cell transplantation.72 Deletions in genes mediating glucocorticoid signaling (BTG1 
and NR3C1) are present in nearly 10% of relapsed ALL treated by the international ALLR3 
protocol, and are associated with inferior outcome and increased risk of progression into 
high risk relapsed ALL.50 Furthermore, loss of MSH6, a critical component of the DNA 
mismatch repair machinery, has been identified in a small subset of relapsed ALL patients.71
The advances of next-generation-sequencing (NGS) technologies have enabled the 
detection of additional single nucleotide variants (SNVs) or point mutations relevant 
to BCP-ALL relapse. Deletions and mutations in the histone acetyltransferase CREBBP, 
for example, have been found to occur in up to 20% of relapsed ALL cases and to be 
particularly prevalent in high hyperdiploid patients.74-76 In addition, mutations in two 
genes mediating purine synthesis, NT5C2 and PRPS1, have been found to be present in 
up to 10% and 7% of BCP-ALL relapse cases, respectively.77-80 Mutations activating the 
Ras pathway (mostly in KR AS, NR AS, PTPN11 and FLT3) have been found to be present 
in 40% of relapsed ALL cases, and to be associated with high-risk features and a poor 
prognosis.75, 81-83 Deletions and mutations in TP53 have been observed in approximately 
10% of relapsed ALL, and to be consistently associated with poor treatment outcomes.50, 
72, 84 Other recurrent mutations in relapsed ALL include mutations in the JAK-STAT 
signaling pathway ( JAK1/2/3), the mismatch repair system (MSH2, MSH6 and PMS2), the 
H3K36 trimethyltransferase SETD2, the lysine- specific demethylase KDM6A and the 




Figure 1.4. Genetic basis of relapsed BCP-ALL. Cooperating genomic alterations in relapsed BCP-
ALL are mainly found in genes involved in B-cell development (IKZF1, EBF1, ETV6 and PAX5), chro-
matin modification (CREBBP, SETD2, KDM6A and MLL2), cell cycle regulation (BTG1, CDKN2A/B and 
TP53), cell signaling (RAS/JAK), DNA mismatch repair (MSH2, MSH6 and PMS2) and drug metabolism 
(NT5C2, PRPS1 and NR3C1). The gene font color marks the functions of proteins encoded by these genes.
CLONAL DIVERSITY AND ORIGIN OF ALL RELAPSE
In 1979, Nowell suggested that cancer is an evolutionary process, which is driven by 
the acquisition of somatic alterations and the sequential selection of subclones.87 This 
hypothesis parallels to Darwin’s evolution theory describing the natural selection of 
species. Cancer clones similarly evolve via a nonlinear branching process, which is 
influenced by internal and external factors, including genomic alterations and micro- 
environmental and therapeutic factors, respectively.69, 88, 89 Like many other cancers, 
ALL shows clonal diversity at both diagnosis and relapse. By using fluorescence in situ 
hybridization (FISH) probes to identify multiple fusions and deletions in single cells, the 
existence of significant genetic heterogeneity has been revealed in individual ALL samples 
at the time of primary diagnosis.90 Likewise, by comparing CNA profiles of xenograft 
samples from the same patient, distinct clonal architectures have been detected, suggesting 
that diagnostic ALL samples contain multiple genetically distinct leukemia-initiating 
cell subclones.91 In addition, by applying targeted sequencing of ALL samples at single-
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cell resolution, multiple genetic subclones with complex clonal architectures have been 
observed.92 Similar to primary diagnosis, detailed genomic profiling of patient samples 
together with mathematical modeling have revealed the existence of multiple subclones 
in relapsed ALL.82, 86
Genomic profiling of matched diagnosis and relapse samples has revealed that most 
alterations responsible for ALL relapse are usually also present at time of initial diagnosis. 
By studying relapsed ALLs with ETV6-RUNX1 translocations, it was shown that leukemic 
cells with this translocation originate from an ancestral clone.93 Similarly, backtracking 
analysis of CNAs identified at relapse revealed that in most ALL patients, the relapse-
specific alterations are also present in dominant clones at the time of initial diagnosis.69, 
71, 94 On the contrary, using ultra-sensitive allele-specific approaches to track Ras pathway 
mutations, Irving and colleagues found that cells carrying these mutations are often derived 
from very low level subclones in diagnosis samples.81 These findings suggest that genetic 
alterations related to relapse are also frequently present at the time of initial diagnosis, 
either in major or minor clones, even in clones present at very low levels.
While many relapse-specific alterations are clearly present at initial diagnosis, some 
alterations cannot always be detected at diagnosis, despite the use of ultra-sensitive 
methods. For example, relapse-specific mutations in NT5C2 are very commonly present 
in relapsed T-ALL, but often not detectable at the time of diagnosis, even when using 
deep sequencing approaches with a sensitivity of 0.005%, such as droplet digital PCR 
and amplicon-based deep sequencing.77, 95 Obviously, these findings do not exclude the 
possibility that these acquired alterations are present at extremely low levels at the time of 
initial diagnosis, but they may as well be induced by the treatment regimens applied in the 
upfront protocols, as has been reported in acute myeloid leukemia (AML) and T-ALL.96, 97
CHEMOTHERAPY RESISTANCE IN ALL RELAPSE
In analogy to the natural selection of species in Darwin’s evolution theory, ALL treatment 
can be considered as a selection process that may cause the survival of certain therapy-resistant 
leukemic cells, which may eventually cause ALL relapse. By in vitro exposure of leukemic cells 
from children with ALL to clinically relevant drugs, sets of differentially expressed genes 
have been identified that are indeed related to chemotherapy resistance. In addition, it has 
been reported that alterations in the CREBBP and NT5C2 genes, which are particularly related 




Glucocorticoids (GCs), such as prednisone and dexamethasone, are key components 
used in the induction therapy phase. They affect cells by binding to the GC receptor 
and up-regulating anti-inflammatory proteins, which induce the apoptosis of leukemic 
blasts. Patients that respond poorly to prednisone on day 8 are stratified into the high risk 
treatment arm in clinical trials.13, 25, 98 Decreased expression of the GC receptor NR3C1 has 
been linked to resistance to GCs.71, 99, 100 In addition, loss of genes regulating GC responses, 
including IKZF1, BTG1 and TBL1XR1, have been found to result in increased resistance 
to GC agonists in BCP-ALL.101, 102 Moreover, alterations in the histone acetyltransferase 
CREBBP have been reported to confer GC resistance in vitro, although the impact might 
be highly dependent on clinical trials and tumor types.75, 76, 103 These data indicate that 
alterations in genes regulating GC responses confer GC resistance during therapy, which 
may result in ALL relapse.
Patients with mutations in genes regulating purine synthesis or DNA mismatch repair 
(MMR) respond poorly to purine nucleoside analogs such as 6-mercaptopurine (6-MP), 
which is the backbone of the maintenance phase of childhood ALL treatment.104 The 
structure of 6-MP is highly similar to that of DNA purine bases, which causes 6-MP to 
interfere with DNA replication by competing with purines during DNA synthesis. In vitro 
studies have revealed that leukemic cells harboring mutations in PRPS1 and NT5C2 exhibit 
less DNA damage and apoptosis after treatment with 6-thioguanine (6-TG) and 6-MP.77-79, 
95 Mutations in NT5C2 and PRPS1 are rarely identified in diagnosis samples and are found 
in up to 10% and 7% of relapsed BCP-ALL cases, respectively. This observation indicates 
that leukemic cells with these alterations are prone to be acquired or to be selected for 
during treatment.77, 95 In addition, leukemic cells with a decreased expression of MMR 
enzymes (for example, MSH2 and MSH6) have been found to show resistance to 6-MP 
or 6-TG.71, 105, 106 Interestingly, loss of MSH6 has also been shown to be associated with 
GC resistance in ALL.71, 107
Chemotherapy resistance may also, at least partly, be attributed to the fact that leukemic cells 
can hide in micro-environments that are less efficiently reached by chemotherapeutics.108 
Xenograft studies of ALL cells have shown that niches that belong to normal hematopoietic 
stem cells (HSC) can be hijacked by leukemic stem cells by secreting specific growth 
factors, signaling molecules and cytokines.109-112 During treatment, leukemic cells within 
these niches may remain in a quiescent stage, and survive from chemotherapeutic drugs 
that target rapidly dividing cells.113, 114 Therefore, the presence of such niches can reduce 
the efficacy of achieving complete remission, and may contribute to undetectable MRD 
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and relapse development. Moreover, after removing chemotherapeutic drugs, quiescent 
surviving leukemic cells may start to proliferate again and acquire additional genetic 
alterations, giving rise to relapse. Indeed, comparisons of matched diagnosis and relapse 
samples of ALL cases have revealed leukemic cell clones that survive the initial therapy and 
acquire relapse- specific mutations.86 For example, in a rare ALL case that relapsed after 22 
years, genomic profiling showed that the initial leukemic clone harboring a BCR-ABL1 gene 
fusion stayed silent, but was reactivated by the acquisition of alterations in potential tumor 
driver genes (such as STAT2 and TRIM29), ultimately resulting in relapse development.115
AIM AND OUTLINE OF THE THESIS
Despite the improved long-term survival rates in pediatric ALL obtained during the last 
few decades, relapse still occurs in 8%-20% of the patients in the developed countries 
and is one of the major results of treatment failure. Leukemic cells that are resistant to 
chemotherapy may lead to relapse. The main aim of this thesis has been to elucidate the 
mechanism underlying relapse development in ALL.
To unravel the process of relapse development in ALL, we have taken several approaches. 
First, we assessed the correlation between upfront treatment protocols and relapse 
development. To achieve this, we studied the genetic architecture of relapsed BCP-ALL 
in the context of upfront treatment protocols (Chapter 2). Next, we sought to understand 
the mechanism underlying relapse development from the perspective of clonal evolution. 
We evaluated the prognostic value of subclonal alterations in ALL (Chapter 4), by using 
our newly developed single molecular molecule inversion probe (smMIP) based NGS assay, 
which could detect low-level mosaic mutations in leukemia samples (Chapter 3). Finally, 
we investigated the mechanism of chemotherapy resistance in ALL. In order to search for 
targets related to therapy resistance, we have developed a CRISPR-Cas9 based genome-
wide screening method (Chapter 5), which allowed us to identify novel genes related to 
increased or reduced sensitivity of commonly used therapeutic drugs in ALL (Chapter 
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Genomic alterations in relapsed B-cell precursor acute lymphoblastic leukemia (BCP- 
ALL) may provide insight into the role of specific genomic events in relapse development. 
Along this line, comparisons between the spectrum of alterations in relapses that arise 
in different upfront treatment protocols may provide valuable information on the 
association between the tumor genome, protocol components and outcome. Here, we 
performed a comprehensive characterization of relapsed BCP-ALL cases that developed 
in the context of three completed Dutch upfront studies, ALL8, ALL9 and ALL10. In 
total, 123 pediatric BCP-ALL relapses and 77 paired samples from primary diagnosis 
were analyzed for alterations in 22 recurrently affected genes. We found pronounced 
differences in relapse alterations between the three studies. Specifically, CREBBP mutations 
were observed predominantly in relapses after treatment with ALL8 and ALL10 which, in 
the latter group, were all detected in medium risk-treated patients. IKZF1 alterations were 
enriched 2.2-fold (P=0.01) and 2.9-fold (P<0.001) in ALL8 and ALL9 relapses compared 
to diagnosis, respectively, whereas no significant enrichment was found for relapses that 
were observed after treatment with ALL10. Furthermore, IKZF1 deletions were more 
frequently preserved from a major clone at diagnosis in relapses after ALL9 compared 
to relapses after ALL8 and ALL10 (P=0.03). These data are in line with previous studies 
showing that the prognostic value of IKZF1 deletions differs between upfront protocols 
and is particularly strong in the ALL9 regimen. In conclusion, our data reveal a correlation 
between upfront treatment and the genetic composition of relapsed BCP-ALL.
33
Upfront treatment influences the genetic alterations in relapsed BCP-ALL
INTRODUCTION
Despite the improved survival rate for B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL), relapsed ALL remains one of the leading causes of cancer related death in 
children.1-3 Since ALL relapse involves the outgrowth of therapy resistant leukemic cells, 
a substantial fraction of genomic alterations identified at relapse can be traced back in 
samples obtained at diagnosis, either fully clonal or as minor clones.4-12 Furthermore, 
additional genomic alterations are usually present at relapse, which are acquired during 
or after therapy and may contribute to relapse development.13-15 Therefore, the origin of 
genomic alterations identified at relapse, may help identify those lesions that are most 
strongly correlated with therapy failure.
Multiple studies have been aimed at investigating the genomic landscape of relapsed BCP-
ALL.4, 11, 12, 16-20 A significant increase in the median number of copy number alterations 
(CNAs) and mutations was observed in BCP-ALL relapse samples, when compared 
to diagnosis.4, 11, 20 These studies show that recurrently affected genes and pathways at 
diagnosis, including those involved in B-cell differentiation, cell cycle regulation, and 
Ras and JAK/STAT signaling, are also observed at relapse, although with different 
frequencies.4, 6, 12, 20, 21 Alterations observed with a higher frequency at relapse, such as 
those affecting IKZF1, TP53, and genes involved in Ras signaling (KR AS, NR AS, PTPN11, 
FLT3 and BR AF), may play a role in therapy resistance and could be of prognostic value at 
the time of diagnosis.6, 22-24 By contrast, mutations in drug metabolism (NT5C2, PRPS1) 
or chromatin modification (CREBBP) regularly appear to arise during initial therapy, and 
become detectable only at relapse.13-16
Different chemotherapy regimens may have different effects on every leukemic subclone 
present in a patient, resulting in changes in clonal dynamics and, in some cases, survival 
of distinct subclones.25 For example, KR AS hotspot mutations were found to be associated 
with methotrexate resistance and vincristine sensitivity of leukemic cells in vitro and in 
vivo.20 Furthermore, mutations in NT5C2 and PRPS1 appear to confer selective resistance to 
6-mercaptopurine, a fundamental drug used in the maintenance phase of ALL treatment, 
and leukemic cells with these mutations, even when present at extremely low numbers, 
have a strong selective advantage during 6-MP treatment, allowing them to grow out into a 
relapse.14-16, 26 In addition, a therapy resistance phenotype has been described for leukemic 
cells with alterations in IKZF1, a gene in which alterations have a strong prognostic value for 
relapse development.6, 22 However, dependent on the protocol, the predictive value of IKZF1 




prognostic effect was much stronger in ALL9 compared to ALL10, while not significant 
in ALL8.27 These findings suggest that the treatment efficacy of IKZF1-altered BCP- ALL 
depends on timing and dosage of individual chemotherapeutics used in these protocols. 
Therefore, the genetic characteristics of relapsed BCP-ALL might be determined by the 
upfront treatment.
In the period 1991-2012, over 2000 children with newly diagnosed BCP-ALL were 
enrolled in three Dutch ALL treatment trials ALL8, ALL9 and ALL10.3, 28, 29 Within 
each trial, patients were stratified in groups based on risk factors to maximize outcome 
with optimal treatment intensity. However, the parameters used for stratification were very 
different between the three protocols. For example, whereas stratification of patients in 
ALL8 and ALL9 was solely based on classical clinical and cytogenetic parameters, ALL10 
stratification was based on minimal residual disease monitoring.3, 28, 29 Furthermore, 
timing and dosage of the various chemotherapeutic drugs differed considerably between 
protocols and treatment arms and, thus, also between patients with comparable risk 
factors (Table S2.1). One major protocol-dependent difference in DCOG trials ALL8, 
ALL9 and ALL10 was the amount of glucocorticoids (GCs) in relation to the intensity 
of additional chemotherapy that was used. In contrast to ALL8 and ALL10, treatment 
in ALL9 heavily relied on high dose of GCs (dexamethasone) during the induction and 
maintenance phases, particularly in the ALL9 non-high risk (NHR) treatment arm.29 This 
variability in upfront treatment protocols creates an interesting opportunity to study the 
impact of these protocol differences on the genomic architecture of relapsed ALL, which 
to date has not been systematically investigated.
In this study, we characterized 123 relapsed BCP-ALL samples that were treated upfront 
by one of three DCOG studies ALL8, ALL9 and ALL10. Our data indicate that the 
composition of genetic alterations in relapsed BCP-ALL is indeed affected by the upfront 
treatment.
MATERIALS AND METHODS
Patient material and DNA isolation
Relapse samples from a total of 123 BCP-ALL patients were included in this study, all of 
which were obtained from the DCOG biobank with informed consent. These patients 
were treated according to one of three DCOG treatment studies ALL8 (n=39), ALL9 
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(n=55) or ALL10 (n=29). The patients included were a good representation of the total 
cohort of relapsed patients from these trials with respect to gender, risk group, remission 
time, and ploidy status at diagnosis, with the exception of remission time in ALL8 relapses 
(Table S2.2). No infant ALL patients were included in this cohort. Patient characteristics 
are listed in Table S2.3. To investigate whether relapse- associated genetic alterations were 
also present at diagnosis, 77 available paired diagnosis samples were analyzed. Mononuclear 
cells were isolated by Ficoll gradient separation and stored in liquid nitrogen. Genomic 
DNA was extracted from mononuclear cells and purified using a QIAamp purification 
kit (Qiagen, Venlo, The Netherlands).
Multiplex ligation-dependent probe amplification
A targeted screen for copy number alterations (CNAs) in BTG1, CDKN2A/2B, EBF1, ETV6, 
IKZF1, PAX5, RB1 and TP53 (Table S2.4) in diagnosis and relapse samples was performed 
by multiplex ligation-dependent probe amplification (MLPA)56 using SALSA MLPA 
kits P335, ME024 and P056 (MRC-Holland, Amsterdam, The Netherlands) according 
to manufacturer’s instructions.
Targeted sequencing and data validation
Sequence mutations in 21 genes (Table S2.4) were determined in the relapse cohort using 
Ion AmpliSeq-based sequencing (Life Technologies, CA, USA). A total of 10 ng genomic 
DNA was used in each AmpliSeq PCR reaction. After barcoding and adaptor ligation, 
products were purified with Agencourt AMPure XP beads (Beckman Coulter Genomics, 
High Wycombe, UK). Emulsion PCR was performed using OneTouch 200 Template kit 
(Life Technologies, CA, USA). Polymerase and sequencing primers were added to final 
enriched spheres before loading onto the chip. Sequence reads were mapped and analyzed 
using SeqNext software V4.1.1 (JSI, Ettenheim, Germany). Validations were performed by 
Sanger sequencing. Hotspot regions for NT5C2 (exons 11 and 15) were sequenced in 104 
relapses using Sanger sequencing. All primers are listed in Table S2.5. Available complete 
remission samples were used to confirm the somatic status of mutations.
Statistical analysis
Statistical analyses were carried out using R version 3.3.2, Pearson’s Chi-square and Fisher’s 






Genomic profiling of relapsed BCP-ALL
To establish the frequency of recurrent genetic alterations in relapsed BCP-ALL samples, we 
collected 123 BCP-ALL relapse samples from patients that relapsed after upfront treatment 
according to ALL8 (n=39), ALL9 (n=55) or ALL10 (n=29, Figure S2.1). The included 
relapses represented approximately half of the total number of relapses that occurred in 
each of these protocols (Table S2.2-3). To enable quantitative comparisons between these 
relatively small groups, we focused our study on copy number alterations and mutations 
in a selected set of 22 genes that were found to be recurrently affected in relapsed BCP-
ALL in previous studies.4, 6, 11- 13, 16-22 This set of genes includes B-cell differentiation genes 
(IKZF1, IKZF2, IKZF3, PAX5, and EBF1), genes involved in Ras signaling (KR AS, NR AS, 
PTPN11, FLT3, and BR AF), JAK-STAT signaling ( JAK1, JAK2, JAK3), cell cycle regulation 
(CDKN2A, CDKN2B, and RB1), and drug metabolism (NT5C2, NR3C1 and BTG1), as well as 
genes encoding the histone acetyltransferase CREBBP (CBP), the tumor suppressor TP53, 
and ETS family transcription factor ETV6. Targeted copy number and mutation screening 
was performed using MLPA and Amplicon-based IonTorrent sequencing, respectively 
(Table S2.4-5). Using this approach, we detected an average of 1.3 CNAs and 0.6 sequence 
mutations in the aforementioned genes per relapse sample (range 0-5 and 0-3, respectively).
Figure 2.1. Genomic profiling of relapsed BCP-ALL. (A) Frequency of genetic alterations in pathways 
studied in relapse samples. B-cell differentiation genes include IKZF1, IKZF2, IKZF3, PAX5 and EBF1. 
Cell cycle regulation genes include CDKN2A, CDKN2B, TP53 and RB1. Transcription regulators include 
CREBBP and ETV6. Ras signaling genes include KR AS, NR AS, PTPN11, FLT3 and BR AF. Drug response 
genes are NT5C2, BTG1 and NR3C1. Genes involved in JAK/STAT signaling are JAK1, JAK2 and JAK3. 
(B) Frequency of genetic alterations in the genes studied in relapse samples.
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Genes involved in B-cell differentiation were affected in approximately half of the cases 
(47%), whereas activating mutations in genes of the Ras pathway were found in 30% of 
the relapses (Figure 2.1A). The most frequent genetic alterations identified in these 123 
relapses involved deletions and mutations in IKZF1 (33%), and deletions of the CDKN2A/2B 
locus (30%; Figure 2.1B and S2).30 Alterations in ETV6 and PAX5 were found in 25% and 
20% of the BCP-ALL relapse samples, and 11% carried mutations in the HAT domain of 
CREBBP. Ras pathway mutations mostly involved KRAS (15%) or NRAS (8%; Figure 2.1B) 
and BR AF mutations were not identified in our relapse cohort. Four relapses were found 
to carry NT5C2 mutations. BTG1 deletions (7%) and NR3C1 mutations (2%), which may 
be correlated with GC resistance,4, 31 were not common in these relapse samples. IKZF1 
alterations (P<0.0001; Fisher’s exact test) and mutations in CREBBP and NT5C2 (P<0.0001 
and P<0.01; Fisher’s exact test) were more frequently found in relapsed ALL compared to 
primary diagnosis (Table S2.6), which is in line with previous studies.11, 13-15, 21
Genomic presentation of relapse is influenced by upfront treatment
To address the question whether the genetic makeup of relapse varies between upfront 
treatment studies, we compared genomic alterations observed in relapses that occurred 
after treatment according to ALL8, ALL9, and ALL10. First, we compared the prevalence 
of genetic alterations in ALL relapses between the three studies as a whole because 
frequencies of these alterations at time of diagnosis, so before risk stratification, will be 
similar. The average number of alterations per relapse sample for the ALL8, ALL9 and 
ALL10 groups was 1.8, 2.1 and 1.8, respectively, which was not significantly different 
(Figure 2.2A). Compared to diagnosis, we indeed observed differences in the pattern of 
genetic alterations between relapses observed after these three upfront treatment studies. 
Whereas CREBBP mutations were particularly enriched in relapses from patients treated 
according to ALL8 and ALL10, mutations in PTPN11 were increased only in ALL9 relapses 
(Figure 2.2B and Table S2.6). IKZF1 alterations seemed to be increased in all three relapse 
groups, although statistical significance was only reached in the ALL8 and ALL9 cohorts, 
where the increase was 2.2 (P=0.01, Fisher’s exact test) and 2.9- fold (P<0.0001, Fisher’s 
exact test), respectively (Figure 2.2B and Table S2.6). In a comparison among the three 
relapse groups, only the low number of CREBBP mutations in ALL9 relapses (2%) relative 
to those observed in ALL8 (21%) and ALL10 (17%) was found to be significant (P=0.01, 
Fisher’s exact test).
To further correlate the observed changes to treatment, we analyzed the risk- stratified 




showed unequal distributions between the total cohorts: IKZF1 and CREBBP. We reasoned 
that differences in genetic alterations between treatment arms at the time of relapse may be 
caused by both the differential stratification in upfront risk groups at the time of diagnosis, 
and the impact of treatment itself. To study these effects separately, we first analyzed the 
distribution of alterations in these genes at the start of treatment, using available MLPA 
data6, 27 and targeted sequence data from diagnosis cohorts. We noticed that patients with 
IKZF1 deleted leukemia at diagnosis were more frequently stratified in higher risk groups 
in ALL8 and ALL10, whereas in ALL9 there was an equal distribution of IKZF1 deletions 
in the NHR and HR groups (Table S2.7). This suggests that in contrast to ALL8 and 
ALL10, IKZF1 alteration status had no impact on the criteria used for stratification in 
ALL9. To make a similar analysis for CREBBP mutations observed at diagnosis, we made 
use of available mutation data in two cohorts of ALL9 and ALL10 diagnosis samples. For 
ALL8, the mutation data at the time of diagnosis were not available. For patients with 
CREBBP mutations no significant differences in distribution between treatment arms was 
detected in ALL9 nor in ALL10 (Table S2.8). Thus, the variability of alterations in IKZF1 
and CREBBP at time of primary diagnosis is limited.
Next, we compared the deletion and mutation frequencies for these genes in each risk 
group between diagnosis and relapse. The most pronounced increase in IKZF1 deletions 
between diagnosis and relapse was observed in ALL9, where both in the NHR and HR 
group a ~3-fold increase was observed in relapse compared to diagnosis (Figure 2.2C and 
Table S2.9). The standard risk (SR) and high risk (HR) groups of ALL10 were too small 
to draw definitive conclusions, but in the larger medium risk (MR) group no significant 
enrichment of IKZF1 deletions at relapse was observed. With respect to CREBBP, all 
mutations found at the time of relapse after ALL10 treatment were in the MR-treated arm 
and were significantly more common than those observed at primary diagnosis (Figure 
2.2C and Table S2.9). Taken together, these data suggest that, with similar numbers of 
alterations, the composition of genetic alterations in relapsed BCP-ALL varies between 
different upfront treatment protocols and risk groups.
Origin of genetic alterations in relapse
An increased frequency of genetic alterations in relapse compared to diagnosis can be the 
result of therapy resistance of clones that carry this alteration at the time of diagnosis, or by 
selective outgrowth of sub-clonal or newly acquired alterations. To discriminate between 
these two options, we performed genomic analysis in paired diagnosis-relapse samples. 
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Figure 2.2. Frequency of genetic alterations in relapse samples classified by upfront treatment protocols. 
(A) Average number of mutations and CNAs in relapse samples treated by upfront protocols, ALL8, 
ALL9 and ALL10. (B) Comparison of affected gene frequency between diagnosis and relapse. Only 
genes showing significant differences between diagnosis and total relapse are depicted. Details of all 
genes are presented in Table S2.6. (C) Comparison of affected frequency in IKZF1 and CREBBP between 
diagnosis and relapse among upfront risk-stratified treatment groups. The number of samples affected 
is indicated on the top of the bar. Details of the comparison are presented in Table S2.9. Significant 
difference (P<0.01) is indicated by double asterisks.
Of 123 relapsed BCP-ALL, paired diagnosis samples were available for 77 patients, of 
which 62 carried alterations in at least one of the 21 genes observed at relapse. For those 62 
cases, all CNAs (n=103) and sequence mutations (n=48) identified at relapse were screened 
in matched samples taken at primary diagnosis using MLPA and Sanger sequencing, 
respectively (Figure 2.3A and Table S2.10). In this way, 47 CNAs (45%) and 16 SNVs 
(33%) were found to be present in major clones at diagnosis. Again, we first compared 
alterations between the three studies and subsequently between treatment arms separately. 
The average number of alterations that were absent in the major clone at diagnosis was 
highest in relapse that occurred after treatment according to ALL8, and lowest in ALL10-




Genetic alterations in B-cell differentiation genes were frequently found to be present 
already at diagnosis, particularly those in IKZF1. In fact, in 23 of the 29 patients with IKZF1 
alterations at relapse (79%), the alteration was preserved from diagnosis (Figure 2.3B). The 
six patients in which the alterations were not observed at diagnosis did not show clustering 
within a specific treatment arm or study. The number of Ras pathway mutations preserved 
from the major clone at diagnosis was highly variable between genes, ranging from 8 out of 
13 mutations (62%) in KR AS to only 1 out of 6 mutations (17%) in PTPN11 (Figure 2.3B). 
By deep-sequencing of diagnosis samples, which was performed for 21 cases, the majority 
of Ras mutations (18/22) could be traced backed to the paired diagnosis sample, 7 of which 
were present as subclones. Deep-sequencing revealed that CREBBP mutations, which were 
found to be more common in relapses treated after ALL8 and ALL10 compared to ALL9 
(Figure 2.1C), were predominantly acquired at relapse (4 out of 6; Figure 2.3B and Table 
S2.10). Deletions of the CDKN2A/2B locus, frequently present in a homozygous state, were 
found to be conserved between diagnosis and relapse in 46% of the cases, but the presence 
of only three MLPA probes in this locus precluded a more detailed comparison. Therefore, 
we reanalyzed these 13 samples using the ME024 MLPA kit, which contains 23 probes 
that span a region of 36.6 Mb surrounding the 9p21.3 locus. For only two cases (15%), the 
CDKN2A/2B deletions appeared to be identical, even after comparison with high-density 
SNP-array-based copy number analysis, whereas in all of the other cases the deletions were 
different (Figure S2.3). This suggests that CDKN2A/2B deletions drive leukemogenesis, 
but are not selected for in upfront therapy
Next, we analyzed the clonal origin of relapse-associated IKZF1 alterations in the context 
of upfront treatment intensity within this paired sample cohort. Notably, whereas the 
frequency of IKZF1 alterations that occurred in ALL8, ALL9 and ALL10 relapses were 
not significantly different (Figure 2.2B and 3A), the fraction of IKZF1 alterations that was 
preserved from the major clone at diagnosis was found to be only 40% in ALL8 compared 
to 89% and 83% in ALL9 and ALL10, respectively (Figure 2.3A). Therefore, to compare 
the IKZF1 alterations in the context of upfront treatment, we selectively focused on these 
preserved IKZF1 alterations. This comparison did result in a striking difference among 
the three studies (P=0.033, Fisher’s exact test; Figure 2.3C). A total of 43% (16/37) of 
relapses treated after ALL9 carried IKZF1 alterations that originated from the major clone 
at diagnosis, compared to 11% in ALL8 (2/19) and 24% in ALL10 (5/21). The preserved 
IKZF1 alterations were detected in 44% and 42% of relapses after ALL9-NHR (11/25) and 
ALL9-HR (5/12), respectively. In the relapses after medium risk regimen of ALL8 and 
ALL10, 15% (2/13) and 31% (5/16) carried IKZF1 alterations originating from a major 
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clone at diagnosis. No relapses with preserved IKZF1 alterations were observed in patients 
with upfront standard risk regimen in ALL8 and ALL10. Together, these data suggest 
that the differences observed at relapse were a direct consequence of the upfront treatment.
Figure 2.3. Origin of genetic alterations in relapsed BCP-ALL. (A) Relapse-associated alterations in 
each patient and their status (preserved or acquired). Patients are displayed in columns sorted by upfront 
treatment protocols. Genes are shown in rows grouped by their corresponding pathways. For genes in-
dicated in bold, double rows represent homozygous or compound heterozygous alterations. Preserved 
alterations are shown in dark grey (CNA) or solid dots (mutation), while acquired alterations are depicted 
in light grey (CNA) or open circles (mutation). Numbers of preserved alterations and total numbers of 
alterations identified at relapse in each patient are shown at the bottom. Five genes not indicated in this 
figure (IKZF3, BR AF, FLT3, JAK1, JAK2) were wild type in all tested samples. Details of all alterations 
are presented in Table S2.10. (B) Frequency of patients that carried preserved alterations in 11 genes 
studied. The number of patients studied for each gene is displayed in brackets. (C) Frequency of patient 





Several studies have demonstrated that the genomic landscape of relapsed ALL differs from 
that observed at diagnosis, both in the number of alterations and the genes that are affected.4, 
5, 11, 12 These differences likely originate from the combined effect of continuous evolutionary 
progression of the dividing leukemic cells, and therapy- induced genomic instability and clonal 
outgrowth. In this study, we have investigated the impact of treatment on the presentation of 
genetic alterations in relapsed ALL. To enable a good comparison between relapses arising 
in different upfront treatment protocols, we have focused on a limited set of 22 genes known 
to be recurrently affected. We collected 123 relapse samples from patients treated according 
to Dutch Childhood Oncology Group studies ALL8 (1991-1996), ALL9 (1997-2004) and 
ALL10 (2004-2012). Although more late relapses in ALL8 and younger relapses in ALL10 
were included in this study, none of the investigated genes showed significant difference 
regarding the remission time in ALL8 relapses and diagnosis age in ALL10 relapse (Table 
S2.12-2.13). The comparisons revealed that relapses that arise in the context of these upfront 
treatment protocols show differences in these common genetic alterations, with frequent 
CREBBP mutations in ALL8 and ALL10 relapses, and IKZF1 alterations being particularly 
common in relapses from patients treated according to the ALL9 protocols.
CREBBP mutations cluster in the histone acetyl transferase (HAT) domain, which mediates 
the acetylation of lysine residues in various proteins, including histone 3 lysine 18 and 27 
(H3K18 and H3K27).13, 32 Mutations affecting CREBBP occur in 18% of relapsed childhood 
ALL cases, and up to 30% in high hyperdiploid and hypodiploid ALL relapses.13, 32-34 These 
mutations originate from major or minor clones at primary diagnosis, but in a similar number 
of cases these mutations are newly acquired at the time of relapse.13, 34 It has been shown 
that CREBBP mutations impair H3K18 acetylation in mouse embryonic fibroblasts, ALL 
cell lines and patient-derived xenografts, and may cause reduced expression of CREBBP 
targets, including glucocorticoid responsive genes.13, 35 Preliminary studies have indicated 
that CREBBP impairment correlates with a glucocorticoid resistance phenotype but since 
this could not be demonstrated in in vitro models, this phenomenon has not yet been fully 
resolved.35 The higher number of CREBBP mutations in ALL8 and ALL10 relapses may be 
explained by the higher frequency of cases with high hyperdipoid cytogenetics (28% and 25%, 
respectively) compared to those observed in ALL9 (15%; Table S2.2). Indeed, the majority 
of CREBBP mutations in our study (62%) were identified in high hyperdiploid cases (Table 
S2.3). However, since none of the eight high hyperdiploid relapses in ALL9 were found 
to carry CREBBP mutations, the possibility remains that these mutations are less likely to 
contribute to relapse in ALL9-based protocols, for example because of the absence of a strong 
selective pressure for these alterations.
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The high frequency of preserved IKZF1 alterations in ALL9 relapses compared to those 
in ALL8 and ALL10 is remarkable. Many ALL study groups have reported that patients 
with IKZF1 alterations at primary diagnosis have a higher risk of relapse, but the prognostic 
value appeared to be different between various protocols.6, 27, 36-42 This observation already 
suggests that the contribution of IKZF1 dysfunction on relapse development is dependent 
on the treatment that patients received at primary diagnosis. We noticed that IKZF1 
deletions in children treated according to ALL9 are equally distributed between the risk 
groups, whereas in ALL10 IKZF1-deleted leukemias are stratified to higher risk groups 
and, thus, received more intense treatment compared to wildtype leukemias. Since the 
stratification in ALL10 is mainly based on early therapy response,1-3 this observation 
indirectly suggests that IKZF1- alterations influence the response during the first courses of 
ALL10 treatment. We previously demonstrated that IKZF1 alterations substantially impair 
the GC-response of both normal and leukemic cells,43 suggesting that the contribution of 
IKZF1 alterations on therapy resistance and relapse may be dependent on the intensity of 
the GCs used in the upfront treatment. The current study is consistent with this notion, 
showing a particularly high percentage of preserved IKZF1 alterations in patients that 
relapsed after ALL9-based treatment, a treatment regimen which heavily relies on high 
doses the GC dexamethasone (Table S2.1).29 In fact, the median risk arm of ALL10, 
which uses similar doses of dexamethasone as the ALL9 arms, has relatively lower number 
of preserved IKZF1 alterations, suggesting that the other administered components in 
ALL10-MR are able to overcome the IKZF1-induced GC resistance in a subset of cases. 
The observations on preserved IKZF1 alterations also illustrate the importance of including 
genomic data at the time of diagnosis to determine the contribution of specific genetic 
events to relapse development.44-46
The differences in common genetic alterations of relapses observed in these three upfront 
treatment studies provide insights that will aid further improvements of childhood ALL 
therapy by adapting risk group stratification or study design. We have recently shown that 
the combined loss of IKZF1 and BTG1 results in even worse survival rates compared to loss 
of IKZF1 alone.47 Furthermore, several studies have demonstrated that IKZF1 deletions in 
the presence of specific other gene deletions are associated with poorer survival, which 
provides a tool for refined risk stratification that will be implemented in future ALL 
treatment studies.44-46 Alterations affecting IKZF1 result in impaired lymphoid maturation 
of precursor B-cells, and are highly frequent in BCR-ABL1-positive leukemia.48-50 A study by 
Churchman et al. revealed that IKZF1 alterations induce a stem-cell like phenotype and act 




poor response to tyrosine kinase inhibitors (TKI) observed in IKZF1-deleted BCR-ABL1- 
positive ALL, which is a tailored therapy for individuals with this type of leukemia,52,53 
could be reversed with retinoids, thus providing an important treatment opportunity that 
deserves further exploration, both in BCR-ABL1-positive and negative ALL.51, 54 Taken 
together, these studies provide promising new concepts for targeting the pathways that 
are affected by IKZF1 deletions.
Glucocorticoids (GCs) are key components in ALL treatment.55 Our results suggest that 
upfront protocols like ALL9, which rely for a significant part on high GCs and lack, for 
instance, intensive asparaginase courses, are less effective in eradicating leukemias with 
IKZF1 alterations. This would imply that such protocols are less favorable for the future 
treatment of patients with IKZF1 deletions.
In conclusion, we have shown that genetic characterization of relapsed ALL in the context 
of upfront treatment reveals striking differences in the composition of common genetic 
alterations of relapse while providing important insight into mechanisms of therapy 
response. Our data indicate that therapy that relies on high doses of GC results in a higher 
percentage of IKZF1-altered relapses. These studies may guide the design of new protocols, 
particularly when extended to larger sample series and more detailed drug comparisons.
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SUPPLEMENTARY MATERIAL



















420 420 1386 1260 350 1050
Vincristine (mg/m
2
) 12 12 68 62 9 48
Daunorubicin (mg/m
2





5 2 11 5 34
High dose methotraxate (gr/m
2
) 8 20 6 12 20 20
Cytarabine (mg/m
2
) 150 1800 0 320 1200 1200
Cyclophosphamide (mg/m
2
) 1000 3000 0 320 2000 2000
Mercaptopurine/methotraxate 
maintain (weeks)
79 75 70 63 81 67
1
For comparison: 10 mg Prednisolone is calculated as 1 mg Dexamethasone; 10 mg Adriamicin is 
calculated as 10 mg Daunorubicin. 
2
Asparaginase is calculated as ‘weeks of Asparagine depletion’ to 
correct for native versus Pegylated Asparaginase. 
3
In ALL8-SR, a randomized 5 versus 25 weeks of 
Asparaginase treatment. Due to the low number of cases relapsed after HR arms in ALL8 (n=2) and 
ALL10 (n=1) that were included in our study, we excluded these treatment arms and do not describe 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S2.3. Characteristics of relapsed BCP-ALL in this study
Details can be found at: http://links.lww.com/HS/A53
Table S2.4. Genes targeted for copy number and mutation analysis
Gene Alterations CNAs Mutations
# of MLPA Probes exons # of Amplicons exons
BR AF MTs 0 na 1 15
BTG1 CNAs 4 1,2 0 na
CDKN2A CNAs + MTs 2 2,5 9 1-4
CDKN2B CNAs + MTS 1 2 7 1,2
CREBBP MTs 0 na 67 1-31
EBF1 CNAs + MTs 4 1,10,14,16 0 na
ETV6 CNAs + MTs 6 1-3,5,8 12 1-8
FLT3 MTs 0 na 16 12-14,16,20
IKZF1 CNAs + MTs 8 1-8 18 1-7
IKZF2 MTs 0 na 18 1-7
IKZF3 MTs 0 na 20 4,8
JAK1 MTs 0 na 5 16-21
JAK2 MTs 0 na 12 16-21
JAK3 MTs 0 na 10 13-16
KR AS MTs 0 na 7 2-4
NR3C1 MTs 0 na 22 1-7
NR AS MTs 0 na 3 2,3
NT5C2 MTs 0 na 2 11,15
PAX5 CNAs + MTs 7 1,2,5-8,10 14 1-10
PTPN11 MTs 0 na 5 3,8,13
RB1 CNAs + MTs 5 6,14,19,24,26 40 1-24
TP53 CNAs + MTs 15 na 18 3-9,11
Total # of probes CNAs + MTs 52 na 306 na
MLPA: Multiplex ligation-dependent probe amplification.
CNAs: Copy number alterations. MTs: Mutations. na: Not applicable.
Table S2.5. Primers used for Sanger sequencing validation
Details can be found at: http://links.lww.com/HS/A53
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Table S2.7. Frequency of IKZF1 alterations in diagnosis stratified by risk group
Upfront protocol IKZF1 altered IKZF1 wildtype Frequency P-value (Fisher’s exact)
ALL8 (1)
SR 2 17 11%
0.330MR 12 31 28%
HR 3 8 27%
ALL9 (2)
NHR 14 89 14%
1
HR 4 24 14%
ALL10 (1)
SR 6 99 6%
0.007MR 37 187 17%
HR 6 21 22%
(1)
Frequency was calculated from a previous study.
27
 The ALL8 cohort used in this study was found to 
be biased due to the higher white blood cell counts. 
(2)
Frequency was calculated from a previous study.
6
Table S2.8. Frequency of CREBBP mutations in diagnosis stratified by risk group
Upfront protocol* CREBBP altered CREBBP wildtype Frequency P-value (Fisher’s exact)
ALL9
NHR 6 91 6%
0.341
HR 0 26 0%
ALL10
SR 3 72 4%
0.452MR 3 158 2%
HR 0 31 0%
*: No data are available for 8 samples in ALL9 and 12 samples in ALL10.
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Table S2.10. Genetic alterations in relapse samples sorted by gene
Details can be found at: http://links.lww.com/HS/A53









Average number of 
alterations per relapse sample
Preserved Acquired Preserved Acquired Preserved Acquired
ALL8 19 8 13 0 15 0.42 1.47
ALL9 37 29 34 7 12 0.97 1.24
ALL10 21 10 9 9 6 0.90 0.71
Table S2.12. Statistical analysis of frequency of alterations in ALL10 relapses in the two age groups (1-9 
years old, and >10 years old) of diagnosis
Gene
Age 1-9 Age >10
Fisher’s exact p value
Mutated Wildtype Mutated Wildtype
IKZF1 7 17 0 5 0.30
PAX5 3 21 2 3 0.19
EBF1 2 22 0 5 1.00
KR AS 5 19 0 5 0.55
NR AS 3 21 0 5 1.00
PTPN11 1 23 0 5 1.00
CDKN2AB 5 19 2 3 0.57
ETV6 6 18 0 5 0.55
CREBBP 4 20 1 4 1.00
RB1 4 20 1 4 1.00
BTG1 1 23 1 4 0.32
TP53 1 23 0 5 1.00
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Table S2.13. Statistical analysis of frequency of alterations in ALL8 relapses with early (<2 years) and 
late (>2 years) relapses
Gene
Early relapse Late relapse Fisher’s exact p value
Mutated Wildtype Mutated Wildtype
IKZF1 2 6 10 21 1.00
PAX5 1 7 3 28 1.00
EBF1 0 8 2 29 1.00
KR AS 1 7 1 30 0.37
NR AS 1 7 4 27 1.00
PTPN11 1 7 1 30 0.37
CDKN2AB 4 4 7 24 0.19
ETV6 2 6 7 24 1.00
CREBBP 3 5 5 26 0.32
RB1 1 7 1 30 0.37
BTG1 1 7 0 31 0.21
TP53 2 6 1 30 0.10
Figure S2.1. Schematic of cohorts and methods used in this study. CNA: copy number alteration; 










































































































































































































































































































Upfront treatment influences the genetic alterations in relapsed BCP-ALL
Figure S2.3. CDKN2A/B deletions in paired diagnosis and relapse ALL samples. (A) Samples were 
analyzed using the MLPA ME024 kit. A total of 33 probes (red vertical lines) are included in this kit, 
which span a 36.6 Mb region from 9p24.3 to 9p13.2. Deletions in diagnosis and relapse samples are 
indicated as brown and dark blue, respectively. Paired samples of cases P0019 (B) and P0021 (C) were 
analyzed by CytoScan HD arrays (Affymetrix), which confirmed that the deletions observed at diagnosis 
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Pathogenic mutations in relapse-associated genes in pediatric acute lymphoblastic leukemia 
may improve risk stratification when detected at subclonal levels at primary diagnosis. 
However, to detect subclonal mutations upfront, a deep-sequencing approach with high 
specificity and sensitivity is required. Here, we performed a proof- of-principle study to 
detect low-level mosaic RAS pathway mutations by deep sequencing using random tagging-
based single molecule Molecular Inversion Probes (smMIPs). The smMIP-based approach 
could sensitively detect variants with allele frequency as low as 0.4%, which could all be 
confirmed by other techniques. In comparison, with standard deep-sequencing techniques 
we reached a detection threshold of only 2.5%, which hampered detection of 7 low-level 
mosaic mutations representing 24% of all detected mutations. We conclude that smMIP-
based deep-sequencing outperforms standard deep-sequencing techniques by showing 
lower background noise and high specificity, and is the preferred technology for detecting 
mutations upfront, particularly in genes in which mutations show limited clustering in 
hotspots.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Although 
long-term overall survival reaches 90% in most Western countries, relapse occurs in at least 
10% of children with ALL.1,2 Recent studies have demonstrated that relapses in pediatric 
ALL can arise from minor subclones present at diagnosis and genetic alterations identified 
at relapse can be traced back to subclonal levels in samples taken at diagnosis, sometimes 
in just a few percent of the tumor cells.3-8 This raises the interesting possibility to use 
subclonal mutations in relapse-associated genes for upfront risk stratification at time of 
diagnosis and during treatment. To determine the prognostic value for risk of relapse of 
subclonal mutations in candidate genes, unselected cohorts of diagnosis samples need to 
be screened for (low-level) mosaic mutations.
Next-generation sequencing (NGS) provides the opportunity to rapidly sequence genes 
of interest at high read depth and commonly uses PCR-based strategies for targeted 
enrichment. The error rate introduced by most sequencing platforms, as well as by the 
DNA polymerase during amplification is reasonably low and can be compensated by 
creating more sequencing depth. However, when applying this approach for the detection 
of low-level mosaic mutations, sensitivity and accuracy of variant calling is challenged.9,10 
Particularly when applying prospective screening of subclonal mutations, where mutation 
status and location is not known in advance, the reliable detection of mutations is 
problematic and validations are demanding. Therefore, it is essential to use an approach 
that minimizes sequencing errors and accurately quantifies subclonal burden of targeted 
genes of interests.
Molecular Inversion Probes (MIPs) have been used to perform targeted deep- sequencing 
using multiplex targeted capture of selected genomic regions of interest.11 Recently, this 
technology was adapted with single molecule tagging to enable the reliable detection of 
low-level mosaic mutations. This so-called single molecule Molecular Inversion Probe 
(smMIP) technology allows the clustering of reads amplified from the same template DNA 
molecule, which is subsequently used to generate single molecule consensus (smc) reads.12 
Variant calls derived from these smc-reads contain much lower per-base substitution 
error rates, hence creating higher specificity for detecting low variant allele frequency 
(VAF) mutations in targeted genes.12 As such, this approach may be highly suitable for 
determination of clinically relevant low-level mosaic mutations in leukemia samples.
In this study, we aimed to develop a smMIP-based NGS assay with a lowest possible false-




samples. As a pilot study, we made use of the fact that mutations in RAS pathway genes are 
common in relapsed ALL, and frequently originate from a minor or major clone at initial 
diagnosis. We applied the smMIP approach to detect subclonal KR AS, NR AS and PTPN11 
mutations in 21 ALL diagnosis samples from patients with mutations in these genes at 
time of relapse. We evaluated the performance of the smMIP approach, and assessed its 
specificity. Our data indicate that smMIP-based NGS is able to accurately detect low-level 
mosaic mutations in leukemia samples down to a level of 0.4%.
MATERIALS AND METHODS
Patient materials and DNA isolation
A total of 21 primary diagnosis ALL samples from children who later developed relapse 
were included in this study. These patients carried previously identified mutations in KRAS 
(n=11), NR AS (n=8) and PTPN11 (n=2) at the time of relapse (Table S3.1). Genomic 
DNA of the diagnosis sample was extracted from mononuclear cells and purified using a 
QIAamp purification kit (Qiagen, Valencia, CA, USA), followed by sequencing of targeted 
amplicons in KR AS, NR AS or PTPN11 using two alternative deep sequencing approaches.
smMIP-based sequencing
The smMIP technology (Figure 3.1) was applied according to a previously published 
protocol.12 These smMIP probes carry two 5-nt stretches of degenerate bases, which offers 
the theoretical possibility to distinguish over 1 million captured molecules (Figure 3.1A). 
The smMIP probes targeting exons in RAS pathway genes that carry hotspot mutations 
were designed (Figure 3.1B and Table S3.2), ordered (Integrated DNA Technologies, 
Leuven, Belgium), pooled and phosphorylated as previously described.12 The genomic 
regions of interest were captured using 100 ng of genomic DNA and 43.8 picomole of 
each probe (resulting 800 smMIP molecules per DNA molecule) for each reaction (Steps 
1-3 in Figure 3.1C). Subsequently, the uniquely- tagged circular molecules were amplified 
in the presence of sample-specific barcodes, using PCR containing 23 cycles of 10 seconds 
at 98°C, 30 seconds at 60°C and 30 seconds at 72°C (Steps 4-5 in Figure 3.1C). PCR 
products were purified using Agencourt AMPure XP beads (Beckman Coulter Genomic, 
Brea, CA, USA). Paired-end sequencing (2x150 bp) was performed using the Illumina 
NextSeq 500 Desktop Sequencer (Illumina, San Diego, CA, USA; Step 6 in Figure 3.1C). 
Reads were mapped to the human reference genome (hg19) using SeqNext software (v4.2.5, 
JSI, Ettenheim, Germany).
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Figure 3.1. Overview of the smMIP approach.
12
 (A) A smMIP consists of two 16–24 nucleotides (nt) 
targeting arms, the extension and the ligation probe, joined by a constant 30 nt backbone. Each smMIP 
molecule contains two unique random 5 nt degenerate molecular tags, which could theoretically dis-
tinguish over 1 million captured molecules. (B) smMIPs are designed to target both the sense and the 
antisense DNA strand. (C) Schematic of the smMIP approach. Phosphorylated smMIP probes hybridize 
to the targeted genomic region. The gap is filled through extension and ligation reactions. After exonu-
clease treatment, only circularized smMIP probes are left, which are subsequently amplified by PCR 
and sequenced. (D) Schematic of the formation of a single molecule consensus read (smc-read) from a 
tag-defined read group (TDRG). Raw reads from the same probe and sharing the same molecule tag 
form a TDRG in which random errors (yellow) are filtered out and true variants (red) are kept based on 
the presence in >70% of the raw reads. (E) The smc-reads are used to call variants. Variants are called if 
they are supported by at least 5 smc-reads.
In order to evaluate the efficiency of random tags in eliminating amplification and 
sequencing errors during data analysis, we analyzed sequencing data in two alternative 
ways: 1) a standard variant calling setting using raw sequencing reads (after trimming the 
10-nt random tags) and, 2) a smMIP-based consensus variant calling setting that makes 




mapped to the human reference genome (hg19) and analyzed using SeqNext software 
(v4.2.5, JSI, Ettenheim, Germany). Variants were called when present in at least 200 raw 
reads with a VAF>0.5%. In the latter method, the raw sequencing reads that align to 
the same genomic region and share the unique molecular tag form a tag-defined read 
group (TDRG; Figure 3.1D and Figure S3.1). Each TDRG composed of at least 5 raw 
sequencing reads was used to form a single molecule consensus read (smc-read). Within a 
TDRG, a variant was established to be valid (and was thus maintained in the smc-read) 
when 70% of the raw reads contained the same nucleotide substitution. Other variants 
were determined random errors and were excluded from the analysis. The smc-reads were 
used to call variants occurring in the samples. Variants were called when present in at least 
5 smc-reads (Figure 3.1E).
Ampliseq-based deep sequencing
As an alternative method for deep sequencing, we used a previously developed Ion 
Ampliseq sequencing panel.13 Primers targeting the three genes were designed using Ion 
Ampliseq designer (version 1.2.9, Life Technologies, Carlsbad, CA, USA; Table S3.3). To 
minimize amplification bias, four independent PCR reactions with each 15 ng of genomic 
DNA as input (60 ng in total) were performed for each amplicon. After barcoding and 
adaptor ligation, products were purified with Agencourt AMPure XP beads (Beckman 
Coulter Genomics, Brea, CA, USA). Emulsion PCR was performed using OneTouch 200 
Template kit (Life Technologies, Carlsbad, CA, USA). Polymerase and sequencing primers 
were added before loading onto the chip. Sequencing was performed on the Ion Personal 
Genome Machine (PGM) System (Life Technologies, Carlsbad, CA, USA). Sequence 
reads were mapped to the human reference genome (hg19) and analyzed using SeqNext 
software (v4.2.5, JSI, Ettenheim, Germany). Variants were called when present in at least 
200 raw reads with a VAF>0.5%.
Sanger sequencing
Sanger sequencing was performed in order to validate one mutation (KRAS p.G12A) in patient 
P0098 observed by the smMIP-based consensus variant calling approach (VAF=16%), but 
missed by standard deep sequencing approaches. The following PCR primers were used 
for amplification and sequencing: forward TCATGAAAATGGTCAGAGAAACC and 
reverse AAAAGGTACTGGTGGAGTATTTGA.
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RNase H2 based PCR
In order to validate low-level mosaic variants identified by the smMIP-based consensus 
variant calling approach, RNase H2 based PCR (rhPCR) assays were performed (Figure 
S3.2).14 The allele-specific primers (Integrated DNA Technologies, Leuven, Belgium) 
contain the mutant RNA base at position -6 and a 3’ mismatch that prevents extension 
during PCR (Figure S3.2A and Table S3.4). Extension can only occur when the DNA-
bound primer is cleaved by the RNase H2 enzyme to remove the 3’ mismatched sequence 
(Figure S3.2B). PCR was performed in 10 µl reactions, each containing 10 ng of genomic 
DNA, 200 nM of each primer, 5ul 2x Bio-Rad iQ SYBR Green Supermix (Bio-Rad, 
Hercules, CA, USA), and 200 mU RNase H2 enzyme (Integrated DNA Technologies, 
Leuven, Belgium). Following 2 minutes at 95°C, the PCR included 40 cycles of 10 seconds 
at 95°C and 30 seconds at the optimal annealing temperature for each primer pair (range 
60-65°C). PCR products were visualized on a 2% gel or the Agilent 4200 Tapestation 
system (Agilent, Santa Clara, CA, USA).
RESULTS
Mutations in the RAS pathway genes KR AS, NR AS and PTPN11 are relatively common 
in relapsed ALL, and frequently originate from a minor or major clone at initial 
diagnosis.5,15,16 To increase the chance to detect low-level mosaic mutations, we made use of 
this phenomenon and selected 21 ALL diagnosis samples in which we previously identified 
mutations in one of these RAS genes in the major clones at relapse (Table S3.1). Next to 
the smMIP-based enrichment of the mutation hotspot regions in these RAS pathway 
genes, we used for comparison an Ampliseq enrichment panel that we previously designed 
for the same regions. Subsequently, we evaluated the performance of low frequency variant 
calling between routine variant calling pipelines applied to both datasets, and a sensitive 
consensus-based variant calling strategy.
Variant calling from deep sequencing raw reads
The smMIP-based and Ampliseq-based amplicons carry linkers for Illumina and 
IonTorrent PGM sequencing platforms, respectively. Although both platforms sequence 
DNA by monitoring the addition of nucleotides during DNA synthesis, they use different 
chemistry, which may result in differences in sequencing performance. Therefore, we 
evaluated the overall performance of the two sequencing strategies, by first applying 
similar analysis and variant calling pipelines to the two raw datasets. Average read depth 




103,763 for the smMIP-based amplification (Figure S3.3). To reveal the level of noise we 
analyzed the results obtained after sequencing of two DNA samples from healthy donors 
and defined that, for both methods, 99.8% of the called variants had a VAF<0.5%, and that 
the number of called variants raised rapidly below a VAF of 0.5%, suggesting that these 
variants predominantly represent sequence errors (Figure S3.4). Based on this observation, 
we only considered variant calls in the leukemia samples with VAF>0.5%.
Figure 3.2. Overview of RAS mutations detected in the diagnosis samples. (A) The total number of 
SNVs observed by Ampliseq and smMIP raw reads. (B) The VAF of 21 variants determined by the two 
approaches correlates well. All of these variants were located in hotspot regions. (C) VAF of variants 
that were only identified by one method. Out of 28 variants, five were located in hotspot regions (HS; 
Orange). (D) RAS mutations detected in the diagnosis samples by analysis of Ampliseq reads and smMIP 
raw reads. Top panel shows sample IDs with the RAS pathway mutation detected in the relapse sample. 
All called variants (before filtering) are depicted as dots, ranked by their genomic position in each vertical 
panel. Variants that did not pass filtering are colored in blue, while variants that passed the detection 
limit are colored in orange (known hotspot mutation) or black (non-hotspot mutation). The cut off 
used for calling of the variants using Ampliseq and smMIP raw reads analysis was VAF >0.5% and 
>200 variant reads. We detected 26 variants using Ampliseq and 44 variants using smMIP raw reads. 
Blue circles mark variants previously identified in the paired relapse sample (Table S3.1). Details of all 
identified mutations are displayed in Table S3.5.
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In the 21 diagnosis samples, a total of 26 single nucleotide variants (SNVs) were called 
in the Ampliseq reads, and 44 SNVs were found in the smMIP raw reads (Table S3.5). 
Of these variants, 21 were identified by both approaches with highly comparable allele 
frequencies (Figure 3.2A and 3.2B), all of which were located in mutation hotspots as 
expected for RAS pathway mutations (Table S3.5 and S3.6).
Discordancy between the two methods was exclusively observed for variants called in 
the low-mosaic range (VAF<2.5%; Figure 3.2C), and the majority of these were located 
outside the hotspots (Figure 3.2C), indicating high false-positive rates in Ampliseq reads 
(3/5; 60%) and smMIP raw reads (20/23; 87%). Furthermore, none of these variants 
reappeared in the relapse sample, whereas 16 variants that were identified by both 
approaches, including 7 with low VAF at time of diagnosis (range 0.8-13%), were present 
at relapse (Figure 3.2D). Collectively, we conclude that the two methods perform similarly 
in detecting single nucleotide substitutions that are present in at least 5% of the leukemic 
cells (VAF>2.5%), but generate many variants with lower confidence below this threshold.
smMIP-based consensus variant calling
The smMIP raw sequence reads carry random single-molecule tags that allow an additional 
analysis step that corrects for post-capture amplification bias and sequence errors by 
generating single molecule consensus (smc) reads (Figure 3.1 and Figure S3.1). This 
provides the opportunity to obtain lower numbers of false positive variant calls and better 
estimates of clonality. Smc-reads had an average 142 underling raw smMIP reads (range 
105-174; Figure S3.5A) and each probe, was covered with an average of 336 smc-reads 
(Figure S3.5B). Up to 75% of the targeted genomic regions was covered with at least 2 
independent probes, mostly in two orientations. All hotspot regions were targeted with 
more than 3 probes, reaching a total average smc- read coverage of 1,432x (range 512-
2,284x; Figure S3.6). Variants were included only if they were supported by at least 5 
smc-reads (Figure 3.1E).
We assessed whether this smMIP-based consensus calling approach could sensitively 
determine the presence of RAS mutations at primary diagnosis. The total number of 
variants detected in smc-reads (301 variants) was drastically lower compared to Ampliseq 
(36,391) and smMIP raw reads (4,258). In total, 29 variants in NRAS (n=13), KRAS (n=13) 
and PTPN11 (n=3) passed filtering, of which 2 were with a VAF below 0.5% (Table 3.1 and 
Figure 3.3A). All mutations were located in known hotspot regions in these genes.5,15,17 




p.G13D) and NR AS (p.G12S, p.G12D, p.G13D), respectively. For each of these two 
samples, one hotspot mutation was detected as major clone at time of relapse (Cases P0098 
and P0160; Table 3.1 and Figure 3.3A). Of the 21 mutations identified at relapse, 18 
could be detected in the paired diagnosis samples, including 2 mutations with a low VAF 
(Figure S3.7). This indicates that the smMIP-based consensus calling approach could 
sensitively detect low-level mosaic mutations.
To confirm low-level mosaic variants called by smc-reads we applied allele-specific RNase 
H2-based PCR (rhPCR), a cost-effective mutation-specific amplification strategy (Figure 
S3.2).14 We analyzed eight low-level mosaic variants including all variants with VAF<1% 
and a variant with a low VAF (1.8%) uniquely detected by the smMIP-based consensus 
approach. Each variant assay was highly specific and did not show cross reactivity for 
variants located in adjacent codons (Figure S3.8 A-B and data not shown). The rhPCR 
technique confirmed all eight variants, including five variants with an allele frequency of 
≤0.6% (Figure 3.3B and Figure S3.8C).
We next evaluated whether the 29 variants called by the smMIP-based consensus approach 
were also found by the above-mentioned strategies, which was the case for 21 mutations 
(72%). One variant was missed by the smMIP raw read analysis, two were missed by the 
Ampliseq-based sequencing analysis and 5 variants were not detected by either of the two 
approaches (Table 3.1). One of these variants was a KR AS p.G12A variant with a VAF 
of 16%. This, however, was most likely caused by the fact that this variant overlapped 
with another KR AS mutation at the same position (p.G12V; VAF=32%). Both variants 
were confirmed by Sanger sequencing (Figure S3.9). Interestingly, of the 13 variants with 
VAF<2.5%, 6 and 5 were missed by Ampliseq and smMIP raw read analysis pipelines, 
respectively (Figure 3.3C and Figure S3.10). Furthermore, whereas all variants detected by 
the smMIP-based consensus approach were hotspot mutations, 23 of the 25 low-frequency 
variants only detected by the standard deep sequencing techniques were located outside 
hotspot regions (Figure 3.3C and Figure S3.10), suggesting that they mainly represent 
false-positives. However, since validation of these 25 variants was not performed, they may 
include some true variants that have been excluded by our stringent filtering approach, 
and should thus be considered as false-negatives of our smMIP-based consensus approach. 
Taken together, we conclude that the random-tagged smMIP approach outperforms 
standard deep sequencing techniques by detecting more low- level mosaic mutations and 
less false positive calls.
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P0053 PTPN11 c.226G>A p.E76K 7 0.4 Yes No rhPCR
P0120 PTPN11 c.205G>A p.E69K 6 0.4 No No rhPCR
P0160 NR AS c.38G>A p.G13D 7 0.6 No Yes (smMIP) rhPCR
P0024 NR AS c.34G>T p.G12C 6 0.6 No Yes (smMIP) rhPCR
P0145 KR AS c.38G>A p.G13D 6 0.6 Yes No rhPCR
P0029 NR AS c.35G>A p.G12D 9 0.8 No Yes (both) rhPCR
P0053 PTPN11 c.205G>A p.E69K 13 0.9 No Yes (Ampliseq) rhPCR
P0151 NR AS c.34G>A p.G12S 14 1.0 Yes Yes (both) no
P0098 KR AS c.38G>A p.G13D 12 1.3 No Yes (both) no
P0160 NR AS c.34G>A p.G12S 21 1.5 No Yes (both) no
P0166 KR AS c.35G>T p.G12V 17 1.8 No No rhPCR
P0151 NR AS c.35G>A p.G12D 29 2.2 No Yes (both) no
P0051 KR AS c.34G>A p.G12S 13 2.4 Yes Yes (both) no
P0160 NR AS c.35G>A p.G12D 59 4.3 Yes Yes (both) no
P0029 NR AS c.34G>A p.G12S 69 5.7 Yes Yes (both) no
P0024 NR AS c.35G>A p.G12D 73 6.4 Yes Yes (both) no
P0128 KR AS c.179G>A p.G60D 91 6.5 Yes Yes (both) no
P0037 NR AS c.35G>A p.G12D 60 8.8 Yes Yes (both) no
P0098 KR AS c.35G>C p.G12A 152 16.1 No No Sanger
P0051 KR AS c.35G>A p.G12D 109 19.0 No Yes (both) no
P0166 KR AS c.35G>A p.G12D 295 28.4 Yes Yes (both) no
P0098 KR AS c.35G>T p.G12V 302 31.9 Yes Yes (both) no
P0111 KR AS c.351A>T p.K117N 608 33.1 Yes Yes (both) no
P0076 KR AS c.436G>C p.A146P 218 33.3 Yes Yes (both) no
P0150 KR AS c.35G>A p.G12D 562 34.7 Yes Yes (both) no
P0063 NR AS c.37G>C p.G13R 386 35.5 Yes Yes (both) no
P0070 KR AS c.35G>A p.G12D 305 40.3 Yes Yes (both) no
P0035 NR AS c.38G>A p.G13D 527 42.3 Yes Yes (both) no
P0143 NR AS c.35G>A p.G12D 601 45.4 Yes Yes (both) no
1




Figure 3.3. Overview of RAS mutations detected in paired diagnosis samples by smMIP single molecule 
consensus reads (smc-reads). (A) A total of 29 mutations and a dramatically decreased background were 
detected in the diagnosis samples by consensus-based variant calling using smc-reads. The top panel 
shows sample IDs with the RAS pathway mutation detected in the relapse sample. All called variants 
(before filtering) are depicted as dots, ranked by their genomic position in each vertical panel. Variants 
that did not pass filtering are colored in blue, while variants that passed the detection limit are colored 
in orange (known hotspot mutation) or black (non-hotspot mutation). The cut off used was presence in 
>= 5 smc-reads. Blue circles mark variants previously identified in the paired relapse sample (Table S3.1). 
Details of all identified mutations are displayed in Table S3.5. (B) Variants with a low VAF identified by 
smMIP consensus variant calling were confirmed by RNase H2 based PCR (rhPCR). The black arrow 
on the right of the gel indicates the expected amplicon size. (C) Comparison of the variants detected 
by smMIP based consensus calling approach and standard deep sequencing approaches. To achieve 
this, we divided all mutations identified from these approaches into two groups according to the VAF. 
Comparison of variants with a VAF<2.5% and VAF>2.5% are shown in Venn diagrams on the left and 
right. The number of hotspot mutations are shown in bold and non- hotspot mutations are underlined 
and italic. Details for variants are displayed in Figure S3.10.
DISCUSSION
In this study, we have developed a smMIP panel to sensitively and accurately detect 
low-level mosaic mutations in leukemia samples. We compared the widely applied deep 
sequencing strategy with a smMIP-based approach, which generates consensus reads for 
variant calling. To test these approaches, we chose to target three commonly mutated 
RAS pathway genes. Driver mutations in these genes cluster in hotspots, which facilitates 
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the discrimination of true mutations from background noise. All methods had high 
sensitivity rates, making them suitable for backtracking of relapse- associated mutations. 
However, variant calling on smMIP-based consensus reads resulted in drastically reduced 
false positive rates, thereby creating much higher specificity in determining the presence 
of subclonal mutations in primary diagnosis samples from ALL patients, irrespective of 
the applied sequence depth. Therefore, this smMIP approach is very suitable for upfront 
detection of subclonal mutations in ALL in an unbiased manner, particularly in genes 
where mutations are more randomly distributed.
The reliable detection of low-level mosaic mutations by NGS sequencing is hampered by the 
occurrence of amplification-based errors that arise during the preparation and sequencing 
processes.9,10 We here demonstrate that common deep sequencing approaches can reliably 
estimate the VAF of variants, but cannot correct for random errors resulting in high error 
rates. Even with very high sequencing depth (>50,000x), the common NGS approach 
could not accurately determine mosaic mutations with a VAF below 2.5%. In comparison, 
the smMIP approach uses a unique tag in each molecule with which we could eliminate 
random errors. This results in a notable reduction of background noise and thus allows 
for the sensitive detection of mutations in leukemia samples with VAF as low as 0.4%.
We experienced a relatively low capture efficiency with our smMIP-based approach, 
which leaves room for improvement. Using 100 ng genomic DNA as input (which equals 
approximately ~15,000 haploid copies) and an average smc-read coverage of 1,432x in the 
hotspot regions (which represents 1,432 unique DNA molecules in the patient sample), 
we detected around 10% of total input, which creates a limit to the detection of very low-
level mosaic alterations (VAF>0.4% when using a 5-smc read threshold). Actual capture 
efficiency may be higher, because inefficiently amplified fragments may have been missed 
with sequencing. This can be easily optimized by deeper sequencing to reach saturation of 
the capture. In addition, the efficacy can be further improved by increasing the DNA input 
during capture, and by applying multiple PCR reactions in parallel. Such improvements 
will directly improve detection variants below 0.4%. For further increase in sensitivity, 
towards levels that enable the detection of minimal residual disease detection (i.e. the 
presence of residual tumor cells <0.01% during or after treatment), alternative strategies 
are required like duplex sequencing or droplet PCR.
18,19
A problem with prospective screening of subclonal mutations is that they are more 




where mutations are scattered throughout the coding sequence, because the region where 
mutations are expected is much larger. In this study, we performed allele-specific rhPCR 
to validate variants with low VAF, a cost-effective technique with improved selectivity 
between the mutant and wild type allele. In addition, we made use of the fact that 
mutations in RAS pathway genes specifically occur in hotspot regions, which provides 
an alternative and indirect way to discriminate between true mutations and noise. The 
combined use of these two approaches allowed us to establish that all variants detected 
by the smMIP-based consensus method between 0.4-1% VAF are indeed true. Therefore, 
with the smMIP-based consensus method and stringent filtering process, we can reduce 
the number of false positive calls to nearly zero, which largely decreases time and costs for 
validation. The consequence of the stringent filtering process is that some true variants 
might be missed. In fact, among the 25 variants detected by the standard deep-sequencing 
strategies that were missed or excluded by filtering in the smMIP-based consensus 
approach, may be true variants present in very small subclones. Therefore, it is crucial to 
establish the desired sensitivity of low-level variants and determine the required smMIP 
sequencing depth. Together, we believe that smMIP based sequencing can be applied to 
detect subclonal mutations in a prospective manner, also in genes like TP53 and CREBBP, 
where true pathogenic mutations show much less clustering.
Common alterations identified in relapsed ALL are frequently present in minor or major 
clones at initial diagnosis. This raises questions about the impact of subclonal alterations 
at the time of initial diagnosis and their prognostic significance on the risk of relapse. 
Prospective screening of leukemia-associated alterations in large unselected ALL cohorts 
can reveal their prognostic relevance. However, this requires a technique that can accurately 
and reliably determine low-level mosaic mutations with low rates of false positives. Since all 
low-level mosaic variants, with VAFs down to 0.4%, could be confirmed independently by 
other techniques, the smMIP-based consensus variant calling approach is highly suitable 
to study the prognostic value of (sub)clonal alterations identified at the time of diagnosis.
In clinical practice, it is important to track multiple genetic markers in follow-up samples 
to monitor leukemia development. Commonly used sensitive techniques like quantitative 
real-time PCR and digital droplet PCR are limited in use due to obstacles for multiplexing 
in one experiment.
20 In contrast, a single smMIP panel is capable of sensitively and 
accurately identifying subclonal mutations and copy number variants in a large set of 
cancer genes,21-23 as was recently demonstrated for leukemia- associated mutations.24-25 In 
addition, probes for new interesting regions can easily be added into an optimized smMIP 
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panel. smMIP offers a scalable and rapid workflow to track genetic alterations in leukemia 
samples and monitor clonal changes during leukemia development in clinical practice.
In conclusion, we have shown that the random tagging based smMIP approach is 
sensitive and can accurately identify subclonal mutations in leukemia samples. Our 
data indicate that the smMIP approach can eliminate mistakes that likely occur during 
PCR and sequencing, thereby drastically reducing the background noise. The technique 
provides opportunities to study prognostic value of low-level mosaic mutations in relapse 





Table S3.1. RAS mutations identified in relapse samples
Sample ID Gene Variant Amino acid change
P0024 NR AS c.35G>A p.G12D
P0029 NR AS c.34G>A p.G12S
P0035 NR AS c.38G>A p.G13D
P0037 NR AS c.35G>A p.G12D
P0039 KR AS c.68T>G p.L23R
P0051 KR AS c.34G>A p.G12S
P0053 PTPN11 c.226G>A p.E76K
P0055 KR AS c.35G>A p.G12D
P0063 NR AS c.37G>C p.G13R
P0070 KR AS c.35G>A p.G12D
P0076 KR AS c.436G>C p.A146P
P0098 KR AS c.35G>T p.G12V
P0111 KR AS c.351A>T p.K117N
P0120 PTPN11 c.172A>T p.N58Y
P0128 KR AS c.179G>A p.G60D
P0143 NR AS c.35G>A p.G12D
P0145 KR AS c.38G>A p.G13D
P0150 KR AS c.35G>A p.G12D
P0151 NR AS c.34G>A p.G12S
P0160 NR AS c.35G>A p.G12D
P0166 KR AS c.35G>A p.G12D
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Ampliseq reads smMIP raw reads
P0024 NR AS c.-17-11G>A No 0 0.9
P0024 NR AS c.-17-12G>A No 0 1.5
P0024 NR AS c.-17-19G>T No 0 1.7
P0024 NR AS c.-17-30C>A No 0.9 0
P0024 NR AS c.34G>T p.G12C Yes 0 0.5
P0024 NR AS c.35G>A p.G12D Yes 5.0 6.9
P0029 NR AS c.-17-11G>A No 0 0.9
P0029 NR AS c.-17-12G>A No 0 1.4
P0029 NR AS c.-17-30C>A No 1.1 0
P0029 NR AS c.34G>A p.G12S Yes 3.4 6.6
P0029 NR AS c.35G>A p.G12D Yes 0.6 0.9
P0035 NR AS c.-17-11G>A No 0 0.9
P0035 NR AS c.38G>A p.G13D Yes 34.5 44.0
P0037 NR AS c.-17-11G>A No 0 1.1
P0037 NR AS c.35G>A p.G12D Yes 7.1 9.2
P0051 KR AS c.34G>A p.G12S Yes 1.6 0.9
P0051 KR AS c.35G>A p.G12D Yes 13.6 17.9
P0051 KR AS c.38G>A p.G13D Yes 0.6 0
P0051 KR AS c.58A>G p.T20A No 0 0.6
P0053 PTPN11 c.205G>A p.E69K Yes 0.9 0
P0055 KR AS c.16C>T p.L6F No 0 0.7
P0063 NR AS c.-17-11G>A No 0 0.9
P0063 NR AS c.-17-19G>T No 0 1.4
P0063 NR AS c.37G>C p.G13R Yes 22.9 35.0
P0070 KR AS c.35G>A p.G12D Yes 34.6 36.1
P0076 KR AS c.436G>C p.A146P Yes 26.5 33.0
P0076 KR AS c.450+32T>C No 0 0.5
P0098 KR AS c.35G>T p.G12V Yes 27.3 28.6
P0098 KR AS c.38G>A p.G13D Yes 0.7 1.5
P0111 KR AS c.351A>T p.K117N Yes 23.0 33.0
P0128 KR AS c.179G>A p.G60D Yes 6.8 7.0
P0143 NR AS c.-17-11G>A No 0 1.1
P0143 NR AS c.-17-12G>A No 0 1.8
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Ampliseq reads smMIP raw reads
P0143 NR AS c.-17-19G>T No 0 1.8
P0143 NR AS c.35G>A p.G12D Yes 38.3 46.0
P0150 KR AS c.35G>A p.G12D Yes 25.0 37.5
P0151 NR AS c.111+12T>C No 0 0.6
P0151 NR AS c.34G>A p.G12S Yes 0.6 1.1
P0151 NR AS c.35G>A p.G12D Yes 1.8 2.9
P0160 NR AS c.-17-11G>A No 0 0.9
P0160 NR AS c.-17-12G>A No 0 1.6
P0160 NR AS c.-17-30C>A No 0.9 0
P0160 NR AS c.34G>A p.G12S Yes 0.9 1.7
P0160 NR AS c.35G>A p.G12D Yes 3.2 5.9
P0166 KR AS c.39C>T p.G13G Yes 0 0.6
P0166 KR AS c.56T>C p.L19S No 0 0.6
1
NR AS mutations at position c.-17 are located in intron 1, upstream of the start codon in exon 2; 
2
Recurrently observed in COSMIC (see Table S3.6).
Table S3.6. Mutation hotspot regions in the three RAS genes
Gene Exon Substitution*
KR AS 2 G12D, G12V, G12A, G12S, G12C, G12R, G12G, G13D, G13C, G13G, G13A, 
V14I, A18D, L19F, Q22K, L23R, D33E
KR AS 3 T58I, A59G, A59E, G60D, Q61H, Q61R, Q61P, Q61L, E63K, Y64N
KR AS 4 K117N, A146T, A146V, A146P
NR AS 2 G12D, G12S, G12V, G12C, G12A, G12R, G12N, G13D, G13R, G13V, G13C, 
G13A, Q22K
PTPN11 3 T52S, N58Y, G60V, G60R, G60A, D61Y, D61V, D61N, D61H, D61G, E69K, 
F71L, A72V, A72T, A72D, A72S, T73I, E76K, E76G, E76A, E76Q, E76V
*Only substitutions that have been recurrently identified in hematologic malignancies are included 
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Figure S3.2. A schematic of the allele-specific RNase H2 based PCR (Adapted from Dobosy et al, 
2011). (A) Structure of the blocked cleavable primer used for RNase H2 based PCR (rhPCR). D and 
M represent DNA bases that match and mismatch to the target genomic region, respectively. The RNA 
base that matches to the mutant is depicted by r. X depicts a C3 propanediol spacer. (B) Schematic 
flow of rhPCR approach. RNase H2 enzyme is an endoribonuclease, which prefers to cleave a single 
RNA residue within the context of RNA-DNA duplex. After cleavage of 3’ RNA residue, the primer is 
activated to amplify the targeted genomic region. However, the blocked primer is not able to support 




Figure S3.3. Read depth per sample at the targeted position of the mutation for the two deep sequencing 
approaches.
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Figure S3.4. Detection limit of deep sequencing approaches using raw reads. In order to define the 
background noise levels, we sequenced the targeted amplicons in DNA from healthy donors. For further 
analysis, we set the detection limit as variant allele frequency (VAF) >0.5% with >200 variant reads, 
which excludes 99.8% of the variants detected in the healthy samples. (A-B) VAF of all variants called 
from reference samples in targeted regions, using Ampliseq-based NGS approach sequenced on the Ion 
Personal Genome Machine platform (A) and the smMIP approach sequenced on the Illumina platform 
(B). The dashed line indicates VAF=0.5%. Genomic position is based on hg19. (C) Cumulative number 
of variants identified from the reference samples by the two approaches. (D-E) Cumulative frequency of 




Figure S3.5. The smMIP-based variant calling performance. (A) Number of raw reads in each tag- 
defined read group (TDRG) for each probe. A TDRG is composed of all raw smMIP sequence reads 
amplified from the same unique molecule present in the patient material (Figure 3.1D). On average, 
each TDRG was comprised of 142 individual raw sequencing reads (range 105-174) (B) Number of single 
molecule consensus (smc) reads for each probe. Each smc-read is derived from a TDRG (Figure 3.1D).
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Figure S3.6. Average smc-read depth of the targeted regions in KR AS (A), NR AS (B) and PTPN11 (C). 
The x-axis shows the genomic position for the targeted region. The y-axis shows average single molecule 
consensus (smc) read depth of the targeted position. The structure of the targeted regions is shown below, 
where bigger boxes represent exons, smaller boxes represent introns and black lines indicate positions for 
hotspots and known RAS mutations. Gradient color represents the number of smMIP probes covering 
the position.
Figure S3.7. RAS mutations detected in relapse samples were determined in the paired diagnosis sam-
ples. The y-axis shows the VAF determined by the smMIP consensus variant calling approach. Details 




Figure S3.8. Variants called by smc-reads were analyzed by RNase H2 based PCR. To assess the spec-
ificity of the assay, we performed RNase H2 based PCR (rhPCR) using allele specific primers on the 
sample with a variant located on the adjacent position in KR AS (A) and NR AS (B). Failure to detect the 
product indicates that concurrent variants within the primer annealing region do not interfere with 
the specificity of the reaction. (C) PTPN11 p.E69K detected by the smMIP consensus variant calling in 
two samples was confirmed by the rhPCR assay and gel electrophoresis. Genomic DNA from a healthy 
donor was used for the negative control.
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Figure S3.9. Variant called from smMIP-based smc-reads validated by Sanger sequencing. Two KR AS 
mutations are observed at the same position in sample P0098 by smMIP-based consensus variant calling 
approach: chr12: 25398284C>A (p.G12V, VAF=32%) and chr12: 25398284C>G (p. G12A, VAF=16%). 
The latter was not called in Ampliseq, but was confirmed by Sanger sequencing.
Figure S3.10. Overview of variants identified from 21 diagnosis samples by approaches studied. Details 
of samples and variants are displayed on top. Variants located in known hotspot regions are colored in 
orange. Variants identified by each deep sequencing approach are shown in bottom. Variants with a 
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Pediatric acute lymphoblastic leukemia (ALL) shows clonal heterogeneity. We assessed the 
clinical relevance and prognostic value of subclonal alterations in the relapse-associated 
genes IKZF1, CREBBP, KRAS, NRAS, PTPN11, TP53, NT5C2, and WHSC1 in 503 ALL cases. 
Using Molecular Inversion Probe sequencing and breakpoint-spanning PCR we detected 
alterations down to 0.1% allele frequency. We identified 660 genomic alterations in 285 
diagnosis samples of which 495 (75%) were subclonal. RAS pathway mutations were 
common, particularly in subclones, and comparisons between RAS hotspot mutations 
revealed differences in their capacity to drive clonal expansion in ALL. We did not find 
association of subclonal alterations with unfavorable outcome. Particularly for IKZF1, an 
established prognostic marker in ALL, all clonal but none of the subclonal alterations were 
preserved at relapse. We conclude that, for the genes tested, there is no basis to consider 
subclonal alterations detected at diagnosis for risk group stratification of ALL treatment.
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INTRODUCTION
Improvements in the treatment of pediatric acute lymphoblastic leukemia (ALL) have 
resulted in high overall survival rates, now approaching 90%.1,2 Nevertheless, relapse still 
remains the most common cause of treatment failure and death in children with ALL, 
and better recognition of individuals at risk of developing relapse will likely aid further 
improvements in outcome. Recent studies describing the genomic landscape of relapsed 
ALL have shown that relapse often originates from a minor (sub)clone in diagnosis, at a 
cellular fraction often undetectable by routine diagnostic methods.3,4 These minor (sub)
clones harbor genomic alterations acquired later during leukemia development, which 
could potentially contribute to clonal drift, but are unlikely to be essential for the primary 
disease initiation. However, selective pressure of the upfront treatment may provide 
competitive advantage to subclones that harbor alterations in cancer genes, enabling 
their selective survival, eventually leading to treatment failure. Alterations in these genes 
are expected to be increased both in number and clonal burden at the time of relapse, 
compared to initial diagnosis. Indeed, mutations in relapse-associated genes, like those in 
the HAT domain of the histone methyltransferase CREBBP, can often be traced back to 
minor subclones in the diagnosis sample.4–6
Genomic characterization of relapsed pediatric ALL has revealed multiple alterations 
that are enriched compared to diagnosis, including activating mutations in RAS pathway 
genes, HAT domain mutations in CREBBP and deletions or mutations in the B-cell 
transcription factor IKZF1.5–12 Presence of these aberrations at the time of diagnosis can 
be of potential prognostic relevance, as has been demonstrated extensively for IKZF1 in 
many different treatment protocols11,13–18 and can even lead to adjustments in stratification 
and treatment.13,19 However, it remains unclear whether mutations in relapse-associated 
genes when present at a subclonal level at initial diagnosis, are also clinically relevant.
Subclonal mutations can be identified using deep targeted next generation sequencing 
techniques.20,21 Despite the sensitivity of these techniques, both amplification and 
sequencing can easily lead to errors that hamper the reliable detection of low-level mosaic 
mutations. We previously demonstrated that single molecule Molecular Inversion Probes 
(smMIP), which use unique molecular identifiers to barcode each DNA copy, can correct 
for sequencing and amplification artefacts, resulting in a reliable detection of low-level 




In this study we used the smMIP-based sequencing approach to perform deep targeted 
sequencing of seven relapse-associated genes in a cohort of 503 pediatric ALL samples taken 
at initial diagnosis, resulting in the detection of 141 clonal and 469 subclonal mutations. In 
addition, we performed real time quantitative PCR (qPCR) to sensitively detect subclonal 
IKZF1 exon 4-7 deletions (del 4-7), which were found at a similar frequency as full-clonal 
deletions. Subsequently, we estimated their potential as drivers of clonal expansion and 
prognostic markers for relapse development.
MATERIALS AND METHODS
Patients and samples
In this study we analyzed two cohorts of diagnosis samples from B-cell precursor ALL (B-
ALL) patients treated according to the DCOG-ALL9 protocol (n=131)and the DCOG-
ALL10 protocol (n=245) (Table S4.1). Both cohorts were representative selections of 
the total studies (Table S4.2).11,23 In addition, we used an extended cohort of diagnosis 
samples from 127 additional ALL patients treated according to the DCOG-ALL9 (n=76) 
or DCOG-ALL10 (n=51) protocols that was enriched for patients who developed a relapse 
and also contained 55 T-ALL patients. The median age at diagnosis for the total cohort of 
503 ALL patients (Table S4.1) was 5 years and, in total, 146 children (29%) developed 
a relapse. DNA was isolated from mononuclear cells obtained from bone marrow or 
peripheral blood. We performed Sanger sequencing or used previously published Ampliseq-
based deep sequencing data to verify alterations observed at diagnosis for 73 (89%) available 
relapse samples.22 Informed written consent was obtained from all patients and/or their 
legal guardians before enrolment in the study.
smMIP-based sequencing and variant calling
In order to accurately detect subclonal alterations in diagnosis samples, a total of 166 
smMIP probes was designed to cover the hotspot regions of the genes CREBBP, PTPN11, 
NT5C2, and WHSC1, and coding regions of TP53, KR AS and NR AS, seven genes that are 
frequently mutated in relapsed ALL. All genomic regions of interest were covered by at 
least two probes, preferably covering both the sense and antisense strands. smMIP-based 
sequencing was performed as previously described using paired-end sequencing on an 
Illumina NextSeq 500 Desktop Sequencer (Illumina, CA), after which smMIP-based 
consensus variant calling was performed.22 We achieved an average on-target read depth 
of 22,985 raw reads per probe (Figure S4.1A). After removing random errors present in 
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less than 70% of raw reads, consensus reads were formed from reads with the same unique 
molecular identifier. We achieved an average on-target depth of 308 unique-capture-based 
consensus reads per probe (Figure S4.1B), which enabled detection of variants with a 
mutant allele frequency as low as 0.1%. After exclusion of the variants called from repetitive 
regions, poorly performing probes, variants called from less than 2 independent probes and 
variants called by less than 5 unique reads in one consensus read, a total of 7,836 variants 
remained with an average on-target depth of 1,419 consensus reads (5 to 23,600). We 
further filtered out variants present in an in-house database of the Radboud University 
Medical Center (Nijmegen, the Netherlands) containing exomes from 20,000 individuals24 
and variants predicted as non-pathogenic (synonymous, phyloP <2.5, CADD score<15). 
For the final list of variants, a correction of the mutant allele frequency was made based 
on the percentage of blast cells determined at the time of diagnosis, which was high for the 
majority of cases (>70% for 93% of cases). In a low number of cases an aneuploidy required 
a correction of mutant allele frequency for copy number as well, which involved WHSC1 
(17 mutations), TP53 (10 mutations), KR AS (6 mutations), NR AS (5 mutations), PTPN11 (3 
mutations) and CREBBP (1 mutation).
IKZF1 deletion detection
IKZF1 status was assessed using the multiplex ligation probe assay (MLPA) SALSA 
P335 ALL-IKZF1 kit (MRC-Holland, The Netherlands), according to manufacturer’s 
instructions and as described before.11,23 Additionally, IKZF1 4-7 deletions were assessed using 
real time quantitative PCR. Primers covering the breakpoint clusters in introns 3 and 7 were 
designed using Primer3 software version 0.4.0. Quantitative PCR (qPCR) was performed 
using an IQ SYBR Green supermix (Biorad, CA) according to manufacturer’s instructions. 
The primer sequences used for qPCR were: 5’- CTCCCAGCCCATAGGGTATAA-3’ 
(forward) and 5’-GTTAAATAAAGAACCCTCAGGCATT-3’ (reverse). The sensitivity 
of the qPCR assay was tested using dilution series of a sample with a high tumor load 
(96% blasts) and a full-clonal IKZF1 del4-7 (detected by MLPA). All qPCR reactions were 
performed in duplicate, and the percentage of cells with IKZF1 exon 4-7 deletions was 
calculated based on the dilution series of the control sample, and a correction was made 
based on the percentage of blast cells determined at the time of diagnosis. For every sample 
with a clonal or subclonal IKZF1 exon 4-7 deletion, PCR products were sequenced with 
both forward and reverse primers using Sanger sequencing, after which the sequences were 
mapped to the reference genome (hg19) to determine the exact breakpoint positions and 




Defining clonal and subclonal alterations
Previous studies have used allele frequency (AF) thresholds to define mutations as subclonal 
or clonal ranging between 20% and 30%.4,9,25,26 In this study, we used an AF threshold of 
25% to separate clonal from subclonal alterations, since mutations below 25% represent a 
minor cell fraction. The same threshold was used for defining clonal IKZF1 4-7 deletions, 
which correlates with deletions that are detectable using MLPA.
Statistical testing
Statistical testing was performed using Wilcoxon signed rank test (R package ggpubr 
Version 0.2). Cumulative incidence of relapse (CIR) with log-rank test was performed 
using R packages survminer Version 0.4.3 and cmprsk Version 2.2-7. Univariate and 
multivariate Cox regression analyses were performed using R package survivalAnalysis 
Version 0.1.1. Data visualization was done using R package ggplot2 (version 3.2.1) and 
cBioPortal MutationMapper.27,28
RESULTS
A total of 503 diagnosis samples from children with ALL (Table S4.1) was subjected to 
targeted deep sequencing of the relapse-associated genes TP53, CREBBP (HAT domain), 
KR AS, NR AS, PTPN11, NT5C2 and WHSC1 using single molecule Molecular Inversion 
Probes (smMIP), which contain random molecular tags to accurately detect low-level 
mosaic variants.22 Each targeted region was covered with an average of 308 unique 
capture-based consensus reads (Figure 4.1 and Figure S4.1A-B), enabling the detection 
of alterations with allele frequencies as low as 0.1%. A total of 7,836 quality-filtered 
variants was detected, of which 610 were absent in public and private variant databases 
and predicted as pathogenic (see methods). The allele frequency of these mutations ranged 
from 0.2-100% (Figure 4.2A). The majority of the mutations (473/610; 78%) was found 
in one of the three RAS pathway genes (KR AS, NR AS, PTPN11), of which 418 (88%) were 
known hotspot mutations.
In addition to sequencing the seven relapse-associated genes, we performed a sensitive 
deletion screening of IKZF1 deletions, which are strongly associated with relapse 
development. We chose to focus on exon 4-7 deletions, which represent 25% of all IKZF1 
deletions, have a similar unfavorable outcome compared to other IKZF1 deletions,29 and 
show the strongest clustering of deletion breakpoints, thus enabling their sensitive upfront 
detection by breakpoint-spanning semi-quantitative PCR.30
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Applying this strategy to the 503 diagnosis samples revealed all 22 IKZF1 exon 4-7 deletions 
previously identified using a standard MLPA method, as well as 28 additional cases carrying 
deletions that were originally missed. All breakpoints were sequenced to determine their 
unique breakpoint-spanning sequences. Using a dilution series of a control sample with a 
full-clonal IKZF1 exon 4-7 deletion, we determined the level of clonality of the deletions, 
which ranged from 100% down to 0.32% (Figure 4.1-4.2 and Figure S4.1C). All but one 
of the subclonal IKZF1 exon 4-7 deletions had allele frequencies below 10%.
Subclonal alterations in relapse-associated genes are common at 
diagnosis
Combining sequence mutations and IKZF1 exon 4-7 deletions, we detected 660 genomic 
alterations in 285 diagnosis samples, of which 165 (25%) were present in the major fraction 
of cells (AF≥25%), which were referred to as clonal. The remaining 495 mutations (75%), 
most of which had AF <10% were referred to as subclonal (Figure S4.2 and Table S4.3). A 
total of 147/285 patients carried at least one clonal alteration, while 138/285 (48%) patients 
carried exclusively subclonal alterations. NRAS and KRAS were the most frequently affected 
genes, showing clonal mutations in 6% and 8% of the cases and subclonal mutations in 
20% and 15% of the cases, respectively (Figure 4.2A-B).
The frequency of subclonal alterations, relative to full-clonal alterations, was variable 
among different genes, ranging from 59% for IKZF1 exon 4-7 deletions to 86% for PTPN11 
mutations (Figure 4.2B). Only one thus far unknown (subclonal) NT5C2 mutation 
(p.Arg507Trp) was identified in a leukemia sample from a patient that did not relapse 
(Figure 4.2A-B). Subclonal mutations were relatively common in hyperdiploid ALL (184 
cases), particularly for mutations in RAS pathway genes (191/256; 75%), WHSC1 (23/26; 
88%) and CREBBP (13/27; 48%) (Table S4.4). Clonal WHSC1 mutations were mostly 
identified in ETV6-RUNX1 positive cases (4/10, 40%).
Potency of RAS pathway genes as drivers of clonal expansion
We identified 473 RAS pathway mutations in 225/503 (45%) cases, of which 78% were 
subclonal (median AF=2%). Over half of the RAS affected cases was hyperdiploid 
(>47chromosomes), in line with previous studies indicating that RAS mutations are 
associated with hyperdiploidy at diagnosis.9,31 The abundance of these mutations in major 
and minor clones suggests that these mutations drive clonal expansion during leukemia 
development.
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Figure 4.2. (A) Violin plot showing the variability in mutation allele frequency at diagnosis in the genes 
studied. Color of the dots indicates whether the mutation was detected in a case without relapse (blue) 
or with relapse (red). (B) Bar plot showing the frequencies of clonal and subclonal alterations per case 
in the genes studied. RAS pathway genes (NR AS, KR AS, PTPN11) were the most frequently mutated. 




Clonal RAS pathway mutations (n=102; all known hotspots) were found to be mutually 
exclusive, and 52/102 (51%) of these RAS mutated cases had at least one additional 
subclonal mutation in one of the three RAS pathway genes. The mutations mostly affected 
codons 12 and 13 of KR AS and NR AS (Figure 4.3A-C), and considerable variability in 
the level of clonality was observed between the different RAS hotspot mutations at the 
time of diagnosis. For example, NR AS G12A (10 cases), NR AS G12V (7 cases), and PTPN11 
E76K (7 cases) were never found to be present in a major clone, whereas 55% (n=11) of the 
KR AS G13D and 27% (n=9) of the KR AS G12D mutations were found to be clonal. With 
these high numbers of RAS mutations, the variability in clonal burden between hotspot 
mutations may provide an opportunity to compare the capacity of different hotspots 
to drive clonal expansion of ALL. In order to test this hypothesis we compared allele 
frequencies and performed statistical analysis. We found that KR AS hotspot mutations 
had a significantly higher allele frequency compared to both NR AS and PTPN11 mutations 
(Wilcoxon signed-rank test, p<0.01) (Figure 4.3D). When comparing the different hotspot 
mutations within KR AS, A146V showed the lowest allele frequency, indicating a weaker 
potential of this hotspot to drive clonal expansion compared to the other KR AS hotspots. 
Furthermore, KR AS G13D had a significantly higher allele frequency compared to the 
NR AS hotspot mutations G13D, G12D and KR AS A146V (Figure 4.3E). This finding 
indicates that some RAS hotspot mutations (e.g. KR AS G12D, G13D, A146T) may result 
in a stronger expansion potential compared to others (e.g. KR AS A146V, NR AS G12D, 
G13D), and further illustrates the complex heterogeneity of RAS hotspot mutations in 
their potential to drive clonal expansion.
Relevance of gene alterations for relapse development
The high number of alterations in these relapse-associated genes at the time of diagnosis 
triggers the hypothesis that these could be used as prognostic biomarkers for relapse 
development, even when present at subclonal levels. To test this hypothesis, we first 
explored whether alterations in each of the eight genes were enriched in diagnosis samples 
that relapsed compared to those that did not relapse. 
Subclonal alterations were very common at primary diagnosis in patients who relapsed 
(60/82; 73%) as well as in patients who did not (165/203; 81%). Whereas we observed a 
higher relapse frequency in cases with clonal IKZF1 alterations compared to cases without 
alterations in these genes, an association with relapse development was not observed for 
subclonal alterations in any of the genes (Figure 4.4A).
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Figure 4.3. Schematic representation of KR AS (A), NR AS (B) and PTPN11 (C) indicating prevalence 
of common hotspot mutations. (D) Violin plot showing allele frequency in hotspot mutations of three 
investigated RAS pathway genes. Median allele frequency was significantly higher in KR AS, indicating 
high potential of KR AS hotspot mutations to drive clonal expansion. (E) Violin plot showing allele fre-
quencies in frequent KR AS and NR AS hotspot mutations. The median allele frequency was significantly 





Univariate and multivariate Cox regression analyses revealed an association of clonal IKZF1 
exon 4-7 deletions with relapse (Table 4.1), and the cumulative incidence of relapse (CIR) 
of cases with clonal IKZF1 exon 4-7 deletions was higher in patients treated with ALL9 
and in ALL10 (Figure S4.3). These data are in line with earlier studies on these cohorts in 
which all IKZF1 deletions were included,11,13 and indicate that the cohort size is sufficient 
to detect the association of this subset of exons 4-7 IKZF1 deletions with relapse. In the 
ALL10 cohort, clonal CREBBP mutations at diagnosis were found to be associated with 
relapse as well (Table 4.1), and the CIRs were slightly increased (Figure S4.3). However, 
when we assessed the clinical relevance of subclonal alterations for relapse development in 
the IKZF1, CREBBP, or any of the other genes, COX regression analysis and CIR analysis 
revealed no significant associations in either the ALL9 or in ALL10 cohorts.
Tracing of clonal and subclonal mutations at the time of relapse
To obtain further insight into the clinical relevance of the identified alterations in relapse 
development, we investigated whether these were preserved in the cases that relapsed. 
For this analysis, we used all 146 cases that later developed a relapse, of which 82 carried 
clonal or subclonal alterations in one or more of the genes (Table S4.6). Overall in these 
cases, we found that for most genes the frequency of subclonal alterations at the time of 
diagnosis was similar or slightly higher compared to the clonal alterations (Figure 4.4B 
and Table S4.6).
We collected 73 relapse samples from patients that carried clonal or subclonal alterations at 
the time of diagnosis (89%), which enabled us to trace 171 of the 185 sequence mutations 
and 25 of the IKZF1 exon 4-7 deletions. Overall, 56% (22/39) of the tested clonal mutations 
were found to be preserved at relapse, whereas for the subclonal mutations this was 7% 
(9/132) (Fisher’s exact test, p < 0.01) (Figure 4.4C). For IKZF1 exon 4-7 deletions, the 
difference was even more striking. Here, the presence of deletions was studied in 19 
available relapse samples using breakpoint- spanning PCR, followed by Sanger sequencing 
to confirm that the breakpoint sequences were identical between diagnosis and relapse 
(Figure 4.4C). All full-clonal IKZF1 exon 4-7 deletions were found to be preserved at the 
time of relapse (n=12), which is in agreement with earlier findings and illustrates their 
relevance for relapse development in these treatment protocols.11,13 In contrast, none of 
the subclonal exon 4-7 deletions in IKZF1 (n=13) were preserved in relapse. Since previous 
studies have demonstrated that the unfavorable outcome of the different types of IKZF1 
deletions is comparable,29 these findings may be extrapolated to all IKZF1 deletions. The 
present study shows that these deletions, when present at initial diagnosis at subclonal level, 
should not be considered as a prognostic marker for relapse in pediatric ALL.
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Figure 4.4. (A) Bar plot showing the relapse frequency in cases with clonal (blue) or subclonal (yellow) 
mutations in seven relapse-associated genes, and in cases that were wildtype (black) for these genes. 
Cases with clonal IKZF1 del4-7 showed a significantly higher frequency of relapse compared to wildtype 
cases (Fisher exact test, p<0.01) (Table S4.5). (B) Bar plot showing alteration frequencies at diagnosis 
for relapsed (red) and non-relapsed cases (blue). Clonal alterations are shown upwards, while subclonal 
are presented downwards. (C) Tracing of clonal (top) and subclonal (bottom) alterations detected in 
initial diagnosis samples from relapsed patients in the matched relapse samples. The pie charts depicts 




Table 4.1. Alteration frequency at diagnosis of non-relapsed (NR) and relapsed (R) cases in 
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183 18 183 18
1
Clonality status based on detection at initial diagnosis; clonal: AF ≥ 25%, subclonal: AF < 25%; 
2
Hazard 
ratio (HR, given with 95% confidence interval), and p-value after multivariate Cox regression analysis 
are shown only for genes with p-value < 0.05. Multivariate Cox regression analysis included gender and 
age at diagnosis as covariates; 
3
Representative ALL9 and ALL10 cohorts are outlined in Table S4.1; 
4
Samples with other deletions in IKZF1, except 4-7 deletion, detected by MLPA (clonal), were excluded.
DISCUSSION
ALL is a heterogeneous disease in which specific genomic alterations show strong 
associations with relapse risk and outcome. In this study, we assessed the clinical relevance 
and prognostic value of subclonal alterations in eight genes frequently mutated in relapsed 
BCP-ALL in a cohort of 503 diagnosis samples. Our data demonstrate that subclonal 
alterations in these genes are very common at the time of diagnosis, but that these 
mutations do not provide a basis for risk stratification in pediatric ALL. This finding is 
particularly relevant for IKZF1 alterations, which are currently used or implemented for 
treatment stratification in multiple upfront treatment protocols.13,19
The selection of these genes was made based on enriched mutation frequencies in relapse 
shown in previous studies. Of all alterations identified in this study, 75% were subclonal 
at diagnosis, suggesting that these relapse-associated gene mutations accumulate during 
progression of the leukemia before the initial diagnosis, thereby increasing the clonal 
complexity. Whereas seven of the genes selected in our study showed this high mutational 
burden at diagnosis, both in terms of numbers and level of clonality, we identified only a 
single, not previously reported, subclonal NT5C2 mutation in a non-relapsed case (follow-
up time 9.5 years). NT5C2 encodes the cytosolic nucleotidase, which is responsible for 
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inactivating cytotoxic thiopurine monophosphate nucleotides, and activating mutations in 
this gene are recurrently found in relapsed ALL, mainly T-ALL.4,8,32-34 One explanation for 
the low number of activating NT5C2 mutations at diagnosis is that these mutations decrease 
cell fitness, and only obtain their selective advantage during treatment with thiopurines.32 
If already present at the time of initial diagnosis, these mutations are usually detectable 
in only a very small subset of cells, far below the detection level of our smMIP analysis.32
Hotspot RAS pathway mutations have been detected in nearly half of the cases, often of the 
hyperdiploid subtype, and their frequency and clonal burden varied between the different 
mutations. In our study, we have used this variability to compare the potential of different 
hotspot mutations to drive clonal expansion under physiological conditions. Compared 
to diagnosis, we observed a less diverse spectrum of KR AS and NR AS hotspot mutations 
in relapse, with G12D, G12V and G13D together representing two-thirds of KR AS and 
NR AS hotspot mutations found in relapse-fated clones. Studies in other cancers have 
demonstrated that the prevalence of different RAS pathway mutations varies depending 
on the cancer type and tissue of origin, with KR AS mutations G12D, G12V, G13D and 
G12C being among the most common ones.35,36 Comparison of oncogenic capacities 
of different RAS hotspots has also been performed using in vitro and in vivo modelling 
studies, focusing primarily on KR AS. These studies identified KR AS mutations G12D, 
G12V and G13D to have higher proliferative and transforming potential compared to 
other common hotspots in various tumors of epithelial origin.35,37,38 Our data indicates 
that in competition of multiple RAS hotspot mutations, some of these not only confer a 
proliferative advantage but can also more effectively sustain a treatment-induced selective 
sweep,4,9 which potentially opens up the possibility to use these mutations as markers for 
MRD.
The presence of IKZF1 deletions has been shown to be associated with relapse and survival in 
multiple clinical ALL studies,11,13–18 and the role of these deletions in resistance to tyrosine 
kinase inhibitors and glucocorticoids has been described.39–42 Therefore, with the advance 
of more sensitive detection techniques, the question whether subclonal alterations are also 
associated with relapse is very relevant, both from a biological and a clinical perspective. We 
here demonstrate that, in contrast to full-clonal IKZF1 exon 4-7 deletions, cases that carry 
this deletion only in a subset of the cells do not show an association with relapse. Moreover, 
whereas all full-clonal exon 4-7 deletions were preserved in the cases that relapsed, none of 
the relapses from cases with subclonal exon 4-7 deletions at diagnosis carried this deletion. 




deletions deletions remains unclear. Possibly, the functional impact of full-clonal IKZF1 
deletions, which arise early during leukemia development, is different from those that occur 
in later stages when the leukemia has already expanded. While we did not directly assess 
the stability and potential prognostic importance of whole gene and rare intragenic IKZF1 
deletions, a previous study has shown that other IKZF1 deletion subtypes have similar 
prognostic relevance compared to exon 4-7 deletions,29 suggesting that subclonal alterations 
in these other IKZF1 deletions may show the same lack of association.
In summary, we show that subclonal alterations in the relapse-associated genes IKZF1, 
CREBBP, KR AS, NR AS, PTPN11, TP53, and WHSC1 in pediatric ALL occur frequently at 
initial diagnosis, often at a subclonal level. At relapse, however, most of these subclonal 
mutations are lost, suggesting that their selective advantages over wildtype clones during 
treatment is limited. This finding has direct implications for clinical practice, particularly 
in the case of IKZF1, where deletion status is used for routine risk stratification. We 
therefore conclude that, at least for the investigated set of genes, there is no basis for the 
use of subclonal alterations at initial diagnosis as a prognostic marker.
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SUPLEMENTARY MATERIAL








Age at diagnosis 4 (range 1-15) 5 (range 1-18) 8 (range 0-18) 5 (range 0-18)
Gender
Female 47 114 37 198
Male 84 131 90 305
Protocol
ALL10 na 245 51 296
ALL9 131 na 76 207
Relapse
Not relapsed 107 218 32 357




3 8 3 14
BCR-ABL1 4 0 4 8
B-other 16 73 15 104
ETV6-
RUNX1
25 69 3 97
Hyperdiploid 68 74 42 184
Hypodiploid 12 5 6 23
MLL 2 6 1 9
T-ALL 0 0 53 53
TCF3-PBX1 1 10 0 11
Treatment arm
ALL10
High risk na 19 16 35
Medium risk na 151 28 179
Standard risk na 75 7 82
ALL9
High risk 28 na 39 67




Table S4.2. Comparison between total ALL10 cohort and representative ALL10 cohort
Total ALL10 cohort
Representative ALL10 
cohort Chi square 
test
P-value
Number Frequency Number Frequency
Gender
0.75 0.39Male 420 54% 159 57%
Female 358 46% 120 43%
Age
4.25 0.24
1-5 361 46% 116 42%
5-10 230 30% 100 36%
10-15 130 17% 41 15%
15-18 57 7% 22 8%
Genetics
7.14 0.21
Down 40 5% 8 3%
ETV6-
RUNX1
168 22% 69 25%
TCF3-PBX1 19 2% 10 4%
HD>50 182 24% 74 27%
B-other 255 33% 78 29%
T-other 110 14% 34 12%
Phenotype
1.27 0.26B-lineage 661 85% 245 88%
T-lineage 116 15% 34 12%
Relapse
0.25 0.61Yes 69 9% 29 10%
No 669 91% 250 90%
113
Multiclonal complexity of ALL and the prognostic relevance of subclonal mutations
Table S4.3. Distribution of detected alterations based on allele frequency (AF)
Gene










CREBBP 15 7 22 3 0 3 10 6 16
KR AS 66 16 82 23 10 33 30 16 46
NR AS 101 47 148 25 6 31 31 12 43
PTPN11 41 30 71 4 2 6 9 4 13
NT5C2 1 0 1 0 0 0 0 0 0
TP53 27 14 41 0 2 2 9 4 13
IKZF1 del4-7 18 7 25 1 0 1 10 14 24
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Table S4.5. Frequency of relapse in total primary diagnosis cohort (n = 503) based on mutation status 
in eight relapse-associated genes
Gene Clonal mutation1 Subclonal mutation1 Wildtype
CREBBP 38% (6/16) 33% (6/18) 29% (134/469)
KR AS 35% (16/46) 20% (15/74) 30% (115/383)
NR AS 28% (12/43) 25% (25/100) 30% (109/360)
PTPN11 31% (4/13) 33% (15/45) 29% (127/445)
TP53 31% (4/13) 37% (13/35) 28% (129/457)
WHSC1 30% (3/10) 19% (5/26) 30% (138/467)
NT5C2 0 0/1 29% (146/502)
IKZF12 58% (14/24) 27% (7/26) 24% (94/394)
1
Clonality status based on detection at primary diagnosis; clonal: AF≥25%, subclonal: AF<25%.
2




Table S4.6. Frequency of the alterations detected at diagnosis in cases that relapsed and frequency of 
the preserved alterations in relapsed clones for available relapse samples
Gene Cohort*
Number of alterations 
at diagnosis in relapsed 
samples
Number of alterations 
at diagnosis in available 
relapse samples
Number of alterations 
preserved in available 
relapse samples
Clonal Subclonal Clonal Subclonal Clonal Subclonal
CREBBP
ALL9 0 1 nd 1 nd 0
ALL10 3 2 3 2 1 0
Extended 3 4 2 3 2 0
Total 6 7 5 6 3 0
KR AS
ALL9 5 7 5 7 2 1
ALL10 2 9 2 9 1 1
Extended 9 10 7 9 6 1
Total 16 26 14 25 9 3
NR AS
ALL9 1 5 1 5 0 0
ALL10 5 17 4 17 2 2
Extended 6 31 5 28 4 2
Total 12 53 10 50 6 4
PTPN11
ALL9 0 6 nd 6 nd 0
ALL10 2 3 2 3 0 0
Extended 2 23 2 22 1 1
Total 3 33 3 22 1 1
TP53
ALL9 1 3 1 3 0 0
ALL10 0 6 nd 6 nd 0
Extended 3 7 2 5 1 1
Total 4 16 3 14 0 0
WHSC1
ALL9 0 1 nd 1 nd 0
ALL10 1 1 1 1 0 0
Extended 2 4 2 4 2 0
Total 2 7 2 7 2 0
IKZF1
ALL9 4 4 4 4 4 0
ALL10 4 2 4 2 4 0
Extended 6 7 4 7 4 0
Total 14 13 12 13 12 0
*ALL9: ALL9 representative cohort; ALL10: ALL10 representative cohort; Extended: extended cohort.
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Figure S4.1. (A) Box plot showing total raw read depth per probe. (B) Box plots showing unique- 
capture-based consensus reads (smc) depth per probe. (C) Schematic representation of the IKZF1 gene, 
indicating the position of the common breakpoint cluster in introns 3 and 7. (D) A representative ex-
ample of qPCR amplification curves of dilution series. (E) The dilution curve from the same experiment 




Figure S4.2. Histogram showing the distribution of the mutant allele frequency in cases with mutations 
(left panel) and deletions (right panel). Allele frequency (AF) of 25% was chosen as the threshold for 
clonal versus subclonal mutations (indicated in red). Mutations above this threshold are present in more 
than 50% of the cells and thus always represent a major clone. As depicted in these panels the majority 
of (subclonal) mutations and deletions have AF below 10%.
Figure S4.3. Cumulative incidence of relapse for CREBBP and IKZF1 in representative ALL9 (left) and 
ALL10 (right) cohorts. P-values are shown for log-rank test.
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Despite the high survival rate of pediatric acute lymphoblastic leukemia (ALL), therapy 
resistance and relapse remain significant problems. Therefore, to improve treatment 
outcome of ALL, it is important to identify pathways that can be targeted to enhance 
the efficacy of different chemotherapeutics. In this proof-of-principle study, we used a 
CRISPR-Cas9 based knockout screen, targeting 507 kinases, in the B cell progenitor ALL 
cell line Nalm-6 to identify novel genes involved in resistance towards the glucocorticoid 
prednisolone, a key component of current ALL treatment protocols. Upon transduction 
of this library, cells were cultured for 17 days in the presence or absence of prednisolone. 
Integration sites were amplified and subjected to targeted deep sequencing. By comparing 
the single guide RNA (sgRNA) abundance in cell populations with or without prednisolone 
treatment, we identified Beta adrenergic receptor kinase 1 (ADRBK1), also known as 
BARK1, a key regulator of B- adrenergic receptor (ßAR) signaling, as an important 
determinant of prednisolone response in this model. By generating BARK1 knockout cell 
lines, we were able to confirm that knockout of BARK1 decreases prednisolone induced 
cell death in vitro. However repression of ßAR signaling using beta blockers sensitized cells 
to prednisolone treatment. We conclude from these results that CRISPR-Cas9 based 
screening can be used to delineate genes that contribute to therapy resistance and identify 
pathways that can be selectively inhibited to improve therapy response.
127
Identification of GC resistance mechanisms by CRISPR-Cas9 based kinome screening
INTRODUCTION
One of the major adverse events in the treatment in childhood acute lymphoblastic 
leukemia (ALL) is drug resistance. To achieve the goal of completely eliminating leukemic 
cells in a patient, ALL treatment protocols make use of chemotherapy regimens, in which 
combinations of multiple drugs such as vincristine, glucocorticoids (GCs) and asparaginase 
are administered.1-4 Most patients respond well to this strategy and achieve long-term 
remission. As a result, the overall survival has been dramatically improved to over 90% in 
most countries during the last few decades.5 However, a subset of patients presents with 
less effective response or even resistance to one or more of those drug components. These 
patients often have a higher risk of relapse, which is the major cause of treatment failure 
in ALL.
GCs, such as prednisolone and dexamethasone, act as one of the key components used 
in the induction stage of ALL treatment. Response to prednisolone at day 8 has been 
regarded as a strong predictor of treatment outcome in many clinical protocols.6-8 Deletions 
or mutations in several genes, including GC receptor NR3C1 and genes regulating GC 
responses, such as IKZF1, BTG1 and TBL1XR1, have already been identified to be relevant 
for therapy resistance to GCs.9-13 In addition, point mutations and deletions in CREBBP 
have been linked to GC resistance in vitro, although the impact may be highly dependent on 
clinical trials and tumor types.14-16 These data indicate that alterations in genes regulating 
GC responses confer GC resistance during therapy, enhancing the chance of ALL relapse. 
Therefore, it is important to identify pathways that can be selectively inhibited to improve 
therapy response.
A recent genome editing approach using the clustered regularly interspaced short 
palindromic repeats (CRISPR) based technology has been applied to identify genes related 
to drug resistance.17-19 In the CRISPR-based system, a single guide RNA (sgRNA) that 
is a 20-bp sequence complementary to the genomic site of interest can direct the Cas9 
endonuclease protein to the target DNA sequence, causing DNA cleavage that needs to 
be repaired. Through this activity, the Cas9-sgRNA complex can introduce frameshift 
mutations at the targeted site, potentially leading to loss-of- function of the gene.20 
Importantly, the CRISPR-based system has been developed into a tool for genome scale 
screening, largely due to chemical synthesis of pooled sgRNAs. For example, an sgRNA 
kinome library targeting 507 kinase genes with 5070 unique guide sequences (10 sgRNAs 
per gene) has been previously generated.17 This pooled sgRNA can be used to generate a 




the pooled knockout cells can be screened under both positive and negative drug selection. 
In this screen, each sgRNA is integrated into the cell genome, and thus would serve as a 
barcode that can be used to count the number of cells carrying this gRNA using high-
throughput sequencing. If loss of gene function reduces response to therapy, the sgRNA 
count, representing the number of cells with loss of the gene, should be significantly higher 
in the cell population with drug treatment compared to that without treatment. Therefore, 
the CRISPR-Cas9 mediated reverse genetic screen could be a powerful method to identify 
genes whose loss confer resistance to therapeutic drugs.
Here, we performed a proof-of-principle study to identify genomic pathways relevant to 
therapy resistance in ALL by CRSIPR-Cas9 based large-scale screen using the sgRNA 
kinome library. To achieve this goal, we applied a kinome-wide screen on the leukemia cell 
line Nalm-6, which is known for intermediate prednisolone sensitivity and rapid growth.17 
After targeted deep sequencing of integration sites in cell populations treated with or 
without prednisolone, we compared the sgRNA abundance in these two populations to 
obtain a set of candidate kinase genes. We were able to identify and validate that ADRBK1, 
encoding the beta adrenergic receptor kinase 1 (BARK1), can modulate prednisolone 
responsiveness in this ALL cell line model. These data indicate that this CRISPR-based 
screening method can be used to identify novel pathways relevant for therapy resistance.
MATERIALS AND METHODS
Cell lines and vectors
We used Nalm-6 cells cultured in RPMI 1640 with L-glutamine (Life Technologies, 
Bleiswijk, The Netherlands) supplemented with 10% of tetracycline-free fetal calf serum 
(Pan Biotech, Aidenbach, Germany) and 1% of penicillin/streptomycin (P/S, Invitrogen, 
Merelbeke, Belgium). The HEK293ft cell line was cultured in DMEM GlutaMAX (Life 
Technologies, Bleiswijk, The Netherlands) supplemented with 10% of fetal bovine serum 
(Pan Biotech, Aidenbach, Germany) and 1% of P/S (Invitrogen, Merelbeke, Belgium). 
The doxycycline (dox) inducible lentiviral vector pCW-Cas9 (Addgene plasmid # 50661) 
and the sgRNA library targeting 507 kinase genes (Addgene # 51044) were purchased 
from Addgene.
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Prednisolone resistance screen
A total of 5 million Nalm-6 cells were transduced first with the pCW-Cas9 vector and 
subsequently the sgRNA library to achieve a density of 1,000 cells for each sgRNA. Cas9 
expression was induced using 1 µg/ml dox for 2 weeks. After 5 days of culturing without 
dox, cells were cultured in the presence or absence of 50 µg/ml prednisolone for 17 days. 
All cells were harvested for genomic DNA extraction.
High throughput deep sequencing
The sgRNA inserts were amplified in a nested PCR approach. In order to maintain kinome 
sgRNA complexity in all samples, we used 15.2 µg genomic DNA as input for the outer 
PCR to achieve an average of 500 unique copies for each sgRNA. For each sample, we 
performed 96 independent 50 µl reactions of 15 PCR cycles. The primers used for the outer 
PCR are listed in table S5.1. After combining the independent PCRs, we purified the 
products using Agencourt AMPure XP beads (Beckman Coulter Genomic, CA, USA) and 
eluted them in 100 µl of low TE buffer. The inner PCR with 12 cycles was performed to 
add sequencing primers to the amplicons and barcode the samples (Table S5.1). This was 
carried out in a 50 µl reaction system with 15 µl of purified product from the outer PCR. 
Inner PCR products were purified using Agencourt AMPure XP beads (Beckman Coulter 
Genomic, CA, USA) and then sequenced on the Illumina HiSeq platform (Illumina, CA, 
USA) using custom designed sequencing primers (Table S5.1). Sequencing reads were 
analyzed using MAGeCK package V0.5.3.21
Generation of BARK1 knockout cells
To validate the target identified from our kinome screening, we sought to examine 
whether knockout of BARK1 decreases prednisolone induced cell death in a cell model. 
First, we generated CRISPR-Cas9 knockouts of BARK1 in Nalm-6 cells. Out of ten 
sgRNAs targeting the first exon of BARK1 from the kinase sgRNA library, we selected 
the top three sgRNAs that were enriched in prednisolone treated cells. In order to ligate 
the sgRNAs into a vector, we added BsmBI ligation adapters to these three sequences and 
their complementary oligo sequences (Table S5.2). Each pair of oligos was annealed 
using T4 polynucleotide kinase in T4 ligation buffer (New England Biolabs, MT, USA) 
by heating 5 minutes at 95oC and slowly cooling down to 25oC. Subsequently, diluted 
(1:200) annealed sgRNAs were ligated into the BsmBI digested pLentiCrispr plasmid. To 
produce lentivirus, the pLentiCrispr_sgRNA was transfected into HEK293ft cells with 
psPAX2 and pVSV-G using 80 ng/ml of polyethylenimine (PEI) (Polysciences, Hirschberg 




the LentiCrispr virus was collected and centrifuged at 18,620 rpm at 4oC for one hour 
to concentrate the virus (10x). The concentrated virus supernatant was transduced 
into the Nalm-6_Cas9 cells supplemented with polybrene. Six hours after infection, 
cells were cultured in fresh medium and 3 days later, cells were treated with 10 ug/ml 
blasticidin to select cells containing LentiCrispr_sgRNA virus. Sanger sequencing was 
performed to assess the presence of BARK1 loss of function mutations in all cell lines 
using the primes: forward 5’- GAGATGTGACCCGAGGTTGT-3’ and reverse 5’- 
GTCTGGGGCTTAGGGTCTG-3’. In order to estimate the percentage of cells deficient 
for BARK1, PCR products were cloned into the pCR4-TOPO TA vector (Thermo Fisher, 
MT, USA). At least ten colonies were picked for each knockout and sequenced by Sanger.
Cell cycle analysis
Nalm-6 cells with or without BARK1 knockout that were treated with 1 ug/ml prednisolone 
for 10 days at the density of 1 x 106 cells/ml were stained with Hoechst (Sigma Aldrich, 
Zwijndrecht, the Netherlands) for 45 minutes at 37 °C in culture medium, centrifuged 
at 500g for 5 minutes and re-suspended in 200 µl cold culture medium. Flow cytometry 
was performed on stained cells using a BD-horizon v450 laser to detect the Hoechst blue 
signal. Acquired data was analyzed using the FlowJo software (V10, FlowJo, OR, USA).
Western blot analysis
Cells were lysed in laemmli protein buffer and incubated with benzonuclease for 30 
minutes to degrade RNA and DNA, prior to boiling. Proteins were separated by SDS- 
PAGE and then transferred to PVDF membranes (Pierce, Amersham Biosciences, UK). 
After protein transfer, membranes were blocked in 5% milk in PBS-0.02% Tween (Sigma 
Aldrich, Zwijndrecht, the Netherlands) and then stained with primary antibodies. 
Membranes were washed three times in PBS-0.02% Tween, followed by horseradish 
peroxidase (HRP) conjugated secondary antibody (DAKO, Agilent, CA, USA). Proteins 
were visualized with ECL reagent (GE Healthcare, Eindhoven, the Netherlands) and 
expression was detected with Fluorchem (Cell biosciences, Santa Clara, USA).
Colony assay
After assessing the number of viable cells, treated cells were seeded in 1 ml medium 
substituted with 0.1% low-melt agar type VII (Sigma Aldrich, cat# A-4018, Zwijndrecht, 
the Netherlands). Cells were incubated for 1 week until colony growth could be observed. 
Colonies were counted and stained by using 0.005% Crystal violet.
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RESULTS
CRISPR-Cas9 based kinome-wide screen in ALL
To identify pathways that modulate GC therapy response in BCP-ALL, we transduced 
a lentiviral library containing 5,070 sgRNAs targeting 507 kinases genes (10 sgRNAs/
gene) into Nalm-6 cells.17 These cells were then divided into two populations that were 
cultured for 17 days in the presence or absence of 50 µg/ml prednisolone (Figure 5.1A). 
Next, we performed high-throughput sequencing to compare the abundance of all sgRNAs 
in these two cell populations.
First, we determined the complexity of the sgRNA library, and monitored the impact 
of culturing in the absence of prednisolone exposure. At the start of the experiment (i.e. 
directly after dox induction), we identified 99.6% (5,049/5,070) of the sgRNAs, with 
a median read count of 3,304x per sgRNA (Figure 5.1B). Furthermore, we observed 
that 97.4% (494/507) of the genes had at least 9 sgRNAs with a read depth above 330x 
(10% of the median; Figure 5.1C). These data indicate that we had almost completely 
maintained complexity of the sgRNA library at the start of the experiment. Importantly, 
this complexity was retained after 17 days of culturing. In the absence of prednisolone, 
the sequenced library reached a median read count of 3,332x per sgRNA, with 96.2% of 
(4,878/5,070) sgRNAs reaching sufficient depth and 93.5% (474/507) of the genes having 
sufficient coverage of at least 9 sgRNAs. In addition, the sgRNA and gene counts from 
days 0 and 17 were very similar (r2=0.984 and r2=0.8, respectively; Figure 5.1D-E). These 
data indicate that the complexity of the sgRNA library was maintained during culturing 
and the culturing process had no major influence on the sgRNA selection.
To identify genes that could potentially affect response to prednisolone, we subsequently 
compared sgRNA abundance between the cells that were treated with high dose of 
prednisolone (50 µg/ml) and the cells that were left untreated. For each gene, we calculated 
the fold change in the abundance of all sgRNAs between treated and untreated cells at 
day 17 using the MAGeCK package. The large majority of sgRNAs were depleted (Figure 





Figure 5.1. Abundance of sgRNAs in the CRISPR-Cas9 based kinome-wide screen. (A) Schematic of 
the methodology applied in this study. Dox: doxycycline. Pred: prednisolone. (B) Violin plot of sgRNA 
read count in three cell populations. Center band depicts median read count. (C) Frequency of genes 
with good performance sgRNAs in the cell population at day 0. sgRNAs with read counts higher than 
10% of the median at day 0 (330x) were regarded as good performance sgRNAs. All genes were targeted 
by at least 7 out of 10 well performing sgRNAs. Scatter plots of sgRNA read count (D) and gene median 
read count (E) show high concordance in day 0 and day 17 untreated cell populations.
Unfortunately, the high dose of prednisolone in our screening approach, did not allow us to 
distinguish cells that died due to prednisolone exposure as a normal response, and cells that 
were sensitized for prednisolone due to knockout of a specific gene. Therefore, we focused 
on genes for which the sgRNAs remained in the pool, suggestive of a knockout-mediated 
prednisolone resistance phenotype. We noticed that cells with knockout of the genes 
IRAK1 and BARK1 were significantly positively selected by prednisolone treatment (Figure 
5.2B). Seven sgRNAs targeting IR AK1 (p=0.0006) and all sgRNAs targeting BARK1 
(p=0.0011) were enriched in the prednisolone treated cells (Figure 5.2C), which shows 
that cells with knockout of IR AK1 or BARK1 better survived the prednisolone treatment.
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Figure 5.2. sgRNAs targeting IRAK1 and BARK1 are selectively enriched in prednisolone-treated Nalm-6 
cells. (A) Scatter plot of normalized sgRNA read count in day 17 untreated and treated cell populations. 
(B) Gene rank based on p value calculated from the MAGeCK package. The two genes indicated in red 
obtained a low false discovery rate (FDR <30%). (C) Normalized read count of the 10 sgRNAs targeting 
IR AK1 (left) or BARK1 (right) from day 17 untreated and treated cell populations. (D) Schematic over-
view of ß-adrenergic receptor (ßAR) and its negative feedback mechanism by ßAR kinase 1 (encoded 
by BARK1). Agonist-bound ßAR causes enhanced downstream cyclic AMP (cAMP) signaling, which 
activates protein kinase A (PKA) and leads to BARK1 protein phosphorylation. BARK1 protein will 
phosphorylate ßAR resulting in receptor internalization and desensitization.
Knockout of BARK1 decreases prednisolone induced cell death
IR AK1 encodes the interleukin-1 receptor-associated kinase 1, which is involved in Toll-
like receptor (TLR) and interleukin-1 receptor (IL1R) signaling pathways.22 However, a 
potential role for IRAK1 protein in modulating GC sensitivity remains largely unknown. 
BARK1 is a negative regulator of ß-adrenergic receptor signaling (Figure 5.2D).23 Agonist-
bound Beta adrenergic receptor (ßAR) causes enhanced downstream cyclic AMP (cAMP) 
signaling, which activates protein kinase A and leads to BARK1 protein phosphorylation. 




desensitization. Since the function of BARK1 is to down-modulate ßAR signaling, and 
given the widespread clinical use of ß- adrenergic signaling antagonists as cardioprotective 
agents, we focused for the remainder of this study on validation of BARK1.
To validate this target, we selected three BARK1 sgRNA oligo pairs from the sgRNA library 
(sgRNA-BARK-1, sgRNA-BARK-4 and sgRNA-BARK-8), which were subsequently 
transduced into Nalm-6 cells. Sanger sequencing revealed the presence of sgRNA-
induced frameshift mutations in BARK1 in a sub-population of cells for two of the three 
pools (Figure 5.3A). To obtain a better estimate of the clonal burden of BARK1 mutated 
cells, we ligated the amplified sgRNA-targeted regions into TOPO- vectors, which were 
transformed in competent E. coli cell, and sequenced 10-13 individual colonies. We observed 
that 69% and 31% of the cells harbored indels introduced by sgRNA-BARK-1 and sgRNA-
BARK-8, respectively, while no BARK1 knockouts were generated by sgRNA-BARK-4 
(Figure 5.3B).
To confirm that knockout of BARK1 in these cells affects prednisolone response, we used 
cell cycle analysis to determine the fraction of cells in the sub-G1 phase, as a measure of 
apoptosis. Without prednisolone treatment, similar fractions of cells were shown to be in 
the sub-G1 phase in all samples studied, suggesting a similar rate of apoptosis between 
control and BARK1 knockout cells (Figure 5.3C and S5.1). After treating the cells with 
1 µg/ml of prednisolone for 10 days, we observed that cells with the BARK1 knockout 
(BARK1-KO-1 and BARK-KO-8) showed fewer cells in the sub-G1 phase, compared to 
the control cells (Figure 5.3C). These data show that knockout of BARK1 in Nalm-6 cells 
decreases prednisolone induced cell death, which illustrates that the relative enrichment 
of BARK1 sgRNAs we found in our screen indeed reflect a selective resistance phenotype 
in a subpopulation of cells.
Antagonizing ßAR signaling sensitized ALL cells to prednisolone
As mentioned above, BARK1 is part of a negative feedback loop that desensitized ßARs 
by triggering internalization leading to reduced downstream signaling.23 Therefore, 
the prednisolone resistance phenotype in the BARK1 knockout cells might be due to 
increased ßAR signaling. We hypothesized that the opposite effect - inhibition of ßAR-
signaling might sensitize leukemic cells to prednisolone. To test this hypothesis, we treated 
Nalm-6 cells with prednisolone in the absence or presence of propranolol, which is a ßAR 
antagonist that inhibits ßAR signaling. 
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Figure 5.3. Knockout of BARK1 decreases prednisolone induced cell death. (A) Sanger sequencing of 
PCR products from Nalm-6 cells with BARK1 knockout induced by CRISPR-Cas9. A pool of differ-
ent cell populations is generated by our CRIPSR_Cas9 knockout approach, resulting in overlapping 
peaks on the chromatogram (BARK1-KO-1 and BARK1-KO-8). sgRNA sequence and protospacer 
adjacent motif (PAM) region are highlighted in blue and pink, respectively. (B) Sanger sequencing of 
plasmid-cloned PCR products. Thirteen single colonies were picked for BARK1-KO-1 and BARK-KO-8, 
and 10 single colonies were picked for BARK1- KO-4. The first row shows the reference sequence with 
the sgRNA sequence and PAM region were highlighted in blue and pink, respectively. Mutations present 
are shown in red. (C) Cell cycle analysis of Nalm-6 cells with BARK1 knockout and control cells. All 
cells were treated without (gray bars) or with (black bars) 1 µg/ml prednisolone for 10 days. * p<0.05, 
t-test. Raw flow cytometry data are shown in Figure S5.1.
We found that PARP cleavage was significantly increased in Nalm-6 cells after 7 days co-
treatment of propranolol and prednisolone comparing to prednisolone single treatment 
(Figure 5.4A). Similarly, cell cycle distribution analysis indicated that a significantly 
higher fraction of cells treated by propranolol and prednisolone were in the sub-G1 
phase in comparison to cells treated by prednisolone alone (Figure 5.4B). Finally, we 




the treatment after 7 days of Nalm-6 cells, identical amounts of viable cells were seeded 
in soft agar to allow colony formation. While Nalm6 cells treated with propanolol alone 
recovered rapidly and ensued proliferation, prednisolone-treated cells formed significantly 
less colonies. However, cells that were treated with a combination of propranolol and 
prednisolone, were effectively eradicated by the combination treatment showing almost 
no colony outgrowth (Figure 5.4C). These findings suggest that propranolol causes a 
significant increase in prednisolone-induced apoptosis. Taken together, these preliminary 
functional data confirm the association between GC resistance and activation of ßAR-
mediated signaling pathway.
Figure 5.4. Antagonizing ßAR signaling sensitizes Nalm-6 cells to prednisolone. (A) Quantification 
of PARP ratio (cleaved/uncleaved] as detected by Western blot analysis. Nalm6 cells were treated for 
7 days with 100 µM antagonist (propranolol, Prop) in presence or absence of 0.5 µg/ml prednisolone 
(Pred). (B) Quantification of SubG1 phase detected by cell cycle analysis measured by Hoechst using 
Flow Cytometry. Nalm-6 cells, which were treated as described in (A). (C) Colony forming capacity of 
Nalm-6 cells after treatment.
DISCUSSION
In this study, we present proof-of-principle for using CRISPR-Cas9 based kinome 
screening as an approach to identify pathways affecting response to glucocorticoids in 
pediatric ALL. We transduced a kinase sgRNA library containing 5,070 gRNAs targeting 
507 kinase genes (10 sgRNAs/gene) in Nalm-6 cells, which we subsequently exposed to 
prednisolone. Our screen revealed two genes, IR AK1 and BARK1, for which knockout in 
Nalm-6 cells results in selective prednisolone resistance. We generated BARK1 knockout 
cell lines and were able to confirm that knockout of BARK1 decreases prednisolone induced 
cell death in vitro. Collectively, our data indicate that CRISPR-Cas9 based screening is able 
to identify pathways associated with prednisolone resistance in pediatric ALL.
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We found that knockdown of interleukin-1 receptor kinase 1 (IR AK1) conferred 
prednisolone resistance in pediatric ALL. A previous study has shown that inhibition of 
IR AK1 in T-ALL suppresses leukemic cell proliferation through delayed cell-cycle entry 
with little effect on cell apoptosis.24 As the downstream target of the Toll-like receptor 
(TLR) signaling pathway, IR AK1 can upregulate transcription factor NF- kappa B 
(NFKB).22 Interestingly, the chromatin-binding profile of p65 (the major NFKB subunit) 
and GR on a genome-wide scale implies a crosstalk between NFKB and glucocorticoid 
receptor (GR).25 Collectively, these data suggest that IRAK1 may play a role in GR response. 
Further studies are needed to elucidate its mechanism.
A second hit from our screen was BARK1. Recent studies have demonstrated that BARK1 
is a potential modulator of some of the hallmarks of cancer, while contributing to 
carcinogenesis in other cell types.26-30 A genome-scale shRNA screening in B-ALL also 
identified BARK1 as a gene involved in resistance to prednisolone.31 BARK1 is a kinase 
involved in a negative feedback loop that desensitizes beta-2-adrenergic receptor (ßAR) 
by triggering internalization leading to reduced downstream signaling.23 Therefore, the 
prednisolone resistance phenotype in the BARK1 knockout leukemic cells might be caused 
by increased ßAR signaling. Accordingly, using antagonists such as propranolol to reduce 
ßAR signaling might sensitize leukemic cells to prednisolone treatment. In line with this, 
asthma patients benefitted from treatment with a combination of glucocorticoids (GC) 
and ßAR agonists, which suggested the interaction between these two pathways.32 Indeed, 
by treating leukemic cells with a combination of these two drugs, we have observed that 
ßAR antagonist sensitizes leukemic cells to prednisolone treatment. Further studies are 
needed to validate this pathway as a therapeutic target in clinically more relevant models 
such as primary patient cells.
The CRISPR-Cas9 based large scale screening approach not only provides a new 
opportunity to identify novel targets associated with drug resistance, but also paves the 
way to discover pharmacologically druggable targets to sensitize leukemic cells to standard 
treatment. In this pilot study, the majority of cells were killed after prednisolone selection 
due to the usage of high dose of prednisolone. Therefore, we cannot distinguish between 
cells with different sensitivity to prednisolone. We hypothesize that with optimized 
reduction of the prednisolone dose, it will be possible to identify knockout targets that 




As a continuation of this screening, more functional studies are required to further 
validate the findings from this proof-of-principle study. As a first but vital step, isolation 
of pure cell clones with complete knock-out of the hit genes should be achieved. To test 
whether these clones have altered prednisolone sensitivity, the extent of cell death in 
response to prednisolone exposure should be measured. Moreover, although we limited 
our investigation to kinase genes related to prednisolone resistance, this approach can be 
applied to induce a wider range of genes. With appropriate sgRNA libraries, this approach 
should enable genomic analysis of ALL cells resistant to prednisolone.
In conclusion, we have shown that the CRISPR-Cas9 based screening approach can be 
successfully used to identify genes that are relevant to prednisolone resistance in ALL. 
This approach also provides opportunities to discover novel targets to enhance treatment 
response in ALL.
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SUPPLEMENTARY MATERIAL
Table S5.1. Oligo sequences used for PCR and sequencing
Name Sequence*
Outer PCR forward primer GCCGGCTCGAGTGTACAAAA
Outer PCR reverse primer AGCGCTAGCTAATGCCAACTT
Inner PCR forward primer AATGATACGGCGACCACCGAGATCTACACCGACTCGG
TGCCACTTTT
Inner PCR reverse primer CAAGCAGAAGACGGCATACGAGATNNNNNNNNTTT
CTTGGGTAGTTTGCAGTTTT
R1 sequencing primer CGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC
TTATTTTAACTTGCTATTTCTAGCTCTAAAAC
Index sequencing primer TTTCAAGTTACGGTAAGCATATGATAGTCCATTTTA
AAACATAATTTTAAAACTGCAAACTACCCAAGAA A
R2 sequencing primer TATGCTTACCGTAACTTGAAAGTATTTCGATTTCTT
GGCTTTATATATCTTGTGGAAAGGACGAAAC
*: N denotes sample barcodes (8bp). All primers are depicted 5’to 3’.












Figure S5.1. Cell cycle analysis of Nalm-6 cells with BARK1 knockout and control cells. All cells were 
treated with (bottom) or without (top) 1 µg/ml prednisolone for 10 days. The fraction of cells in sub- G1 
phase is shown for each cell line.
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Asparagine depletion by the protein drug asparaginase (ASNase), has been a mainstay of 
Acute Lymphoblastic Leukemia protocols for decades and shows promise in the treatment 
of a variety of other cancers. Metabolic drugs, such as ASNase, are attractive anti cancer 
agents as they show little long term adverse effects. Here, we employed a CRISPR/cas9-
based screen to identify actionable signaling intermediates that enhance/improve the 
response to ASNase. We find that both genetic inactivation of Bruton Tyrosine Kinase 
(BTK) as well as pharmacological targeting by the BTK inhibitor Ibrutinib, strongly 
synergizes with ASNase. We further show that BTK acts upstream of General Control 
Nonderepressible-2 kinase (GCN2), a key component of the amino acid response (AAR) 
pathway, an evolutionarily conserved mechanism that protects cells from amino acid 
starvation, while inhibition of BTK prevents activation of the AAR. In an ex-vivo screen 
using a panel of 38 ALL patient-derived xenografts (PDX), synergy was observed between 
ASNase and Ibrutinib in about 90% of the cases, irrespective of the genomic subtype. In 
addition, Ibrutinib substantially improved ASNase treatment response in a murine PDX 
model. Hence, Ibrutinib may be used to enhance the clinical efficacy of ASNase in ALL, 
while pharmacological inhibition of the AAR may broaden its use to other tumor types.
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INTRODUCTION
The protein drug Asparaginase (ASNase) is a key component of Acute Lymphoblastic 
Leukemia (ALL) treatment regimens worldwide, and has shown clinical efficacy in other 
cancers such as T-cell lymphoma subtypes, acute myeloid leukemia and even some solid 
tumors.1,2 In contrast to other chemotherapeutic agents, this metabolic therapy is not 
associated with long term adverse effects, a benefit that could be exploited by increasing the 
efficacy of this drug in the treatment of ALL and other cancers. ASNase acts primarily to 
catalyze the conversion of L-Asparagine (Asn) into L-Aspartate (Asp), leading to depletion 
of Asn from the blood. As leukemic blasts and some other tumor cells are selectively 
dependent on the exogenous supply of Asn, sustained exposure to ASNase leads to amino 
acid starvation, a cessation of growth, and ultimately, the induction of apoptosis.1
In spite of the fact that ASNase is a cornerstone drug of ALL treatment regimens, its 
clinical efficacy is often compromised. This can be due to inactivation of the drug, for 
instance by the formation of inhibitory antibodies, or a result of therapy violations in 
response to allergic reactions or treatment related toxicities. In addition, incomplete 
depletion of Asn can occur because of poor penetrance of the drug in the central nervous 
system or by secretion of Asn by stromal cells in the bone marrow niche.3-5 Suboptimal 
Asn depletion at these sanctuary sites may be sufficient to maintain leukemic blasts in 
a state of cellular quiescence rather than to induce apoptosis, increasing the chance of 
relapse once treatment is discontinued. Therefore, obtaining a detailed understanding 
of the cell intrinsic and extrinsic factors that affect the opposing cellular responses to 
ASNase is needed to further optimize ASNase therapies in leukemia, and to broaden its 
use in other tumor types.
MATERIALS AND METHODS
Ethical statement
Patient derived xenografts were generated from samples of patients collected from 
different countries within the International BFM Study Group (I-BFM-SG) and the 
Dutch Childhood Oncology Group. All patients were enrolled in trials on treatment of 
pediatric ALL conducted by individual member groups of the I-BFM-SG: the AIEOP- 
BFM study group (Austria, Germany, Italy and Switzerland), the FRALLE study group 
(France) and the United Kingdom (UK) National Cancer Research Institute (NCRI) 




respective national institutional review boards, and informed consent for the use of spare 
specimens for research was obtained from study individuals, parents or legal guardians.
Plasmids
The following plasmids were obtained via Addgene: pS-Pax2 (#12260), pMD2.G (#12259), 
pCW-Cas9 (#50661), gRNA library targeting kinases (#51044), pLentiCRISPR-v1 (no 
longer available via Addgene).
GuideRNAs libraries were amplified as instructed (Addgene). Library complexity was 
verified using next generation sequencing. For targeted knockout, gRNA sequences (Table 
S6.1) were cloned into pLentiCRISPRv1 using the BsmBI sites and the resulting vector 
was verified using Sanger sequencing.
Reagents
Asparaginase (Paronal) was purchased from Takeda (Hoofddorp, the Netherlands). 
Ibrutinib, GCN2 inhibitor (A-92), Nfkb inhibitor (BAY11-7082), mtor inhibor 
(rapamycin), Erk inhibitor (SCH772984) and JNK inhibitor (SP600125) were purchased 
from Selleckchem (Munich, Germany) and dissolved as instructed by the manufacturer.
Cell culture
Nalm6 (ACC 128), Sem (ACC 546) and Reh (ACC 22) were obtained from the Leibniz 
Institute DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, 
Germany) and maintained in RPMI (Invitrogen, Thermo Fisher Scientific, Breda, the 
Netherlands), supplemented with 10% fetal bovine serum (FBS, Greiner Bio-One, Essen, 
Germany) and 1% penicillin/streptomycin solution (Invitrogen) at a cell density between 
0,25 and 3x106 cells per milliliter.
Hek293FT cells were purchased from Invitrogen and maintained in DMEM, supplemented 
with 10% FBS, 1% Non-essential amino acids (Gibco, Thermo Fischer) and 1% penicillin/
streptomycin solution. Cell cultures were tested regularly for the presence of mycoplasm.
Lentivirus production and transduction
HEK293FT packaging cells (Invitrogen) were co-transfected with the viral backbone 
encoding the sgRNAs or Cas9 and the helper plasmids for virus production (psPAX2 
and pMGD2), using Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instructions or Polyethylenimine (PEI). Virus containing supernatant was collected 2 
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days after transfection. Virus was concentrated by centrifugation at 25,000g for 1 hour 
at 4°C and resuspended in the cell culture medium required by the target cells. Target 
cells (0,5-1x106) cells were transduced with 1 ml virus (1-10 times concentrated) using 
spinoculation for 45 min at 700g (25°C) in the presence of 5 ug/mL polybrene (Santa 
Cruz Biotechnology, Dallas, TX). Selection was started 72-96 hours after transduction.
CRISPR/Cas9 screen
First, Nalm6 cells were transduced with lentivirus encoding a doxycycline inducible Cas9.6 
After puromycin selection, inducible Cas9 expression was verified by immunoblotting. 
Next, lentivirus encoding the kinome library was introduced at an MOI<1 and infected 
cells were selected using blasticidin. After selection, genomic DNA was extracted from 
this cell pool and subjected to targeted amplification and sequencing (Illumina HiSeq 
2500 platform) to confirm that library complexity was sufficiently maintained. Single 
cell clones were selected by limiting dilution and Sanger sequencing revealed that each 
analyzed clone contained a single gRNA (not shown). Cas9 expression was induced by 
incubating the cells with doxycycline (2 ug/ml) for 2 weeks. Next, cells were split into 2 
pools and 1 pool, containing 10 x 106 cells was treated with an IC50 dose of ASNase (5 
IU/ml) for 2 weeks. The change in abundance of each sgRNA between the initial seeding 
and the ASNase treated population was determined by deep sequencing.
High throughput deep sequencing
The sgRNA inserts were amplified in a nested PCR (see TableS6.1 for primer sequences). 
We purified the products from the first PCR using Agencourt AMPure XP beads 
(Beckman Coulter Genomic, CA, USA) and eluted in 100 µl of low TE buffer. The inner 
PCR with 12 cycles was performed to add sequencing primers to the amplicons and 
barcode the samples (Table S6.1). Inner PCR products were purified using Agencourt 
AMPure XP beads (Beckman Coulter Genomic, CA, USA) and then sequenced on the 
Illumina HiSeq platform (Illumina, CA, USA) using custom designed sequencing primers 
(Table S6.1). Genes targeted by gRNAs that were significantly enriched or depleted during 
treatment were identified using the MAGeCK algorithm (V0.5.3).7
Cell viability assays
Cell viability was determined using a MTS assay and flow cytometry using Hoechst or an 
amine staining to discriminate between live and dead cells. For the MTS assay 100.000 
cells were seeded in a well of a 96 well plate, flow cytometry cells were seeded in a 24-well 




were counted after 4 days and reseeded at 500.000 viable cells per ml in medium with 
inhibitors. In case of ASNase, the replacement medium was pre-incubated with ASNase 
to ensure depletion of asparagines before addition to the culture. After the indicated 
incubation times, relative cell viability was assessed using the CellTiter 2 96® AQueous 
One Solution Cell Proliferation (MTS) Assay (Promega, Madison, WI). Absorbance 
was acquired using a plate reader (Infinite F50; TECAN, Männedorf, Switzerland). 
Alternatively, cells were stained with LIVE/DEAD™ Fixable Dead Cell Stain Sampler Kit 
(Thermo-Fischer, L34960) according to the manufacturer’s instructions or by incubating 
the cells with 7,5 µg/ml Hoechst 33342 (Sigma Aldrich (Zwijndrecht, the Netherlands) 
for 45 minutes at 37 °C in culture medium. Stained cells were analyzed by Fluorescence 
Activated Cell Sorting (FACS) using an LSRII flow cytometer (BD Biosciences, Breda, 
The Netherlands). For co-culture experiments, MSCs were gated out via FSC/SSC gating. 
The data were collected and analyzed by FlowJo V10 software (FlowJo, Ashland, Oregon).
Colony assay
Cells were counted and 5000 (Nalm6) or 10.000 (Sem) viable cells were seeded in 1 ml 
medium substituted with 0.1% low-melt agar type VII (Sigma Aldrich, cat# A-4018). 
Cells were incubated for 1 – 2 weeks until colony growth could be observed. Colonies 
were counted and stained by using 0.005% Crystal violet.
Ex vivo culture of patient derived xenografts
Patient derived xenograts (PDXs) were generated as described by intrafemoral injection 
of 1 × 105 to 5 × 106 viable primary ALL cells in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ 
(NSG) mice.8 The ex vivo co-culture has been described previously.9 In short, hTERT 
immortalized MSCs were seeded in a 384 or 96-wells format 24 hours prior to the addition 
of ALL xenografts.10 ALL cells were allowed to settle for 24 hours before chemotherapeutic 
agents were added in increasing concentrations. After 3 days of incubation, cell death was 
analyzed by 7-AAD staining using flow cytometry (for details see Cell viability assays).
Automated viability assay
hTERT immortalized MSCs were seeded in a 384-wells format (14.000 cells/well) 
24 hours prior to the addition of ALL xenografts (140.000 cells/well). ALL cells were 
allowed to settle for 24 hours before chemotherapeutic agents were added in increasing 
concentrations. Serially diluted drugs were prepared by using epMotion 5070 and 
TecanD300 robots. After 3 d or 7 d of drug incubation, cells were stained using the 
CyQUANT direct cell proliferation assay (Life technologies) and automated imaging 
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was performed using an ImageXpress Micro microscope (Molecular Devices). Images have 
been processed using CellProfiler software (Broad Institute) to define the number of viable 
cells in each well, and drug response have been normalized to PDX cells treated with the 
drug vehicle alone. Data were analysed using the SynergyFinder software.11
Immunoblotting
Cells were lysed in laemmli protein buffer and treated with benzonuclease for 30 minutes, 
prior to boiling. Purified proteins were separated by SDS-PAGE and then transferred 
to PVDF membranes (Amersham Biosciences). After protein transfer, membranes were 
blocked according to the specific antibody and stained with primary antibodies (Table 
S6.2), washed in PBS-0.02% Tween, followed by horseradish peroxidase (HRP) conjugated 
secondary antibody (DAKO, Agilent, Santa Clara, CA.). Proteins were visualized with 
ECL reagent (GE Healthcare, Eindhoven, the Netherlands) and expression was detected 
with Fluorchem (Cell biosciences, Santa Clara, USA).
Reverse Phase Protein Array
Reverse Phase Protein Array (RPPA) analysis was performed as described.12 Briefly, 
samples were normalized to a concentration of 1 × 104 cells/ml and printed in five (1:2) 
serial dilutions onto slides along with normalization and expression controls. Slides 
were probed with 230 strictly validated primary antibodies and a secondary antibody 
to amplify the signal, and finally a stable dye was precipitated. Protein expression data 
from treated samples were normalized relative to untreated samples and subjected to a 
principal component analysis. From this, the top 50 proteins that contributed most to 
principal component 1 were selected and unsupervised hierarchical clustering (Ward’s 
linkage) was applied.
In vivo synergy study
All animal experiments were approved by the Animal Experimental Committee of 
the Radboud university medical center (RU-DEC-2015-005-009) and were performed 
in accordance with institutional and national guidelines. NSG-mice were injected 
intrafemurally with 0.5-1x106 viable cells into each femur. Two weeks after injection, 
mice were randomized into 4 groups (7 mice per group) and treated with control solvents, 
ibrutinib or ASNase alone or both compounds for 9 consecutive days. Asparaginase was 
dissolved in PBS and administered i.v. (300 IU/kg in 100 µl) on days 1, 4 and 7. Ibrutinib 
was dissolved in 5% DMSO+30% PEG 300+5% Tween 20 in water and administered 




weekly by flowcytometric detection of human cells as measured by staining for human 
CD10, CD45, CD22 and CD19 and murine CD45. cells. Mice were sacrificed after the 
human CD45+ reached 50% of total CD45+ cells.
Statistical analyses
The statistical analyses for the cell viability assays and quantitative real-time polymerase 
chain reaction (qRT-PCR) were performed using PRISM6 (GraphPad Software, La 
Jolla, CA). For the Amine stainings and qRT-PCR, a student’s t test was performed. All 
statistical tests were two-sided and p values of less than 0.05 were considered statistically 
significant. For animal studies, the log-rank (Mantel cox) test was used for comparison 
between groups and Kaplan-Meier test was used to test for differences in survival times.
RESULTS
CRISPR/Cas9 based Kinome screen identifies genes involved in 
Asparaginase sensitivity
To identify actionable cell intrinsic modifiers that control the delicate balance between 
cell survival and apoptosis during ASNase treatment in ALL, we performed a CRISPR/
Cas9 based loss-of-function screen in the pre-B ALL cell line Nalm6. We used a previously 
described lentiviral vector system to express a doxycycline-inducible Cas9 (Figure S6.1A) 
in combination with a gRNA library targeting the genes encoding the complete human 
kinome (507 kinase) with 10 distinct gRNAs per gene.6 After selection using blasticidin, 
genomic DNA was extracted from this cell pool and subjected to targeted amplification 
and sequencing to confirm that library complexity was sufficiently maintained. At the 
start of the experiment (i.e. directly after dox induction), we found that 89% of the 
kinases was targeted by 6 or more individual gRNAs (not shown). These data indicate 
that we had sufficiently maintained the complexity of the sgRNA library at the start of 
the experiment. Lentivirally transduced cells were treated for two weeks with 5IU/ml 
ASNase. To identify gRNAs that were selectively enriched or depleted during treatment, 
genomic DNA from treated and untreated control cells was isolated and subjected to 
paired-end deep sequencing (Figure 6.1A-B and Figure S6.1B). Remarkably, the relative 
frequency of most sgRNA was largely unchanged upon ASNase treatment (Figure 6.1C), 
suggesting that under these experimental conditions, ASNase treatment does not result 
in massive cell death. The MAGeCK algorithm was used to prioritize genes of which 
gRNAs were selectively enriched or depleted during treatment.7 This algorithm ranks genes 
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based on a consistent differential effect of multiple gRNAs targeting the same gene. This 
analysis yielded 20 genes for which loss of function was associated with resistance (enriched 
gRNAs) while gRNAs for 31 genes were selectively depleted during treatment, suggesting 
that loss of these kinases enhances sensitivity to ASNase (Figure 6.1D and Figure S6.1C). 
Figure 6.1. CRISPR-Cas9 based kinome screen identifies modifiers of ASNase sensitivity in BCP-
ALL. (A) Schematic representation of the screening strategy. Nalm6 cells were transduced stepwise 
with a doxycycline inducible Cas9 and a kinome sgRNA library. Cells were cultured for 2 weeks 
in the presence of 2 ug/ml doxycycline to induce Cas9 expression and 1 week in the absence of 
doxycycline. Then, cells were treated for 2 weeks with 5 IU/ml ASNase, DNA was isolated, subjected 
to NGS and results were analyzed using the MAGeCK algorithm. (B) Immunoblot analysis of Cas9 
protein expression in cells during culture. (C) The number of reads per sgRNA in the DNA extracted 
from the cell populations before and after treatment. (D) Gene list of gRNA targets that significantly 
modulate ASNase response, ranked by p-value calculated using the MAGeCK algorithm.
Asparaginase response is affected by pathways regulating protein 
translation and cell survival
The molecular responses that follow in response to amino acid starvation have been 
described in detail. The Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4 
(EIF2AK4), better known as general control nonderepressible 2 (GCN2), is a cellular amino 
acid sensor. Under conditions of amino acid shortage, GCN2 is activated by uncharged 
tRNAs, leading to a global suppression of protein translation by phosphorylation of the 
eukaryotic initiation factor 2 (eIF2), which causes cells to arrest in G1 of the cell cycle.13 
At the same time, translation of activating transcription factor 4 (ATF4), which is eIF2-




a wide range of adaptive genes within the Amino Acid Response (AAR) pathway, which 
acts to maintain cellular homeostasis in response to amino acid stress. One of these genes 
is asparagine synthetase (ASNS), the enzyme responsible for the cellular production of 
Asn. In experimental ALL models, resistance to ASNase was found to be associated with 
increased expression of ASNS, although its mRNA expression in patient cells does not 
appear to be a reliable predictor of ASNase resistance.14 This suggests that other effectors 
of the AAR, such as amino acid transporters and autophagy regulating genes, may 
also allow cells to overcome periods of amino acid shortage. However, under persistent 
stress conditions, ATF4 will start a transcriptional program that favors the induction of 
apoptosis.15
Consistent with its central role in the response to amino acid starvation, we identified 
GCN2 as one of the kinases for which gRNAs were selectively depleted in response 
to Asparaginase exposure (Figure 6.1D and Figure S6.1D). In addition, Eukaryotic 
Elongation Factor 2 Kinase (eEF2K), another regulator of protein translation required 
for cell survival under acute nutrient stress16 and RPS6KL1, also known as P90RSK, which 
acts to directly regulate the activity of eEF2K,17 were identified as potential modifiers of 
ASNase therapy response. These results illustrate that translational control in response to 
ASNase-induced nutrient starvation is key to ASNase induced cell survival, and suggest 
that targeting these kinases may enhance treatment efficacy (Figure S6.1E).
In addition to gRNAs that were selectively lost in response to ASNase exposure, other 
gRNAs, such as those targeting the pseudokinase Tribbles 3 (TRIB3), were enriched upon 
selection, suggesting that loss of these gene products contributes to ASNase resistance 
(Figure 6.1D and Figure S6.1D-E). TRIB3 is an effector of the AAR, implicated in the 
induction of apoptosis in response to nutrient stress.18 More specifically, TRIB3 is one of the 
genes selectively upregulated by the transcription factor ATF4 in response to repression 
of global protein translation.18
To assess the validity of our screening results, we used targeted CRISPR/Cas9 mediated 
deletion of GCN2 and TRIB3 and tested how deletion of these genes affected the response 
to ASNase. We generated unselected pools of GCN2 and TRIB3 targeted cells and used 
Western blotting to confirm diminished protein expression in these pools (Figure 6.2A-
B). Wild type and targeted cells were exposed to ASNase and DNA fragmentation was 
determined by flow cytometry as a measure of cell death, while metabolic activity was 
used to determine cell viability.
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Figure 6.2. Kinases involved in metabolic stress signaling modulate sensitivity to Asparaginase. 
Immunoblot analysis of TRIB3 (A) or GCN2 (B) protein expression in pools of cells upon CRISPR/
Cas9-based targeting of TRIB3 or GCN2, respectively. (C) Proliferation assay of untreated or 
ASNase (5IU/ml) treated Nalm6 wt and Nalm6 TRIB3 deleted cells. Data points represent mean +/- 
SEM, n=3. (D-E) ASNase induced cell death as determined by quantification of cells in subG1 phase 
using flow cytometry of Hoechst stained cells. Bars represent mean +/- SEM of n=3 independent 
experiments. *** P< 0.001, ** P< 0.01, *** P< 0.05, two-tailed unpaired t-test. (F-G) Cell viability as 
measured by MTT in Nalm6 wt, TRIB3del and GCN2KO cells. after treatment with the indicated 
dose of ASNase. Bars represent mean +/- SEM of n=3 independent experiments. *** P< 0.001, ** P< 
0.01, *** P< 0.05, two-tailed unpaired t-test.
Despite the incomplete loss of GCN2 expression in these cell pools, targeted deletion of 
GCN2 enhanced the response to ASNase treatment, by promoting the apoptosis-inducing 




deleted Nalm6 cells were more resistant to ASNase induced growth inhibition (Figure 
6.2C) and the induction of apoptosis (Figure 6.2D-E). We conclude from these findings 
that our reverse genetics screening approach can be successfully used to (i) delineate 
pathways that contribute to therapy resistance and (ii) identify protein (kinase) targets 
that can be selectively inhibited to modulate therapy response. 
Brutons tyrosine kinase (BTK) protects against ASNase induced 
apoptosis
In addition to regulators (or effectors) of protein translation, we identified a number of 
kinases implicated in cell survival that can be targeted to enhance the apoptosis induction 
in response to ASNase. These include- the Src-like kinase YES1, the Ser-Thr kinase AKT3 
as well as Bruton Tyrosine kinase (BTK) (Figure 6.1D), a key component of the B cell 
antigen receptor (BCR) signaling pathway and essential for B cell development and 
survival.19 BTK is predominantly expressed in cells of hematopoietic origin, although 
ectopic expression in various solid tumors, such as breast cancer and neuroblastoma has 
been reported.20-22 Targeting of BTK using the kinase inhibitor Ibrutinib has shown 
impressive clinical efficacy in the treatment of mature B cell malignancies, including 
Mantle Cell Lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s 
marcoglobulinemia while it is under clinical evaluation for the treatment of B cell 
lymphomas.23-26 Both its restricted expression pattern and the availability of a clinical 
grade small molecule inhibitor prompted us to investigate a potential synergy between 
BTK inhibition and ASNase therapy. First, we used targeted knockout of BTK to validate 
the results from our screen. Single cell clones fully deficient for BTK were selected by 
limiting dilution (Figure 6.3A and Figure S6.2A) and exposed to ASNase. Again, we 
used flow cytometry to test for DNA fragmentation and membrane integrity as a measure 
of cell death. In addition, we used Western blotting to analyze the extent of PARP cleavage 
(Figure 6.3A). In control cells, exposure to ASNase induced cell cycle arrest, while no 
significant induction of the level of apoptosis was observed (Figure 6.3A and 6.3C; Figure 
S6.2C-D). In contrast, ASNase efficiently induced apoptosis in the BTK knockout cells 
(Figure 6.3A and 6.3C; Figure S6.2C-D).
To discriminate between the effects of ASNase treatment on either growth arrest or the 
induction of apoptosis, we performed ‘wash-out’ experiments in which cells were allowed 
to recover by reseeding in soft agar or normal growth medium in the absence of the drug 
(Figure 6.3B). 
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Figure 6.3. Targeted KO of BTK sensitizes BCP-ALL cell lines to ASNase. (A) Immunoblot analysis of 
BTK protein expression in single cell clones upon CRISPR/Cas9-based targeting of BTK and apoptosis 
induction as measured by immunoblot analysis of PARP in Nalm6 wt and Nalm6 BTK deleted cells 
after a 7 day treatment with 5 IU/ml ASNase. Representative blot of three independent experiments. (B) 
Schematic overview of experimental procedure. Nalm6 wt and Nalm6 BTK deleted cells were treated 
with 5 IU/ml ASNase for 7 days, followed by direct evaluation of apoptosis or recovery capacity in a 
clonogenic assay after washout of the ASNase. (C) ASNase induced cell death as determined by quan-
tification of cells positive for amine-reactive dyes using flow cytometry in Nalm6 wt and Nalm6 BTK 
deleted cells after a 7 day treatment with 5 IU/ml ASNase. Each data point represents a mean of one 
clone of 3 independent experiments. Mean of all clones is indicated by line. *** P< 0.001, ** P< 0.01, 
*** P< 0.05, two-tailed unpaired t-test. (D-E) Clonogenic proliferation assay of Nalm6 wt and Nalm6 
BTK deleted cells. After a 7 day treatment with 5 IU/ml ASNase 5000 viable (trypan blue negative) 
cells from each sample were seeded in soft agar. Recovery capacity was determined by quantification of 





While control Nalm6 cells recovered rapidly and ensued proliferation, resulting in the 
outgrowth of colonies, cells deficient for BTK showed a strongly reduced ability to recover 
from ASNase therapy (Figure 6.3D-E and Figure S6.2B-D). We conclude from these 
experiments that BTK is essential for cell survival of ALL cells under conditions of Asn 
depletion.
The BTK inhibitor Ibrutinib potentiates ASNase induced apoptosis 
in B-cell progenitor ALL cell lines
The availability of FDA approved BTK inhibitors, such as Ibrutinib, opens the possibility 
for combination therapies exploiting the synergy between ASNase and loss of BTK 
function. Therefore, we tested Ibrutinib/ASNase combinations in three different BCP-
ALL cell lines (Nalm6, Sem, Reh) (Figure 6.4A). In contrast to treatments with ASNase 
and Ibrutinib as a single agent, which were effective in inhibiting proliferation, but unable 
to induce cell death, we observed that a combination of the two drugs potently induced 
apoptosis (Figure 6.4B-C and Figure S6.3A). To further test this premise, we repeated 
washout experiments with either Nalm6 cells or the KMT2A-rearranged B cell precursor 
leukemia cell line Sem. Following removal of the drugs, the capacity of cells to grow 
out was tested using colony assays. Similar to BTK knockout cells, cells that had been 
treated with ASNase or Ibrutinib alone remained viable and grew out to form colonies, 
whereas cells that had received a combination of ASNase and Ibrutinib were effectively 
eradicated by the treatment (Figure 6.4D-E), even after only 3 days of treatment (Figure 
S6.3B). We conclude from these experiments that treatment of ALL cell lines with either 
ASNase or Ibrutinib as a single agent induces a state of cellular quiescence, allowing cells 
to resume proliferation after the treatment is stopped, while a combination of the two 
drugs efficiently induces cell death.
BTK signaling intersects with the AAR
To determine how inhibition of BTK may synergize with ASNase, we performed reverse-
phase protein array (RPPA) as an unbiased approach to test which proteins/pathways are 
affected in response to ASNase, Ibrutinib or a combination of both drugs. The RPPA panel 
used allows the determination of global differences in expression and/or phosphorylation 
of 236 key cancer-related proteins in response to treatment.12 Using this platform, we 
compared the RPPA proteome from Nalm6 and Sem cells that were either left untreated, 
exposed to ASNase or Ibrutinib as a single agent or in combination. Protein expression 
levels from treated samples were normalized relative to untreated samples and subjected 
to a principal component analysis. 
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Figure 6.4. The BTK inhibitior Ibrutinib potentiates ASNase induced apoptosis. (A) Schematic 
overview of the experimental procedure. BCP-ALL cell lines were were treated with ASNase, 
Ibrutinib or a combination of both for 7 days, followed by direct evaluation of apoptosis or recovery 
capacity in a clonogenic assay after washout of the ASNase. (B) Cell death as determined by 
quantification of cells in subG1 phase using flow cytometry of Hoechst stained cells. Nalm6, Sem 
and Reh cells were treated with indicated doses of ASNase and Ibrutinib. Bars represent mean +/- 
SEM of n=3 independent experiments. *** P< 0.001, ** P< 0.01, *** P< 0.05, two-tailed unpaired 
t-test. (C) Apoptosis induction as measured by immunoblot analysis of PARP in BCP-ALL cell lines. 
Representative of three independent experiments. (D-E) Clonogenic proliferation assay of Nalm6 
and Sem cells. After 7 days treatment with indicated doses of Ibrutinib and ASNase 5000-10000 
viable (trypan blue negative) cells from each sample were seeded in soft agar. Recovery capacity was 
determined by quantification of colonies. Bars represent mean +/- SEM of n=3 replicates of one 





From this, the top 50 proteins that contributed most to the difference between the 
treatments (PC1) were selected and unsupervised hierarchical clustering (Ward’s linkage) 
was applied (Figure 6.5A).
Although we did observe clear similarities between the changes in protein expression 
in both cell lines in response to single agent treatments, these effects were moderate. 
In contrast, the combination treatment profoundly affected protein expression/
phosphorylation in both cell lines, consistent with the observed strong synergy between 
ASNase and Ibrutinib (Figure 6.5A). In line with our previous results, pro-apoptotic 
activators such as cleaved caspase (7 and 9) or PARP and Bcl2L11 (Bim) remained largely 
unchanged or were only slightly upregulated upon single agent treatment, while strongly 
increased when the two drugs were combined. Of note, the combination treatment 
specifically affected expression and phosphorylation of a number of proteins involved in 
the AAR, including the phosphorylated form of translation factor eIF2α, suggesting that 
Ibrutinib suppresses the ability of cells to mount the AAR (Figure 6.5A).
We used western blot to further study the modified response to combination treatment 
and showed that protein expression of the essential effectors required for the adaptation 
to ASNase treatment (ATF4 and ASNS) is suppressed by ibrutinib (Figure 6.5B). We 
conclude that ASNase exposure leads to GCN2-mediated activation of the AAR and 
the upregulation of ATF4 target genes, while the combination of ASNase and Ibrutinib 
prevents activation of ATF4 and its target genes.
In addition to the effects on translation and the subsequent activation of salvage 
mechanisms, the cell also prepares for the execution of apoptosis by downregulation of 
BCL2 through the ERK-JNK pathway and expression of the pro-apoptotic pseudokinase 
TRIB3. To acquire further insight into how BTK inhibition potentiates ASNase induced 
apoptosis by suppression of the GCN2-ATF4 axis, we studied how inhibition of different 
pathways downstream of GCN2 affected ASNase induced cell death (Figure S6.4A). 
Inhibition of mTORC1, JNK and ERK failed to synergize with ASNase in both of the 
tested ALL cell lines (Figure S6.4B). As expected, inhibition of GCN2 function, either by 
use of a small molecule inhibitor or by genomic knockout potently promoted apoptosis in 
combination with ASNase (Figure S6.4B-C). An inhibitor of NfKb, which is activated in 
response to GCN2 mediated phosphorylation of eIF2a [28], also synergized with ASNase 
(Figure S6.4B).
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Figure 6.5. BTK signaling intersects with the Amino Acid stress response pathway. (A) Proteome 
expression of Nalm6 and Sem cells treated with ASNase, Ibrutinib or a combination of both as deter-
mined by RPPA. Quantified protein expression levels from treated samples were normalized relative 
to untreated samples and subjected to a principal component analysis. From this, the top 50 proteins 
that contributed most to the difference between the treatments (PC1) were selected and unsupervised 
hierarchical clustering (Ward’s linkage) was applied. (B) Immunoblot analysis of ATF4 and ASNS 
protein expression. Nalm6 and Sem cells were treated with indicated doses of ASNase and Ibrutinib. 
Representative of three independent experiments.
Moreover, loss of BTK function, either by genomic knockout or pharmacological inhibition 
using Ibrutinib, repressed GCN2 protein expression. Conversely, BTK expression is 
elevated in GCN2 knockout clones suggesting that there is reciprocal control of expression 
(Figure S6.5A-B). Of note, in BTK deficient cells we could still observe some degree of 
synergy between Ibrutinib and ASNase (Figure S6.5C). This indicates that inhibition of 
other Ibrutinib targets, such as EGFR, TEC family kinases or Src like kinase, may also 
contribute to the observed synergy. Importantly, no further synergy between ASNase and 
Ibrutinib was seen in GCN2 knockout cells, consistent with our observations that BTK 
represses GCN2 to potentiate ASNase mediated cell death (Figure S6.5D). Together, 
these results support our model that BTK signaling modifies the AAR pathway through 




Ibrutinib potentiates ASNase induced apoptosis of ALL xenografts 
across cytogenetic subtypes
To validate our results in cells that more closely reflect primary human leukemia, we 
analyzed the potential synergy between ASNase and Ibrutinib in patient-derived 
xenografts, grown on feeder layers of immortalized bone marrow stroma cells.9 To this 
end, we performed co-titration experiments using 10 different concentrations of ASNase 
and Ibrutinib and their combinations, resulting in a 10X10 matrix. A panel of 38 ALL 
xenografts was incubated with these compounds for 3 and/or 7 days before automated 
microscopy-based image analysis was used to quantify living cells (Figure 6.6A). Data 
were plotted as dose-response curves and interaction landscapes and average synergy were 
calculated using the zero interaction potential (ZIP) method by use of the synergyfinder.11 
We observed a synergistic interaction between ASNase and Ibrutinib in approximately 
90% of patient-derived xenografts (Figure 6.6B). Of note, the synergistic effects appeared 
to be independent of the ALL subtype (Table S6.2). Importantly, the interaction 
landscape showed that synergistic interaction was observed at a clinically relevant dose 
(Figure 6.6C). Five of our tested xenografts showed no synergistic interaction between 
ASNase and Ibrutinib. Three of these appeared to be extremely responsive to ASNase as a 
single agent (as exemplified in Figure 6.6C, sample SK-5942D), which could explain the 
lack of synergy in these cases. Similar results were obtained using 7-aminoactinomycin 
D (7-AAD) to measure the extent of cell death following treatment, revealing synergy in 
eight out of ten tested xenografts (Figure 6.6D).
Finally, we assessed whether Ibrutinib could potentiate the response to ASNase in freshly 
isolated cells obtained from a refractory ALL patient, that showed a non-response to 
ASNase. Indeed, the addition of Ibrutinib was able to reverse ASNase resistance in this 
patient (Figure S6.6).
Ibrutinib/ASNase combination therapy delays leukemia develop-
ment and prolongs survival in vivo
We next tested whether the combination of ASNase and BTK inhibition would also 
be effective at concentrations that are manageable in vivo. Therefore, non-conditioned 
immunocompromised mice were engrafted with patient derived BCP-ALL cells by 
allowing the cells to home and expand for two weeks following intrafermural injection. 
After engraftment, mice were treated with either vehicle alone, Ibrutinib alone, ASNase 
alone or the combination (Figure 6.7A). 
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Figure 6.6. The BTK inhibitior Ibrutinib synergizes with ASNase treatment in a large panel of ALL 
PDX. (A) Schematic overview representing the workflow used to determine ex-vivo drug responses 
in PDX samples. ALL-PDX were seeded on hTERT immortalized MSCs and treated with ASNase, 
Ibrutinib or combinations of both. After 3 and 7 days of incubation cell death was either analyzed by 
7-aminoactinomycin D (7AAD) staining using Flow cytometry or automated microscopy using a live 
cell staining using CyQuant (synergy matrix). (B)Overview of the calculated drug interactions between 
ASNase and Ibrutinib in the PDX samples. (C) Dose-response curves and synergy matrix plots showing 
δ-scores of 3 representative ALL PDX samples treated with drug matrix of ASNase and Ibrutinib (upper 
panel). (D) Apoptosis induction as a result of drug treatment, determined by quantification of 7AAD 
positive cells using flow cytometry. PDX samples were treated 3 days with increasing doses of ASNase 




Figure 6.7. Ibrutinib delays leukemia development and prolongs survival in ASNase treated mice. (A) 
Schematic overview of the experimental procedure. NSG mice were engrafted with ALL PDX two 
weeks before start of treatment with vehicle, 300 IU/kg ASNase (days 1,4,7), 25mg/kg Ibrutinib (days 
1-9) or a combination of both. Leukemia development was followed over time by weekly determination 
of percentage of human CD10 positive cells in blood. Post mortem, histological analysis of organs was 
executed. (B) Leukemia development as determined by percentage of human CD10 detected by flow 
cytometry in peripheral blood samples of mice treated with Ibrutinib, ASNase or a combination of both. 
Data points represent mean +/- SEM of 6 mice per treatment group. (C) Survival analysis of mice of 
different treatment groups. *** P< 0.001, ** P< 0.01, *** P< 0.05, Log-rank (Mantel-Cox) test.
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The duration of treatment was limited by the poor tolerance of these mice for ASNase 
treatment. Indeed, we observed adverse effects from the treatment with ASNase, 
as exemplified by a sharp but transient drop in body weight during treatment, but no 
additional signs of toxicity were observed when Ibrutinib was combined with ASNase 
(Figure S6.7A). Post mortem histological analysis of liver and pancreas showed no toxicity 
related to any treatment.
After treatment, leukemia development was followed over time by analyzing the 
percentage of leukemic cells in peripheral blood using flow cytometry (Figure 6.7B and 
Figure S6.7B), and mice were sacrificed when the leukemic clone expanded to over 50% 
of the total number of lymphocytes. Mice treated with Ibrutinib alone did not benefit 
from the treatment and developed leukemia at a rate comparable to the vehicle treated 
group. In contrast, mice treated with ASNase alone, initially showed suppression of 
leukemia development. However, this response was not durable and the delay in leukemia 
development lasted approximately as long as the treatment (7 days). This is in accordance 
with our in vitro data showing that exposure to ASNase effectively inhibits cell growth, 
without the widespread induction of apoptosis. Importantly, despite the use of only a 
single, short block of treatment, we observed a significant delay in leukemia development 
and survival when using the combination treatment, indicating that BTK inhibition 
strongly synergizes with ASNase to induce leukemic cell death in vivo (Figure 6.7B-C).
DISCUSSION
Amino acid deprivation has recently gained interest as a therapeutic intervention beyond 
hematological malignancies, both in the treatment of primary tumors as well as prevention 
of metastasis.2,29-33 The successful application of such a metabolic therapy may allow less 
intensive use of classical chemotherapeutics such as DNA damaging agents, reducing the 
potential risk of long-term adverse effects or the occurrence of secondary malignancies. In 
this study we show the potential of combining amino acid depletion with small molecule 
inhibitors that further sensitize tumor cells to this form of treatment. A CRISPR-Cas9 
based loss-of-function screen, which was limited to an actionable set of genes, the kinome, 
allowed us to identify a therapeutic target that strongly enhances the clinical efficacy of 
ASNase. We discovered that inhibition of BTK function, either by induction of genomic 
mutation or use of the small molecule inhibitor Ibrutinib synergizes with ASNase 
treatment to induce leukemic cell death. This effect is seen both in cell lines and xenografts 




In contrast to treatment with ASNase or Ibrutinib as a single agent, which induces a 
reversible state of cellular quiescence, the combination therapy effectively kills the leukemic 
cells. Our findings further indicate that BTK signaling interferes with GCN2 protein 
function, a critical regulator of the amino acid response (AAR) pathway. A central 
component of the AAR acting downstream of GCN2 is the stress activated transcription 
factor ATF4. Whereas exposure to ASNase induced expression of ATF4 and upregulation 
of the ATF4 target gene asparagine synthetase (ASNS), combined exposure to ASNase 
and Ibrutinib effectively interfered with activation of ATF4 and the ATF4 target ASNS. 
We speculate that the observed inhibition of GCN2 protein expression and function and 
the resulting decrease in EEIF2 phosphorylation limits the ability of leukemic cells to 
activate ATF4 and adapt to amino acid deprivation.
GCN2 is an essential regulator of the cellular response to amino acid limitation in all 
tissues. Although the use of a GCN2 inhibitor has been explored in pre-clinical studies, 
observations in GCN2 knockout mice suggest that loss of GCN2 function enhances 
the risk of treatment related morbidities such as liver toxicity and pancreatitis.34-36 In 
contrast, BTK expression in healthy individuals is largely restricted to the hematopoietic 
compartment and therefore allows tissue specific treatment. Although the use of ASNase 
in NSG mice is limited by toxicity, as displayed by a sharp but transient weight loss, 
the addition of Ibrutinib did not cause any additional toxicity, nor did it enhance the 
toxic effects of ASNase. Ibrutinib is currently used for the treatment of indolent B cell 
malignancies, particularly chronic lymphocytic leukemia (CLL), and is generally well 
tolerated. Although BTK function is mostly associated with B cell receptor (BCR) 
signaling, it has other functions independent of the BCR.37 Recently, a potential clinical 
use of Ibrutinib in pre-BCR positive acute lymphoblastic leukemia was suggested.27
One of the intriguing observations of our study is the finding that the combination 
therapy is effective across BCP-ALL subtypes, irrespective of B-cell maturation status or 
the presence of an active pre-BCR, and is therefore more broadly applicable.
Combining Ibrutinib with ASNase in the treatment of BCP-ALL may have several 
additional benefits. Leukemic cell infiltration of the central nervous system poses a 
challenge for successful treatment, for instance due to the limited penetrance of therapeutic 
compounds through the blood-brain-barrier. Although the therapeutic protein ASNase 
will not cross the blood brain barrier (BBB), it is effective in lowering asparagine levels in 
the cerebrospinal fluid (CSF) through exchange with the blood. However, depletion in 
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the CSF can be incomplete, creating a sanctuary site allowing leukemic cells to survive.3,38 
Importantly, Ibrutinib was shown to cross the BBB and have clinical efficacy in patients 
with CNS infiltrated Waldenström’s marcoglobulinemia (WM) and CNS relapsed mantle 
cell lymphoma.39-41 Therefore, we hypothesize that ASNase/ Ibrutinib combination therapy 
may also effectively reduce the threshold for ASNase induced apoptosis in the CNS.
Moreover, in CLL patients, Ibrutinib treatment leads to transient lymphocytosis, forcing 
the leukemic cells out of the bone marrow as a result of repression of expression of adhesion 
receptors.42 Since the bone marrow microenvironment has been recognized as a potential 
protective niche that supports leukemic cells survival during ASNase treatment, this may 
be an additional therapeutic benefit. Finally, since Ibrutinib was shown to inhibit mature 
B cells, it may prevent the formation of inhibitory antibodies or immune cell related 
toxicities, the most frequently occurring adverse effects of ASNase treatment.43
In summary, our study shows that a reverse genetics screen can successfully identify tissue-
or tumor cell specific modifiers of the Amino Acid Response (AAR). In addition, we show 
that inhibition of BTK signaling effectively suppresses the AAR, sensitizing BCP-ALL 
cells to ASNase induced apoptosis. As ectopic expression of BTK has been reported in a 
variety of other tumor types responsive to Asn depletion,20,21 the results from our study 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S6.2. Sample details












m1227 mouse na nd
x 10.63
x nd
m1307 mouse na E2A-HLF
x 10.12
x 9.09
m1339 mouse na nd
x 14.9
x 8.85
m1371 mouse na nd
x 4.81
x 6.11
m1560 mouse na nd
x 3.2
x 4.98
m1594 mouse na E2A-PBX1
x 7.72
x 7.17
m1600 mouse na E2A-PBX1
x 16.4
x nd
m1675 mouse na nd
x 9.17
x 0.945
m1717 mouse na E2A-PBX1
x 10.43
x 960.78
m1730 mouse na E2A-PBX1
x 2.18
x 2.28
m3147 mouse na nd
x 3.31
x 9.31
m3153 mouse na nd
x 1.25
x 8.13
m3285 mouse na DS-ALL, TEL-AML
x nd
x 11.52
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Table S6.2. Continued




m3596 mouse na MLL-AF4
x 7.27
x 6.86
m3657 mouse na E2A-HLF
x 13.73
x 11.21
m3794 mouse na E2A-HLF
x 1.59
x 5.65
m3810 mouse na E2A-PBX1
x 1.16
x 0.674
m4136 mouse na nd
x 4.44
x 1.43
m4138 mouse na nd
x 4.3
x nd
m4206 mouse na Hyperdiploid
x 5.58
x 4.1
m764 mouse na HHD, E2A-PBX1
x 5.48
x 3.53
m838 mouse na MLL-AF4
x 9.08
x nd
m877 mouse na E2A-PBX1, t(2;12)
x 10.15
x -1.62
X-R-IV-109 PDX diagnosis BCR-ABL1
x 4.15
x 9.11
X-SK-14316 PDX diagnosis B-other
x 4.77
x nd
X-SK-5486R PDX relapse nd
x 8.99
x 24.966
X-SK-5864D PDX diagnosis t(17,19)
x nd
x 8.76
X-SK-5942D PDX diagnosis B-other
x -0.15
x -0.59











X-SK-8266 PDX diagnosis E2A-PBX1
x -6.28
x 2.4
XX-IV-113 PDX diagnosis CRLF2-P2RY8
x 15
x 3.35
XX-IV-121 PDX diagnosis B-other
x 11.64
x -0.35
XX-IV-153 PDX diagnosis ABL+
x 15.41
x 0.57
XX-IV-182 PDX diagnosis B-other
x 6.76
x 0.62
XX-SK-15723 PDX diagnosis nd
x 11.22
x 2.17
PDX: patient derived xenograft. na: no applicable. nd: no data.
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Table S6.3. Antibodies used in this study
Antibody Supplier Cat. number Solvent Dilution
ATF4 Cell Signaling Technologies 11815S 1% BSA 1:1000
Trb3 Santa Cruz Biotechnology Sc-34211 1% ELK 1:500
GCN2 Cell Signaling Technologies 3302 1% ELK 1:1000
ASNS Santa Cruz Biotechnology Sc-365809 1% ELK 1:500
BTK Cell Signaling Technologies 3533 1% ELK 1:1000
Phospho-BTK Abcam Ab68217 1% BSA 1:1000
PARP Cell Signaling Technologies 9542 1% ELK 1:1000
Tubulin Genetex GTX628802 1% ELK 1:10000
Actin Sigma Aldrich A4700 1% ELK 1:10000
Flag M2 Sigma Aldrich F3165 1% ELK 1:1000
hCD19-PE-Cy7 eBiosciences 25-0199-42 0,02% BSA in PBS 1:100
hCD10 - PE BD 555375 0,02% BSA in PBS 1:50
mCD45 –V500 BD 561487 0,02% BSA in PBS 1:100




Figure S6.1. CRISPR-Cas9 based kinome screen identify modifiers of ASNase sensitivity in BCP-ALL. 
(A) Immunoblot analysis of Cas9 protein expression in Nalm6 cells transduced with a doxycycline 
inducible Cas9 and gRNA Kinome library. Cells were treated with 2ug/ml dox for 3, 7 and 14 days 
where after dox was washed away. (B) Recovery of gRNAs at the start of the experiment. Close to 85% 
of all guides included in the library could be retrieved from the cell pool at the start of the experiment. 
(C) Median log fold change of gRNA targeting genes that significantly modulate ASNase response. 
(D) Counts of individual gRNAs targeting TRIB3, GCN2 and BTK respectively before and after 
ASNase treatment. (E) Simplified scheme of the Amino Acid Response pathway. Kinases identified in 
the CRISPR/CAs9 loss-of-function screen as modifiers of the ASNase response are boxed in purple 
(sensitizers) or blue (desensitizers).
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Figure S6.2. Genetic loss of BTK inhibits recovery of Nalm6 cells after ASNase treatment. (A) DNA 
sequence of the BTK gene of Nalm6 BTK knockout clones around target site of gRNAs (2.1, 2.2, 4, 5) 
as determined by Sanger sequencing. In most clones a homozygous mutation was found. (B) Clonogenic 
proliferation assay of Nalm6 wt and Nalm6 BTK deleted cells. After treatment with 5 IU/ml ASNase 
the same amount of viable cells were seeded in soft agar. A representative example of three independent 
experiments is shown. (C-D) ASNase induced cell death as determined by quantification of cells in 
subG1 phase using flow cytometry of Hoechst stained cells after treatment with 5 IU/ml ASNase (7d). 
After treatment, 5000-10000 viable (trypan blue negative) cells from each sample were seeded in soft 
agar. Recovery capacity was determined by quantification of colonies. Lines indicate the mean of the 




Figure S6.3. Short term exposure to ASNase and Ibrutinib induces cell death. (A) ASNase induced cell 
death as determined by quantification of cells positive for amine-reactive dyes using flow cytometry in 
ALL cell lines after treatment with 1 IU/ml (Nalm6, Sem) or 0.001 IU/ml (Reh) ASNase in the presence 
or absence of Ibrutinib. Each bar represents a mean of 3 independent experiments. *** P< 0.001, ** P< 
0.01, *** P< 0.05, two-tailed unpaired t-test. (B) Clonogenic proliferation assay of Nalm6 and Sem cells. 
After 3 days of treatment with the indicated doses of Ibrutinib and ASNase the same amount of viable 
cells were seeded in soft agar. Outgrowth was determined by quantification of colonies. Bars represent 
mean +/- SEM of n=3 replicates of one experiment. Representative of three independent experiments. 
*** P< 0.001, ** P< 0.01, *** P< 0.05, two-tailed unpaired t-test.
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Figure S6.4. ASNase induced apoptosis can be potentiated by inhibition of GCN2 and downstream 
effectors, but not other modulators of AAR pathway. (A) Simplified schemes of the Amino Acid Re-
sponse pathway and B Cell Receptor pathway. Inhibitors targeting components of both pathways are 
highlighted. (B) Cell death as determined by quantification of cells in subG1 phase using flow cytometry 
of Hoechst stained cells or by quantification of cells positive for amine-reactive dyes using flow cytom-
etry. Nalm6 and Sem cells were treated with 1 IU/ml ASNase in combination with indicated doses of 
different inhibitors. (C) ASNase induced cell death as determined by quantification of cells positive for 
amine-reactive dyes using flow cytometry in Nalm6 wt and Nalm6 GCN2 deleted cells after treatment 




Figure S6.5. Loss of BTK potentiates ASNAse induced apoptosis by repression of GCN2. (A) Immuno-
blot analysis of BTK and GCN2 protein expression in control and knockout Nalm6 cells. Representative 
of three independent experiments. (B) Quantification of GCN2 and BTK protein expression. Bars 
represent the average expression of single cell clones normalized for Actin expression. (C) Cell death 
as determined by quantification of cells in subG1 phase using flow cytometry of Hoechst stained cells. 
Nalm6 wt and Nalm6 BTK KO were treated with 1IU/ml ASNase in combination with indicated doses 
of Ibrutinib. Each data point represent mean of n=3 independent experiments. Line represents mean of 
clones. (D) Cell death as determined by quantification of cells in subG1 phase using flow cytometry of 
Hoechst stained cells. Nalm6 wt and Nalm6 GCN2 KO were treated with 1IU/ml ASNase in combina-
tion with indicated doses of Ibrutinib. Each data point represent mean of n=3 independent experiments. 
Line represents mean of clones. (E) Working model of synergistic interaction of BTK inhibition and 
ASNase treatment. Upon ASNase treatment cells upregulate the AAR pathway via GCN2 to adapt 
to nutrient stress. Upon BTK inhibition GCN2 is repressed and cells are not able to induce the AAR 
pathway if treated with ASNase and eventually die.
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Figure S6.6. Ibrutinib render ASNase resistant primary patient material sensitive to ASNase ex vivo. 
Cell death as determined by quantification of cells positive for amine-reactive dyes using flow cytometry. 
Primary ALL-patient material co-cultured with MSCs was treated with increasing doses of ASNase in 
combination with 0, 1 or 10 uM Ibrutinib. Each data point represents one experiment.
Figure S6.7. Ibrutinib does not promote ASNase induced toxicities, but delays leukemia development 
in mice. (A) Weight analysis of NSG mice. Line represent mean +/- SEM of 6 mice per treatment group. 
Data points represent mean of +/- SEM of 6 mice per treatment group. (B) Leukemia development as 
determined by percentage of human CD10 detected by flow cytometry in peripheral blood samples of 
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Relapse development is a major cause of treatment failure in children with acute 
lymphoblastic leukemia (ALL). Prevention of relapse is, therefore, one of the main aims 
of upfront therapy. In the past decades, improved stratification strategies have contributed 
significantly to decrease relapse rate. Many features including clinical characteristics, 
genomic alterations and minimal residual disease (MRD), the latter of which provides 
a quantitative measurement of remaining leukemic cells in the bone marrow during 
treatment, have been used to stratify patients into different risk groups. Each of these 
risk groups receives treatments with different intensities.1,2 This strategy has resulted in 
a continuing decrease in relapse rate, which is currently below 10% in several studies.3,4 
However, children that do relapse under these regimens are the most challenging to cure, 
thus a much better understanding of relapse development is needed to improve treatment 
outcome. The aim of the research described in this thesis was to study the mechanism(s) 
underlying relapse development in ALL.
There are several general principles that may contribute to relapse of ALL in a child. 
For example, complications such as infections may occur during upfront therapy, which 
requires interventions before anti-leukemic treatment can be continued. In some cases, 
severe toxicities for specific agents may require adaptation of the standard protocol. The 
absence of therapeutic pressure may enable leukemic cells to recover and proliferate. 
Another possibility is that leukemic cells harboring alterations that are associated with 
therapy resistance may survive the treatment and lead to relapse. Lastly, a sub-population 
of the leukemic cells may survive because it is not susceptible to therapy due to a dormant 
(non-dividing) state of the cells or to spatial isolation in regions that are not reached 
effectively during therapy. Preventing relapses in upfront treatment protocols, therefore, 
requires that we obtain a better understanding of these principles and in which patients 
and under what circumstances they apply.
An important way to unravel relapse development in ALL is to assess which genomic 
aberrations contribute to the development of relapse. Recent advances in next-generation 
sequencing (NGS) technologies have revolutionized this field of research, which has 
led to the identification of many genomic alterations relevant to relapse development in 
ALL. One highly rewarding strategy has been to analyze ALL diagnosis samples and to 
study associations with relapse development. Genomic profiling of diagnosis samples has 
led to the identified recurrent alterations in ALL, such as deletions in the IKZF1 gene, 
which encodes the lymphoid transcription factor IKAROS.
5,6 Recent survival analyses 
and in vitro studies have confirmed the important role and the strong prognostic value of 
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IKZF1 in relapse development.7-10 However, the characterization of relapses themselves can 
add an important extra layer of information, since new aberrations may have occurred 
and clonal selection may have taken place since the start of upfront treatment. Indeed, 
several genes have been found to carry new aberrations at relapse, including alterations 
in CREBBP and TP53 and gain-of-function mutations in NT5C2, which are common in 
relapsed T-lineage ALL (T-ALL), but also occur in B cell precursor ALL (BCP-ALL).11,12 
The latter gene encodes a 5’-nucleotidase, which is responsible for the maintenance of 
intracellular nucleotide pools. Finally, a paired genomic analyses of diagnosis and relapse 
samples may provide an additional layer of information, since insights can be obtained in 
how genomic aberrations change during treatment in individual patients.
To understand the mechanisms of relapse development in ALL, we have taken several 
approaches as described in this thesis. We have compared the genomic composition of 
relapsed samples between different upfront protocols in order to find clues between 
therapies and relapse development. Furthermore, we have compared genetic alterations 
between diagnosis and relapse for individually relapsed patients in order to understand 
which clones grow out to relapse and how they evolve. Since minor clones at diagnosis 
might survive treatment and grow out to relapse, we have investigated whether such clones 
can be recognized already at the time of diagnosis and whether their detection may be 
relevant for predicting relapse. Finally, using reverse genetic screens, we have searched 
for genes that contribute to a reduced or an increased sensitivity for two individual 
components of upfront treatment, i.e., prednisone and L-asparaginase. Each of these 
approaches is further discussed in the paragraphs below.
GENOMIC CHARACTERIZATION OF ALL RELAPSES
Some alterations commonly identified at diagnosis are also recurrent at relapse. For 
example, deletions in CDKN2A/B are equally common at both diagnosis and relapse, 
affecting around 30% of patients (Chapter 2). Along with this, point mutations in Ras 
genes are identified in similar amounts of patients at diagnosis and relapse. Alterations in 
IKZF1 present in over 30% of relapse samples (Chapter 2), are found in 10-15% of diagnosis 
samples.8,13,14 On the other hand, some alterations appear to be typical of relapse, such as 
point mutations in NT5C2, PRPS1 and CREBBP. We found that 4% of BCP-ALL relapses 
carry NT5C2 mutations (Chapter 2), and are rarely detected at diagnosis (Chapter 4), in 




attention in recent years in many studies, because they provide clues for therapy failure and 
relapse development and provide new insights for improving therapy regimens.
EVOLUTIONARY PATTERNS FROM DIAGNOSIS TO RE-
LAPSE
During the process from diagnosis to relapse, we have observed distinct phenomena for 
individual leukemic clones. Some clones were found to be shared between diagnosis and 
relapse, while others were found to decrease (fall) or rise during relapse development 
(Figure 7.1). Backtracking of relapse-specific alterations in paired diagnosis samples 
allowed us to identify which alterations are preserved and which are acquired (Chapter 
2). For example, we have studied the origin of clonal IKZF1 deletions that are identified 
in relapse samples, and found that the vast majority of these deletions is already present 
at diagnosis in major clones. This observation was also made in earlier studies, and is 
completely in line with the association of these alterations with relapse showing that IKZF1-
altered clones indeed give rise to relapse in these cases.8,14 The high frequency of preserved 
IKZF1 alterations suggests that elimination of clones harboring these alterations during 
upfront treatment is less effective. This was also shown in vitro where IKZF1 was related to 
resistance to glucocorticoids (GCs), which are major compounds used in current treatment 
protocols.9
In contrast, we found that clones carrying NT5C2 mutations are usually arising at the time 
of relapse and are rarely present at diagnosis (Chapter 2 and 4).9,11,12 Recently, we have 
unraveled the clonal evolution mechanism of NT5C2 mutated ALL and suggested that 
6-mercaptopurine (6-MP) may serve as a selection force driving clonal outgrowth.16 Taken 
together, we conclude that studies assessing evolution patterns of individual clones may 
provide major insights for exploring the mechanism(s) underlying relapse development.
In individual patients, the evolution pattern may include multiple distinct processes and 
show a dynamic pattern (Figure 7.2). In an ongoing project, we are performing whole 
genome sequencing (WGS) of paired diagnosis and relapse samples from two ALL 
patients with very early relapses (remission time less than one year) and are comparing 
the genomic landscape of the two time points. Preliminary data show that of all single 
nucleotide variants (SNVs) identified at diagnosis, the vast majority was preserved at 
relapse. Along the same line, previous studies have revealed other evolutionary patterns 
in ALL patients.14,17–19 Together, the observed evolutionary patterns in patients mainly 
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include: 1) relapse developed from a major clone at diagnosis, 2) relapse developed from a 
minor clone at diagnosis, and 3) multiple (sub)clones at diagnosis that persist as multiple 
(sub)clones at relapse (Figure 7.2). In about 55% of the cases, relapses developed from 
minor clones present at diagnosis, representing the most common evolutionary pattern. 
The different evolutionary patterns from diagnosis to relapse indicate that the intrinsic 
capacities of cells to resist therapy vary between patients and treatment regimens, and are 
due to different cellular processes.
Figure 7.1. Evolutionary patterns of individual leukemic clones from diagnosis to relapse. The evolution 
process may involve three major scenarios: 1) clones are shared between diagnosis (inner circle) and 
relapse (outer circle) or 2) clones (blue) are rising in relapse, 3) clones (purple) are falling from diagnosis 




UPFRONT TREATMENT AFFECTS THE SPECTRUM OF 
GENOMIC ALTERATIONS AT RELAPSE
Clinical studies differ in composition and dosage of different drugs in order to find the 
optimal therapy for patients with different risks of relapse.3,4,20 Statistical values such as 
overall survival and cumulative incidence of relapse are commonly used to evaluate the 
effectiveness of treatment. The overall and event-free survival analyses reveal whether 
new protocols have significantly improved outcome compared to historical studies or 
control treatment arms.21,22 However, such studies are not able to provide insight into 
the mechanism of treatment failure, the understanding of which is extremely helpful for 
the design of new generation protocols. Although the genomic structures of BCP-ALL at 
diagnosis among different clinical studies are in principle identical, the genomic landscapes 
in relapse can be distinct due to the varied efficacy of upfront regimens. Comparing the 
genomic architecture of relapses from different treatments at diagnosis may, therefore, 
provide important insights into the associations between intensity and/or composition of 
therapy and the mechanisms of relapse development. When performing such comparisons, 
some aspects should be carefully taken into consideration. First, since new studies are 
usually designed based on the backbone of preceding studies, differences are expected to be 
small. To obtain the power to detect such small differences, large numbers of relapses are 
required which, with decreasing numbers of relapse rates, are difficult to obtain. Second, 
risk stratification creates variability in the subtype distribution per risk group, which 
hampers comparisons between these risk groups. Third, the so-called cocktail therapies 
that use combinations of drugs in each treatment arm hamper direct correlations between 
genomic alterations at relapse and specific chemotherapeutics applied in upfront treatment. 
Together, these difficulties may explain why such comparisons have not been reported 
in the literature so far. In this thesis, we have presented such a study, in which we have 
addressed at least to some extent the challenges mentioned above (chapter 2). The next 
paragraph outlines in more detail how this was done.
Between 1991 and 2012, the Dutch Childhood Oncology Group (DCOG) has 
completed three consecutive studies, namely ALL8, ALL9 and ALL10. One of 
the major differences between ALL9 and the other two studies is the amount of 
glucocorticoids (GCs) applied in protocols, particularly in relation to other drugs. 
Patients enrolled in the ALL9 study received high doses of GCs, regardless of the 
risk stratification. With this very different conceptual design of ALL9, the upfront 
treatment between ALL8, ALL9 and ALL10 showed major differences, which 
created an opportunity to perform a detailed genomic comparison of relapse. 
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Figure 7.2. Evolutionary patterns in individual patients. (A) Major clone (yellow) present at diagnosis 
leads to relapse development. (B) Minor clone (blue) at diagnosis leads to relapse development. (C) 
Multiple (sub)clones present at diagnosis develop into multiple (sub)clones at relapse. Each colored circle 
represents a cell. The number of cells indicates the level of clonality.
Next to comparing the spectrum of genomic alterations between total protocols, we 
analyzed which alterations in each of the treatment arms were enriched or depleted 
compared to the initial diagnosis. In this way, an analysis of the impact of treatment within 
a group of risk-stratified patients was possible, and a comparison of fold-changes between 
diagnosis and relapse per gene of interest between treatment arms could be performed.
After comparing the genetic composition of relapses from these three studies, we were 
indeed able to identify different mutation distributions among ALL8, ALL9 and ALL10 
relapses (Chapter 2). Most strikingly, we found that IKZF1 deleted relapses were more 
common in ALL9 than in the other two relapse cohorts, which is in line with previous 
studies indicating that the prognostic value of IKZF1 deletions differs between protocols 
and is particularly strong in the ALL9 study.8,23 Meanwhile, CREBBP mutated relapses 
were found to be significantly less frequent in ALL9 compared to those in ALL8 and 
ALL10. Together, such comparisons of genomic alterations between relapses in the 
context of upfront treatment regimens indeed provides a unique opportunity to study 




Despite the undisputed and continuously improving success rates for cocktail therapies,3,4 
the observed differences in relapse alterations between these protocols must somehow find 
its origin in differences in the upfront treatment regimens. Unfortunately, we were not 
able to correlate these differences with specific chemotherapeutic drugs due to the complex 
design of the respective treatment arms and the low number of relapses from these two 
studies. This is particularly true for ALL8 and ALL10 relapses which, in contrast to the 
ALL9 relapses, showed multiple CREBBP mutations. However, clinical studies with less 
complex compositions of chemotherapeutics may provide opportunities to identify relevant 
associations. The design of the ALL9 protocol, which was heavily based on high doses of 
glucocorticoids (GCs) in both high risk and non-high risk patients, and relied much less 
on other commonly used drugs, suggests an association between GCs and IKZF1 deleted 
relapses. Importantly, these findings were supported by in vitro studies, which demonstrated 
that IKZF1 alterations may diminish GC responses in both normal and leukemia cells.9 This 
result nicely illustrates how these in vitro studies can be used to support the findings made 
in primary samples to obtain insights into the correlation between genomic alterations 
in ALL and drug resistance and relapse, particularly when dealing with relatively low 
numbers of available relapse samples to compare between. Finally, reporting the genomic 
architecture of relapses in clinical studies may provide great opportunities for meta-analysis 
to combine similar upfront protocols and examine the cause of treatment failure.
THE PROGNOSTIC VALUE OF MINOR SUBCLONES
Clonal heterogeneity potentially increases the capacity of a leukemia to adapt to different 
circumstances and, thereby, to evolve more rapidly. These evolutionary mechanisms may 
affect patient outcome. Backtracking of relapse-related alterations has indicated that ALL 
relapse arises from minor subclones at diagnosis, suggesting a mechanism of selective 
survival and/or outgrowth during therapy.14,17,19 One clear example of this phenomenon is 
NT5C2, mutations in which if detectable at diagnosis are present in minor subclones.11,12,16 
With strong selection by therapy, these NT5C2 mutation-carrying subclones may grow out 
to major clones at relapse. This observation raises the interesting question whether minor 
subclones are relevant for risk stratification. To address this issue, an approach to accurately 
detect subclones in a large cohort is required.
Various methods have been developed to detect subclones in ALL. One such method is 
digital droplet PCR (ddPCR), which selectively amplifies alternate variants, even when 
present in minor amounts. The ddPCR is a powerful tool to detect sub-clonal mutations 
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with a high specificity and sensitivity as low as 2 in 10 000.16 A limitation of this technology, 
however, is that it is variant-specific. As a result, ddPCR is highly effective in backtracking 
or following variants that have already been identified, but is not able to identify novel 
minor sub-clonal variants in a high-throughput manner. For these kinds of studies, next 
generation sequencing (NGS) is a better alternative. The lower accuracy due to synthesis 
errors during amplification, a fundamental problem for many NGS-based approaches, can 
be addressed by the introduction of unique molecular identifiers (molecular tags), which 
significantly increases the accuracy to identify variants with low allele frequency.24,25 We 
have made use of this principle by applying single molecule molecular inversion probes 
(smMIPs), in which each captured DNA template received a unique barcode.26 Improved 
analysis algorithms allowed to eliminate random errors introduced during amplification 
27 and to detect minor sub-clonal mutations with allele frequencies as low as 0.4% in ALL 
(Chapter 3). We subsequently used this approach to accurately detect sub-clonal mutations 
in a large unselected diagnosis cohort, thereby providing an opportunity to study the 
prognostic value of subclones in ALL.
Due to the high sensitivity, fast speed and reduced cost per sample, NGS is being 
incorporated more and more in routine diagnostics of ALL. With the increasing sensitivity, 
it is to be expected that sub-clonal alterations in clinically relevant genes will be identified 
more often. However, the impact of sub-clonal alterations on therapy response and outcome 
has not been investigated and may very well be different from that in cases carrying full-
clonal alterations.
In this thesis we have presented such a study to determine the impact of sub-clonal 
alterations to relapse development by making use of a large cohort of diagnosis samples 
from 503 patients, of which 146 relapsed. A set of genes (CREBBP, IKZF1, KR AS, NR AS, 
PTPN11, NT5C2, TP53 and WHSC1) that are common in relapse was selected to allow deep 
sequencing in a cost-effective and high-throughput manner, and to increase the chance 
to identify a high number of alterations that increases statistical power. Out of these 
eight genes, only IKZF1 is currently used as a prognostic marker in diagnostics, because 
of its strong prognostic value for relapse development. Other studies have demonstrated 
enrichment of mutations in these genes at relapse, including the CREBBP, NT5C2 and 
RAS genes.11,12,15,27,28 We found that sub-clonal alterations may occur very frequently at 
initial diagnosis, but are not of prognostic value. In patients developing relapse, sub-clonal 
alterations were often found to be frequently lost whereas clonal alterations were found to 




The studies mentioned above mainly focused on secondary alterations, i.e. alterations that 
occur across subtypes and are not considered as initiating events in leukemia development. 
It could be argued that structural chromosomal alterations that serve as hallmark subtypes 
of leukemia would have a stronger prognostic values even when present as a sub-clonal 
alterations. For example, the BCR-ABL1 rearrangement, which is known to be associated 
with a poor prognosis in leukemia,29–31 has been very rarely reported as a sub-clonal 
alteration in a few ALL and AML patients, but also in these cases it was suggested that 
these sub-clonal rearrangements did not have any effect on prognosis.32,33 Along the 
same line, clonal PR2Y8-CRLF2 rearrangements are associated with an increased risk of 
relapse.34–36 In spite of the fact that the clonal size of the PR2Y8-CRLF2 rearrangement is 
not relevant for the respective relapse risk and overall survival, sub-clonal lesions rarely 
persist in relapse.37 These data suggest that sub-clonal alterations at diagnosis may represent 
relatively late events in leukemogenesis that are less likely to drive relapse development.
The finding that sub-clonal IKZF1 deletions are not associated with relapse development is 
unexpected, since previous studies have shown a strong association between clonal IKZF1 
deletions and relapse.8,13,23 The biology underlying this phenomenon remains largely 
unknown. To explain these findings, we speculate that the game of clones in ALL relapse 
is a game of numbers and chances, together with the fact that alterations randomly appear 
during the process of DNA synthesis. The allele frequency from bulk sequencing data 
represents the number of tumor cells carrying the alteration. The more cells with certain 
alterations, the higher the chance that this type of tumor cells will randomly accumulate 
additional alterations that are needed to induce relapse development. In contrast, the 
chance of minor clones to accumulate sufficient numbers and types of additional alterations 
is lower. We did not find a strong association between sub-clonal alterations and relapse 
development (Chapter 4) and, thus clinical practice may need to be adjusted. A patient 
with a blast count of 98% and an IKZF1 deletion in 5% of the cells would, accordingly, not 
receive an extra year of maintenance treatment as our study now suggests.
Since the consequences for a patient of having a clonal or a sub-clonal IKZF1 deletion are 
substantial, a good definition of what is called sub-clonal is critical. The cutoff for the allele 
frequency that is used in the literature to define sub-clonal alterations generally ranges 
between 20% and 30%.18,38-40 Obviously, no matter what threshold is chosen, for alterations 
with allele frequency close to this value a decision is difficult to make and should always 
be taken with extra care. Likely, evaluating those individual alterations in a case-by-case 
manner would help to improve the accuracy of diagnosis. Alternatively, tracking these 
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alterations in MRD samples enables us to follow the leukemia development status and, 
subsequently, base a decision on the response of the IKZF1-deleted subclone relative to the 
major clone rather than on the presence of the subclone at the time of diagnosis. A poorer 
response relative to the wildtype clone would indicate that the IKZF1-deleted cells are 
more resistant and may become enriched which, in turn, may lead to relapse development.
Taken together, our study has suggested that sub-clonal alterations in the genes studied are 
unlikely to contribute to risk stratification in clinical practice. Nevertheless, monitoring 
the alteration status in MRD samples may help to track the leukemia developing process.
CRISPR SCREEN IN ALL
Therapy resistance continues to be a major impediment in ALL treatment, as most 
chemotherapy will lead to resistance after prolonged use.41,42 To reverse the poor 
responsiveness of therapy-resistant cells, alternative therapeutic strategies may be beneficial. 
This could potentially involve novel compounds, preferably targeting leukemia-specific 
alterations or vulnerabilities, or strategies to increase the efficacy of existing drugs. 
Therefore, it is important to understand the underlying biology of resistance and to 
discover cellular pathways that could be selectively regulated to improve therapy response. 
One way is to perform genome wide screens to identify targets related to therapy resistance.
CRISPR-Cas9 based knock out screens enable us to identify targets of which loss may cause 
a resistance phenotype. By applying CRISPR-Cas9 based loss-of-function (LOF) screen 
in leukemia and melanoma cell lines, previous studies have revealed genes related to drug 
resistance.43,44 In a proof-of-principle study (Chapter 5), we performed a drug resistance 
screen in NALM6 cells and identified ADRBK1 and IR AK1 as kinases that may affect 
prednisone resistance in ALL. Despite the fact that future functional studies are required 
to confirm this finding, these positive screens helped us to understand the mechanism 
for prednisone resistance in leukemia. More importantly, if validated in patients, these 
findings could guide the design of future therapies.
An even more interesting group of targets that may result from this kind of CRISPR-
Cas9 based LOF screens are those genes that sensitize treatment, although these 
are more challenging to identify these. Nevertheless, using a dual sgRNA system to 
simultaneously knock out two genes, Han and colleagues found that co-treatment 




enhance the responsiveness to imatinib.45 We applied a similar approach using a sgRNA 
library targeting all known kinase genes (‘kinome screen’) in the context of Asparaginase 
(ASNase) resistance and found that inactivation of Bruton Tyrosine Kinase (BTK) 
strongly synergizes with ASNase in ALL. BTK can pharmacologically be targeted by 
the BTK inhibitor ibrutinib and may, thus, be a promising new drug to be added to the 
treatment regime of ALL (Chapter 6). Our collaborators from the Van Leeuwen group 
have validated these results both in vivo and in vitro and found that the combination of 
ibrutinib and ASNase largely induces leukemic cell apoptosis (Chapter 6). Taken together, 
we conclude that CRISPR-Cas9 based high throughput screening represents an effective 
strategy to identify synergistic drug combinations. These may benefit the design of future 
clinical trial.
While preparing NGS libraries, many efforts have been made to maintain the sgRNA 
complexity and cellullar heterogeneity, such as including a massive amount of cells for 
PCR, minimizing amplification cycles and increasing sequencing depth. As a result, we 
could indeed identify all sgRNA sequences in the control cell population, although it 
remains to be established whether these reads are from a single knockout clone or from an 
accumulation of many clones. Recent studies have suggested to include unique molecular 
identifiers (UMIs) in the sgRNA library design to solve this problem.45–47 Indeed, 
barcoding each sgRNA molecule using UMIs would enable us to estimate sgRNA off-
target efficiencies, which could accurately indicate the amount of templates present for 
PCR. More importantly, this approach would allow us to track down individual cells 
infected by a sgRNA and, thus, helps us to estimate the cellular heterogeneity and the 
clonal changes occurring during screening.
FUTURE PERSPECTIVES
The research described in this thesis provides distinct directions for future research aimed 
at understanding the mechanism(s) underlying relapse development in ALL.
As one of the major causes of therapy failure in ALL, intra-tumor heterogeneity has 
been documented for many years and has been detected using microarray- and NGS- 
based technologies at a whole genome scale. However, current models are based on bulk 
sequencing analysis and the assumption that variants with the same variant allele frequency 
(VAF) are present in the same clone. The same variant may, however, be present in multiple 
subclones and show an equal accumulative VAF. Therefore, to comprehensively understand 
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cellular heterogeneity and clonal evolution patterns, future single cell resolution studies 
at a multi-omics scale are warranted. These studies will help us to more comprehensively 
identify tumor cell populations related to treatment failure, to understand a signature 
of combined genes rather than that of a single gene related to ALL relapse at a single cell 
resolution and to estimate whether clonal heterogeneity is related to prognosis.
With the advancement of NGS technologies, genomic landscape studies have increasingly 
revealed ALL related genes, some of which could be potentially used as diagnostic markers 
in clinical practice. As yet, however, the prognostic value of these newly identified genes has 
not been thoroughly assessed. With the ability to accurately detect low level alterations, 
the smMIP approach provides unique opportunities to assess the prognostic value of 
alterations in ALL related genes. Additionally, this approach may be of help to monitor 
leukemia development. To achieve this, a smMIP panel targeting ALL relapse related 
genes could be generated, allowing us to estimate the level of clonality in MRD samples.
Despite the high survival rate obtained in ALL, patients carrying leukemic cells with 
specific alterations often respond poorly to chemotherapeutic drugs. Therefore, it is 
important to understand the mechanism(s) of treatment failure in specific genomic 
contexts. For example, IKZF1 alterations are very common in ALL, however, the prognostic 
value of IKZF1 is decreasing due to improved treatment regimens. Therefore, diagnostic 
markers that are currently considered as risk factors should continuously be updated. 
Furthermore, new treatment approaches such as immunotherapy are being developed 
rapidly. Already, chimeric antigen receptor T (CAR-T) cells based immunotherapy has 
been applied to patients with a high risk to relapse. Relapses occurring after these clinical 
studies should be thoroughly evaluated, with the aim to understand the mechanism(s) 
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Despite the increased survival rate in pediatric acute lymphoblastic leukemia (ALL), relapse 
still occurs in about 10% of patients and is one of the major causes of treatment failure. 
Therefore, a major focus of current research is to understand the mechanism(s) underlying 
relapse development, which could help us to improve treatment outcome and prevent 
relapse in upfront therapy for this remaining subgroup. The first step to unravel relapse 
development is to investigate which genomic alterations are associated with ALL relapse. 
Based on these observations, insights can be obtained in the clonal evolution during ALL 
relapse development, and how this process is influenced by therapy. In Chapter 1, we 
introduce the topic of this thesis with a comprehensive overview of the knowledge in the 
field of genomics of ALL and the concepts of clonal evolution in relapse development. In 
the following chapters, we have used three different approaches to understand the game 
of clones in childhood ALL in order to gain insight into the biology underlying relapse 
development in ALL.
The first approach we have taken was to compare the genomic composition between 
relapses of different upfront treatment protocols. In Chapter 2 of this thesis, we examined 
the presence of recurrent relapse-associated aberrations in 21 genes in relapses from three 
consecutive DCOG studies (ALL8, ALL9 and ALL10). We observed that upfront 
treatment indeed influences the frequency of mutations, resulting in differences in the 
genomic composition of relapses between these three studies. For example, the ALL9 
protocol, which for its efficacy relies on high dose of glucocorticoid (GC) treatment, 
appeared to result in a higher frequency of IKZF1 deleted relapses compared to ALL8 and 
ALL10. Furthermore, compared to ALL8 and ALL10, the IKZF1 deletions in relapses 
from ALL9 were found to be more frequently preserved from diagnosis, and thus represent 
clones that survived therapy. These findings are in line with previous reports from clinical 
trials in which the impact of IKZF1 deletion status on outcome was investigated, which 
demonstrated that the prognostic value of IKZF1 deletions varied considerably between 
studies and was found to be particularly strong in the ALL9 study. Furthermore, we 
identified that the frequency of CREBBP mutations are particularly more common in ALL8 
and ALL10 relapses compared to those in ALL9. Together, these data suggest that upfront 
treatment influences the composition of genomic alterations in relapsed ALL.
As a second approach we investigated whether aberrations frequently detected in relapse 
have prognostic value when they are present in subclones at diagnosis. The presence 
of subclonal aberrations in these genes at time of diagnosis had not been investigated 
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in much detail, and the impact of these aberrations on the risk to develop relapse was 
therefore unknown. To investigate this, we first implemented an approach to accurately 
and sensitively detect subclonal alterations, using single molecule molecular inversion 
probes (smMIP) (Chapter 3). The smMIP approach is featured by the random tagging 
on each captured locus of the genome, which increases the sensitivity and specificity of 
detecting subclonal mutations in a quantitative manner. During the data analysis process, 
this random tagging allowed us to eliminate amplification and sequencing errors revealing 
only true mutations. As a result, the smMIP approach enabled us to identify subclonal 
mutations with mutant allele frequencies as low as 0.4%.
Using this newly developed smMIP approach, we subsequently assessed the prognostic 
value of subclonal mutations in the ALL relapse-associated genes CREBBP, KR AS, NR AS, 
PTPN11, TP53, and WHSC1 (Chapter 4). In addition, we studied one of the most frequent 
alterations in IKZF1, an intragenic deletion of exons 4-7 by semi-quantitative PCR. We 
screened these genes in a large cohort of 508 diagnosis samples from patients with B cell 
precursor ALL (BCP-ALL) enrolled in DCOG ALL9 and ALL10 studies, and found that 
56% of all samples harbored at least one alteration in the genes studied. A total of 660 
alterations were identified, of which 495 (75%) had mutant allele frequencies less than 
25%, indicating that subclonal alterations are very common at diagnosis. With this high 
number of subclonal alterations at diagnosis, we next investigated whether these alterations 
were related to relapse development. Statistical analysis showed that clonal IKZF1 deletions 
were associated to relapse development, while clonal CREBBP mutations showed a weak 
association with relapse development only in the ALL10 cohort. Importantly, no 
association with relapse development was observed for subclonal alterations in any of the 
seven genes studied. Furthermore, we traced the detected alterations in paired relapse 
samples, showing that whereas 56% of clonal alterations were found to be preserved at 
time of relapse, this was the case for only 7% of the subclonal alterations (Fisher’s exact 
test, p<0.01). Most strikingly, all subclonal IKZF1 exon 4-7 deletions were lost, while all 
full-clonal deletions were found to be preserved to relapse. These data suggest that the 
selective advantage of subclonal alterations during treatment is very limited.
The last approach we took to unravel the underlying biology of relapse development was 
to identify targets and pathways that are contributing to reduced or increased sensitivity 
to drugs that are used in upfront therapy of ALL, with the ultimate aim to improve 
the efficacy of these therapies. To achieve this, we implemented a CRISPR-Cas9 based 




phenotype (Chapter 5). As a proof-of-principle study, we applied this approach with 
an sgRNA library targeting 507 kinases in the B-ALL cell line Nalm-6 to determine 
targets related to prednisolone resistance. After transduction of the sgRNA library, cells 
were cultured for 17 days in the presence or absence of prednisolone. For each gene, we 
compared the abundance of sgRNAs in the cell populations treated with prednisolone 
relative to those that were untreated. We found that loss of BARK1, a negative regulator of 
β-AR signaling, affects the resistance to prednisolone (p=0.0011). By generating BARK1 
knockout cell lines, we subsequently showed that loss of BARK1 decreases prednisolone 
induced cell death in vitro. In contrast, when repressing β-AR signaling using beta blockers, 
cells were found to be sensitized to prednisolone treatment. Therefore, the CRISPR-Cas9 
based genome-wide screen is a powerful tool to study the biology underlying ALL therapy 
resistance and relapse development.
In Chapter 6, we applied this CRISPR-Cas9 based approach to search for targets that 
could improve a leukemic cell response to asparaginase (ASNase), a key component of 
ALL treatment. We found that cells with a knockout of Bruton tyrosine kinase (BTK) 
were more sensitive to ASNase treatment compared to wild type cells. Furthermore, the 
Van Leeuwen group, with whom we actively collaborated in this study, subsequently 
demonstrated that inhibition of BTK signaling effectively suppresses the amino acid 
response, thus sensitizing BCP-ALL cells to ASNase induced apoptosis. They have shown 
that targeted inhibition of BTK by the FDA approved cancer drug Ibrutinib improved the 
response of BCP-ALL cells to ASNase. Together, we conclude that CRISPR-Cas9 based 
screening can be used to identify pathways that can be selectively inhibited in order to 
improve therapy response during treatment of ALL.
This thesis not only reports mechanisms underlying ALL relapse using three distinct 
approaches, but also presents two powerful techniques that could be potentially used to 
study the biology related to ALL relapse. In Chapter 7, we extensively discuss the effect of 
upfront treatment on genomic architecture in relapse, evolutionary patterns from diagnosis 
to relapse and the prognostic value of subclonal alterations. At the end we also elaborate on 
future perspectives regarding unraveling clonal heterogeneity and evaluating prognostic 




Ondanks het hoge overlevingspercentage van acute lymfatische leukemie bij kinderen 
(ALL), treedt een recidief op bij ongeveer 10% van de patiënten. Bij deze kinderen is 
de overlevingskans helaas aanzienlijk lager. Het begrijpen van de mechanismen die 
ten grondslag liggen aan de ontwikkeling van een recidief is daarom een belangrijk 
aandachtspunt van het huidige onderzoek. Inzicht in deze mechanismen gaat ons helpen 
om de behandelresultaten te verbeteren en de ontwikkeling van een recidief te voorkomen. 
De eerste stap om de ontwikkeling van een recidief te ontrafelen, is te onderzoeken welke 
genomische veranderingen in dit stadium van de ziekte veel voorkomen. Op basis van deze 
gegevens kunnen inzichten worden verkregen in de klonale evolutie tijdens de ontwikkeling 
van het recidief en hoe dit proces wordt beïnvloed door therapie. In Hoofdstuk 1 wordt 
een algemene introductie gegeven met een uitgebreid overzicht van de kennis op het gebied 
van genomics van ALL en de concepten van klonale evolutie in recidiefontwikkeling. In 
de volgende hoofdstukken hebben we drie verschillende benaderingen gebruikt om het 
spel der klonen (“the game of clones”) in ALL bij kinderen te begrijpen om zo inzicht te 
krijgen in de biologie die ten grondslag ligt aan de ontwikkeling van recidief bij ALL.
Als eerste benadering hebben we het spectrum aan genomische afwijkingen vergeleken 
tussen recidieven die ontstaan na verschillende behandelprotocollen, waarvan de resultaten 
zijn beschreven in Hoofdstuk 2 van dit proefschrift. Hierbij hebben we ons gericht 
op veel voorkomende recidief geassocieerde afwijkingen in 21 genen bij recidieven uit 
drie opeenvolgende behandelprotocollen van de Stichting Kinderoncologie Nederland 
(SKION; ALL8, ALL9 en ALL10). We vonden aanwijzingen dat de behandeling 
voorafgaand aan het recidief de frequentie van mutaties inderdaad beïnvloedt. Zo bleek 
het ALL9 protocol, waarvan de effectiviteit vooral wordt veroorzaakt door de hoge dosis 
glucocorticoïden, te resulteren in een hogere frequentie van recidieven met een deletie van 
het gen IKZF1 in vergelijking met ALL8 en ALL10. Bovendien bleek dat, in vergelijking 
met ALL8 en ALL10, de IKZF1 deleties in recidieven van ALL9 vaker terug konden 
worden gevonden in de diagnose. Het ging hierbij dus vaker om klonen die de therapie 
hadden overleefd, terwijl in ALL8 en ALL10 juist vaker nieuwe IKZF1 deleties ontstonden. 
Deze bevindingen komen overeen met eerdere studies waarin de impact van de IKZF1 
deleties op genezing werd onderzocht. Hieruit bleek dat de prognostische waarde van 
IKZF1 deleties aanzienlijk varieerde tussen studies en bijzonder sterk was in de ALL9 
studie. Verder hebben we vastgesteld dat de frequentie van CREBBP mutaties vooral hoger 




gegevens dat behandeling vooraf de samenstelling van genomische veranderingen in ALL 
recidieven beïnvloedt.
Als tweede benadering onderzochten we of genomische afwijkingen die vaak worden 
gedetecteerd bij recidief ALL een prognostische waarde hebben wanneer ze aanwezig 
zijn in subklonen bij diagnose. De aanwezigheid van subklonale mutaties en deleties in 
deze genen op het moment van diagnose was tot dusver niet in detail onderzocht en de 
impact van deze afwijkingen op het risico op recidief was daarom onbekend. Om dit 
te onderzoeken, hebben we eerst een aanpak geïmplementeerd om subklonale mutaties 
nauwkeurig en gevoelig te detecteren met behulp van zogenaamde single molecule molecular 
inversion probes (smMIP) (Hoofdstuk 3). De smMIP benadering wordt gekenmerkt 
door het met willekeurig gegenereerde moleculaire labels individueel markeren van 
moleculen die worden gedetecteerd in een leukemie sample, waardoor bij gevonden 
mutaties gecorrigeerd kan worden voor amplificatie artefacten. Deze methode verhoogt 
de specificiteit en sensitiviteit van mutatiedetectie aanzienlijk, waardoor ook mutaties 
die in lage hoeveelheden aanwezig waren (tot 0,4% mutant allelfrequentie) gevoelig en 
nauwkeurig konden worden bepaald.
Met behulp van deze nieuw ontwikkelde smMIP benadering hebben we vervolgens de 
prognostische waarde van subklonale mutaties in de ALL recidief geassocieerde genen 
CREBBP, KR AS, NR AS, PTPN11, TP53 en WHSC1 beoordeeld in een groot cohort van 508 
diagnosemonsters van patiënten met B-celprecursor ALL (BCP-ALL) uit de ALL9 en 
ALL10 studies (Hoofdstuk 4). Daarnaast hebben we, met een semi-kwantitatieve PCR, 
dit cohort gescreend op één van de meest voorkomende veranderingen in IKZF1, een 
intragene deletie van exonen 4-7. We ontdekten dat 56% van alle monsters tenminste 
één afwijking in de bestudeerde genen bevatten. Er werden in totaal 660 veranderingen 
geïdentificeerd, waarvan 495 mutaties (75%) allelfrequenties hadden van minder dan 25%, 
wat aangeeft dat subklonale veranderingen zeer vaak voorkomen bij diagnose. We hebben 
vervolgens onderzocht of deze veranderingen verband hielden met de ontwikkeling van een 
recidief. Statistische analyses toonden aan dat klonale IKZF1 deleties geassocieerd waren 
met recidiefontwikkeling, terwijl klonale CREBBP mutaties alleen in het ALL10 cohort een 
zwak verband vertoonden met recidiefontwikkeling. Belangrijk was dat er geen verband 
werd waargenomen van subklonale veranderingen in één van de zeven onderzochte genen 
met de ontwikkeling van recidief. Verder hebben we de gedetecteerde veranderingen bij 
diagnose in de bijbehorende recidief monsters getraceerd. We toonden aan dat, terwijl 
56% van de klonale veranderingen behouden bleken te zijn op het moment van recidief, dit 
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slechts het geval was voor 7% van de subklonale veranderingen (Fisher’s exact test, p <0,01). 
Het meest opvallende was dat alle subklonale IKZF1 exon 4-7 deleties verloren waren 
gegaan, terwijl alle volledig klonale deleties bleken te worden behouden in het recidief. 
Deze gegevens suggereren dat het selectieve voordeel van subklonale veranderingen tijdens 
de behandeling zeer beperkt is.
De laatste benadering die we hebben gekozen om de onderliggende biologie van de 
ontwikkeling van een recidief te ontrafelen, was het identificeren van centrale spelers 
en functionele routes die bijdragen aan een verminderde of verhoogde gevoeligheid voor 
geneesmiddelen die worden gebruikt in de therapie van ALL, met als uiteindelijk doel 
de effectiviteit van deze therapieën te verbeteren. Om dit te bereiken, hebben we een op 
CRISPR-Cas9 gebaseerde techniek gebruikt om een grote groep voorgeselecteerde genen 
individueel uit te schakelen om zo die genen te identificeren waarvan het verlies leidt tot 
resistentie of juist verhoogde gevoeligheid (Hoofdstuk 5). Het uitschakelen van genen 
gebeurt met zogenaamde guide RNA moleculen (sgRNA’s). Als proof-of-principle-studie 
hebben we deze aanpak toegepast met een sgRNA-bibliotheek gericht op 507 kinases in 
de B-ALL-cellijn Nalm-6 om zo de genen te vinden die verband houden met prednisolon-
resistentie. Na transductie van de sgRNA-bibliotheek werden cellen gedurende 17 dagen 
gekweekt in aan- of afwezigheid van prednisolon. Voor elk gen werden de sgRNA’s in 
de cel populaties die wel en niet waren behandeld met prednisolon nauwkeurig bepaald 
en vergeleken. We ontdekten dat verlies van BARK1, een negatieve regulator van β-AR-
signalering, de resistentie tegen prednisolon verhoogt (p = 0,0011). In cellijnen waarin 
we BARK1 hadden uitgeschakeld, toonden we vervolgens aan dat dit effect wordt 
veroorzaakt doordat verlies van BARK1 de door prednisolon veroorzaakte celdood 
vermindert. Bovendien bleken cellen waarbij de β-AR-signalering met bètablokkers was 
onderdrukt, wat resulteert in verhoogde BARK1 expressie, gevoeliger voor prednisolon 
behandeling. Deze op CRISPR-Cas9 gebaseerde genoombrede analyse is een  krachtig 
hulpmiddel om de biologie te bestuderen die ten grondslag ligt aan ALL therapieresistentie 
en recidiefontwikkeling.
In Hoofdstuk 6 hebben we deze op CRISPR-Cas9 gebaseerde benadering toegepast 
om te zoeken naar centrale spelers die de respons van leukemie cellen op asparaginase 
(ASNase), een belangrijk onderdeel van ALL behandeling, zouden kunnen verbeteren. 
We ontdekten dat cellen met een knock-out van Bruton tyrosinekinase (BTK) gevoeliger 
waren voor ASNase behandeling in vergelijking met wildtype cellen. Verder heeft de Van 




remming van BTK-signalering de aminozuurreactie effectief onderdrukt, waardoor BCP-
ALL cellen gevoelig worden voor ASNase geïnduceerde apoptose. Hieruit is gebleken 
dat gerichte remming van BTK door het door het geregistreerde kankergeneesmiddel 
Ibrutinib de respons van BCP-ALL cellen op ASNase verbeterde. Op basis van deze 
resultaten concluderen we dat CRISPR-Cas9 screening kan worden gebruikt om cruciale 
routes te identificeren die selectief kunnen worden geremd om de therapierespons tijdens 
de behandeling van ALL te verbeteren.
Dit proefschrift rapporteert niet alleen drie verschillende benaderingen om mechanismen 
die ten grondslag liggen aan ALL recidief in kaart te brengen, maar presenteert ook twee 
krachtige technieken die mogelijk kunnen worden gebruikt om de biologie te bestuderen 
die verband houdt met ALL recidief. In Hoofdstuk 7 bespreken we uitgebreid het effect van 
de diagnose behandeling op genomische architectuur bij recidief, evolutionaire patronen 
van diagnose tot recidief en de prognostische waarde van subklonale veranderingen. Aan 
het eind gaan we ook in op toekomstige perspectieven met betrekking tot het ontrafelen 
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